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PREFACE 
With the near disappearance of chimpanzees as an animal model on one 
side, and the approval of direct acting antiviral drugs by regulatory agencies on 
the other, this thesis is positioned in an era of changing perspectives in HCV 
research. It summarizes the key-role of chimpanzees in HCV research so far. 
This thesis elaborates on potential mechanisms behind successful prophylactic 
vaccine candidates, but also the consequences of chronic HCV are discussed. 
 
GENERAL INTRODUCTION 
 
Chronic hepatitis, caused by persistent infection with hepatitis C virus 
(HCV) is a major health concern worldwide 1. The number of chronic HCV 
carriers is estimated to be 170 million, about 1 to 2% of the total world 
population (Figure 1). The virus was first described in 1989 2. Before reliable 
diagnostic tests were introduced, HCV was primarily spread via blood 
transfusions 3.  
 
 
 
 
 
 
Figure 1; World wide prevalence of HCV and subtypes 
Adapted from Gravits et al 1 
 
Egypt prevalence 
>14% 
90% intravenous 
drug users 
India; mild epidemic 
due to historically  
underderveloped 
health care system  
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Life cycle of HCV 
HCV is a 9600 nucleotide, single-stranded positive-sense RNA virus that 
belongs to the Flaviviridae. The structural proteins form the virus particle, while 
the nonstructural proteins are involved in replication, maturation and assembly 
4 (Figure 2).  
The surface of an infectious HCV particle is composed of a lipid bilayer 
with the envelope glycoproteins. Inside are the viral Core protein and viral 
RNA. After cell entry, host machinery is utilized to translate viral RNA into one 
large precursor polyprotein. The structural proteins Core, E1 and E2 are 
separated from the nonstructural proteins NS1, NS2, NS3, NS5A and NS5B by 
p7, a presumed viroporin 5. During and after the translation process, host and 
viral-encoded proteases cleave the polyprotein into 10 mature viral proteins. 
Post-translational processing is orchestrating the heterodimeric complexing of 
NS3 and NS4A proteins (NS3/NS4A) where NS3 has proteolytic activity and 
NS4 acts as a cofactor 6. 
 
 
 
Figure 2; HCV genome and translation.  
Adapted from Bartenschlager et al 2 
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Genetic diversity HCV 
There are seven major genotypes of HCV 7, 8. Each genotype consists of 
a cluster of different subtypes, and within each patient, closely related quasi-
species are present. The difference between two distantly related HCV isolates 
can be as high as 30% at the nucleotide level 9. The genetic variation of HCV 
has implications for the development of a successful vaccine. In addition, the 
circulating quasi-species can easily adapt, especially in the hypervariable 
regions (HVR) in the envelope proteins, and are notorious for escaping the 
immune system as well as drugs that are used for treatment.  
 
 
Transmission 
Transmission of HCV occurs via blood-blood contact. Nowadays in the 
western world, the majority of the new infections are associated with 
intravenous drug use. Not only via the sharing of contaminated needles but 
also other injection-equipment 10. Still, there are several examples of drastically 
declining numbers of new HCV cases, after the introduction of surveillance 
programs and the distribution of fresh disposable needles amongst intravenous 
drug users 11, 12.  
In other geographical regions, the mode of transmission is different. The 
situation is especially worrying in Egypt, where an estimated 12% of the 
population is infected with HCV. The high prevalence is the result of an unsafe 
treatment-procedure of an endemic schistosomiasis infection during the years 
60-80s of the last century. Currently, the infrastructural organization of the 
Egyptian health care system is, at least partially, responsible for ongoing 
transmission in the region 13. Recently, WHO has declared the large reservoir 
of chronic HCV carriers a serious risk, as tourism and migration can contribute 
to spreading of the virus to places outside the region. 
 
 
Chronic infection 
HCV infection is characterized by a high propensity for the development 
of life-long viral persistence. Only 25% of the acute infections is spontaneously 
eradicated, normally within the first six months after infection 14. During acute 
HCV infection, clinical symptoms are mild or even absent. For that reason 
acute HCV infections are often unrecognized. When acute HCV infection 
develops into a persistent infection, the majority of the patients develop chronic 
hepatitis and over decades the virus causes subtle progressive hepatic 
damage. Ultimately, this may lead to cirrhosis, decompensating liver 
14	  	   	   	   	   	   	  	   	   CHAPTER	  1	  
congestion or hepatocellular carcinoma (Figure 3). It has been calculated that, 
worldwide, 27% of the cases of liver cirrhosis can be accounted for by HCV 
and overall, persistent HCV infection accounts for 3 million deaths each year 
(source WHO).  
 
 
 
 
Therapeutic drugs or a vaccine? 
Soon after the discovery of HCV, it was clear that investigating this virus 
was going to be an even bigger challenge compared to HIV. Many of the tools 
that were available for HIV research, were not available for HCV. HCV was 
found to have a narrow host range; only humans and chimpanzees were 
susceptible for infection. Unlike the S(H)IV model for HIV infection in humans, 
there was no surrogate model available for HCV. And, before 2003, there was 
no in vitro method available to culture HCV. The lack of these tools, and the 
unknown virus’ life cycle, made it clear it would be sheer impossible to develop 
specific therapeutic antiviral drugs. For that reason, it was believed that the 
development of a vaccine would be a more efficient approach to fight the HCV-
epidemic.  
Figure 3; Schematic overview course HCV infection. 
The course of HCV infection is very heterogeneous. Depending on age of, genotype, 
lifestyle and many other factors, HCV infection can run an aggressive course or a more 
mild course, with severe or mild pathophysiological damage in the liver. The time between 
infection and actual clinical symptoms is sometimes more than 30 years. 
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Chimpanzees in biomedical research 
Humans and chimpanzees (pan troglodytes) share a common ancestor 
who lived approximately 30 million years ago, before the hominoid lineage 
split. Chimpanzees are humans’ closest living relatives with 98.9% identity at 
DNA level 15. Since the 40s of the last century, chimpanzees have been used 
in research. First in the US space program and later also in biomedical 
research. The colonies of chimpanzees in research facilities were founded 
from animals that were imported from the wild in Western Africa. Soon, 
breeding programs assured enough offspring for experimental work. Facilities 
became self-sustainable and no longer required import of chimpanzees from 
the wild.  
Public concerns about research with non-human primates, in particular 
chimpanzees, has eventually led to the total ban of the use of apes for 
research in Europe, and a significant reduction of the number of animals used 
in the US 16.  
 
Chimpanzees and HCV research 
No doubt, chimpanzees have been the most important animal model to 
study HCV 17. In the late 80s, after it became clear that the majority of blood 
borne chronic liver inflammations was not caused by hepatitis A or B virus, 
serum from a non-A-non-B hepatitis patient was inoculated into a chimpanzee 
2. From this chimpanzee, a cDNA bank was derived and in 1989 Michael 
Houghton and his coworkers at Chiron Inc., identified HCV as the main 
causative agent for non-A-non-B hepatitis 2.  
To date, the chimpanzee is the only validated animal model to study 
immunity associated with acute resolving infection, and protective immunity 
against HCV reinfection. Over the past 35 years, experimental HCV infections 
of chimpanzees has provided groundbreaking information regarding the 
identification, characterization, transmission and early responses after HCV 
infection. Studies in chimpanzees have enabled us to identify immune 
mechanisms that are associated with viral clearance or chronic infection. This 
was critical for the design of prophylactic vaccine candidates. Subsequently, 
chimpanzees were used to evaluate the efficacy of vaccines and different 
vaccination strategies.  
 
Primary HCV infection in chimpanzees 
To be able to study the effect of a vaccine or vaccination strategy, it was 
necessary to identify the virological characteristics of HCV without any 
intervention. There are numerous reasons why it is difficult to study early 
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events in HCV infection in humans. Firstly, the vast majority of the acute HCV 
infections are asymptomatic and patients therefore rarely seek medical 
attention. Secondly, collecting serial blood samples and occasional liver-biopsy 
material from one individual during acute HCV infection is very difficult. 
Additionally, collecting pre-exposed bio-specimen from the same patient was/is 
nearly impossible, especially since the high-risk groups for contracting HCV 
had not been identified at that time. Therefore, experimental inoculation of 
chimpanzees was pivotal to be able to study early virological and 
immunological events. 
 
In chimpanzees, similar to humans, intravenous exposure to HCV can 
lead to either a transient self-limiting infection or it may develop into a 
persistent infection 18. In both humans and chimpanzees, viral RNA is 
detectable by RT-PCR in plasma and liver tissue 19. In addition, anti-HCV 
antibodies appear in peripheral blood of both species 6 to 8 weeks after HCV 
exposure 20, 21. In the majority of human individuals, antibodies remain 
detectable in blood after viral clearance, while in chimpanzees sometimes a 
gradual loss of HCV specific antibodies after viral elimination has been 
reported 19, 22. However, in humans, HCV specific cellular immune responses 
have been observed in seronegative individuals, implying that in humans the 
loss of HCV-specific antibodies after viral clearance also occurs 18, 23-25. 
Published data on cellular immune responses showed that HCV specific 
CD4 and CD8 T-cell responses in both humans and chimpanzees are weak 
after infection. Spontaneous clearance was associated with relatively strong 
cellular responses compared to the individuals that became persistently 
infected 26-30. Also in liver biopsies from HCV infected patients and 
chimpanzees, virus-specific CD4 and CD8 T-cells were observed 31-34. 
Relatively strong liver-associated T-cell responses were associated with viral 
clearance 34. 
 
HCV reinfection in chimpanzees 
Documented reinfection studies in humans are relatively sparse 35-38. 
Longitudinal analysis of human intravenous drug users were performed, but 
results were inconclusive as to whether a previously cleared HCV infection 
induces functional immunological memory 14, 36, 37. Important insights were 
obtained from chimpanzees in which experimental HCV re-exposure was 
studied in a controlled setting as far as genotype, dose and route of infection, 
and longitudinal follow up studies could be performed 39-46.  
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Reinfection studies in chimpanzees have demonstrated that all of the 
three possible outcomes: i.e. protection from infection 43, 44, protection from 
viral persistence 39, 43-45 and persistent HCV infection 39, can occur. Pairwise 
comparison of virological parameters during primary infection versus 
chimpanzees that were rechallenged, showed that previous HCV clearance 
provided some protection 47. This was characterized by reduced duration, peak 
virus load and reduced frequency of development of persistent HCV infection 
47.  
Understanding the underlying mechanisms that contribute to protection 
against chronic infection has been an important research goal, and was pivotal 
for further HCV vaccine development. Since HCV-induced liver damage only 
leads to a fatal condition after decades of ongoing immunopathogenesis, a 
vaccine achieving a similar rate of protection from chronic infection as 
observed after reinfection, would already be of great value.  
 
Viral persistence in humans and chimpanzees 
The vertebrate immune system comprises two interrelating systems, the 
innate and the adaptive immune system. The innate system is rather rigid and 
partly orchestrated by the genome. Adaptive immunity, with its variability and 
memory, is based on somatic gene rearrangements, and the repertoire of 
antigen-specific receptors is presented on the surface of immune cells. The 
intense communication between the innate and adaptive immune system is 
regulated via soluble chemokines and cytokines, and the expression of cell-
associated receptors. Taken together, this enables the recruitment of specific 
effector cells to the site of infection. In order for a pathogen to survive and 
persist in this hostile environment, it needs to evade the immune system of the 
host.  
Based on antibody data, the WHO estimates that 55 to 85% of the HCV 
infections eventually develop into a persistent infection. The documented 
percentages of chimpanzees with persisting HCV infection varies between 
different laboratories from 39 to 70% 22, 47-49. This indicates that HCV is very 
successful in evading immunity. In the following paragraphs, the main evasion 
strategies of HCV will be discussed. 
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Immune correlates  
A schematic overview of the immune mechanisms during HCV is shown 
in Figure 4. 
 
 
A) Immunogenetics. 
 
MHC class I genes 
The main function of MHC class I and class II molecules is the binding of 
pathogen-derived peptides, and present them to CD8 and CD4 effector T-cells. 
In humans, the outcome of HCV infection is associated with protective HLA 
class I alleles HLA-B27, HLA-B57 and HLA-A2, and class II molecules HLA-
DRB1*0101, HLA-DRB1*0401, HLA-DRB1*1101 and HLA-DRB1*0301 50-53. 
 
Figure 4; Schematic overview of cellular effector responses during HCV infection. 
Antigen presenting cells (DCs) or Kupffer cells in the liver, present HCV peptides in the 
context of MHC class II molecules to the T-cell receptor (TCR) on CD4 T-cells. CD4 
cells may activate B-cells. Antibodies produced may be neutralizing, bind to circulating 
HCV particles and prevent the infection of new hepatocytes. Or the antibodies may be 
non-neutralizing and potentially play a role in ADCC. CD4-helper T-cells can also 
stimulate cytolytic T-cells (CTL). CD8 T-cells may be directly responsible for lysis when 
they produce degranulation molecules like granzymes or perforin after the recognition of a 
peptide on the surface of an HCV infected hepatocyte. Or indirectly, mediated by 
secretion of cytokines. CD8 T-cells affected by Tregs or express markers that are 
associated with exhaustion. In that case CD8 T-cells are functionally impaired and 
incapable of lysing HCV infected hepatocytes.  
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Although the exact same MHC class I alleles that are associated with HCV 
clearance are not present in chimpanzees, homologues with similar peptide-
binding characteristics have been identified in these animals 54. All these 
findings may be important in the development of a successful vaccine.  
 
Interferon stimulating genes 
Genome wide association studies in humans have shown that 
spontaneous clearance, and better chance of sustained virological response 
after IFNα treatment, is associated with polymorphism near the IFNλ, IL-28B 
gene 55, 56. Although, in vitro studies have shown that IFNλ is produced by 
hepatocytes 57, 58 in the liver. different genotypes do not have a direct 
regulatory effect on the transcription of IFNλ, as shown by similar levels of the 
protein in serum 59. They do however correlate with serum levels of another 
IFNγ induced protein, IP-10 60, 61. If or how these pathways interrelate, and how 
innate effector functions are affected, is still under investigation.  
In chimpanzees, similar mechanisms may play a role. Not only have there 
been reports on up-regulation of intrahepatic ISGs in HCV infected 
chimpanzees 59, 62, it was also reported that ISG up-regulation was 
accompanied by robust intrahepatic responses of natural killer (NK) cells in a 
chimpanzee reinfected with HCV 63.  
 
KIR genotypes 
The lymphocyte population in the liver is enriched with NK cells, and NK 
cells play an important role in host defense against viral infections. In humans, 
the role of NK cells during HCV infection and HCV-associated liver damage is 
ambiguous (reviewed 64). NK cells are associated with hepatic fibrosis, while 
on the other hand it was demonstrated that NK cells have anti-fibrotic 
properties, and that they control HCV replication by killing HCV infected 
hepatocytes. Additionally, successful antiviral therapy was found to be 
associated with activation of NK cells.  
The activation of NK cells is partly regulated at genetic level. Killer cell 
immunoglobulin-like receptors (KIR) are members of the CD158 gene family. 
KIRs are part of the extensive repertoire of receptors expressed by NK cells 65. 
Depending on the presence of immune tyrosine-based inhibitory motif (ITIM) in 
the cytoplasmic domain, NK receptors are either inhibitory or activating. KIRs 
bind to MHC class I molecules, and in this respect, MHC molecules can be 
divided into two groups. C1-KIRs contain an asparagine at position 80 in the 
α1 domain, while C2-KIRs contain a lysine at this position. The combinatorial 
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expression of class I molecules and KIRs determine the development and 
activation of NK cells.  
In humans, homozygosity for C1 type HLA-C, in combination with the 
inhibitory KIR2DL3, is associated with HCV clearance 66. In chimpanzees, also 
a relation between KIR and MHC class I was found. Homozygous C1 type 
Patr-B combined with Pt-KIR3DS2 or Pt-KIR2DL9 is associated with HCV 
persistence 67.  
 
B) Innate immune cells 
 Dendritic cells 
The main function of immature dendritic cells (DCs) is to scan the 
environment for antigens of potential pathogens. Internalization of the antigen 
leads to DC maturation and migration to the draining lymph node. Meanwhile, 
the antigen is processed and subsequently presented to T- and B-cells. DCs 
are innate immune cells that orchestrate and modulate adaptive immune 
responses. 
Documentation of phenotype and function of DCs during chronic HCV 
infection in humans is contradictory. Several papers reported no changes 68-71 
while others showed impaired function of DC during HCV infection 72-77. It was 
hypothesized that this impairment is one of the key-determinants in facilitating 
HCV persistence. Analysis of DC function in chimpanzees showed that the 
function of monocyte derived DCs was maintained during acute and chronic 
infection 78, 79. Therefore it can be concluded that impaired DC function is not 
the only mechanism leading to virus persistence. 
In addition, the IFNα-producing capacity of one particular subset of DCs, 
plasmacytoid DC (pDC), was studied in human patients during acute and 
chronic HCV infection 80. Here, it was found that both the frequency, as well as 
IFNα-producing capacity of pDCs were reduced during acute HCV infection 
and remained poor during chronic HCV infection. There is no data available on 
the frequency and function of pDCs in HCV infected chimpanzees. 
 
NK cells 
NK cells are innate immune effector cells with the ability to lyse infected 
target cells without prior activation. NK cells are also recognized for their 
immune modulatory function that influence downstream adaptive immune 
responses 81, 82. Communication between NK cells and other immune cells is 
regulated via a wide range of soluble factors like chemokines, cytokines and 
surface associated receptors 83. On the cell surface of NK cells both activating 
and inhibiting recognition-structures are presented. Not only the earlier 
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discussed KIRs, but also the so-called natural cytotoxicity receptors (NCRs), 
play an important role in NK activation 84. NK cells are important immune cells 
in the first line of defense to several viral infections. Many have reported dys-
balanced NCR expression and impaired NK function in relation to HCV 
infection but the results are inconclusive 85-92. Although microarray analysis of 
an HCV infected chimpanzee demonstrated up-regulation of NK-associated 
genes 93, chimpanzee NK cells have been poorly studied so far 63. This is 
mainly due to the ubiquitous expression of CD56 on chimpanzee NK cells that 
prevents the identification of CD56bright and CD56dimCD16pos subsets in these 
animals. 
 
C) Adaptive immune cells  
As schematically depicted in Figure 5, four different scenarios can be 
used to describe the course of HCV infection and the specific adaptive immune 
responses. 1) Spontaneous clearance of HCV infection (Figure 5A); 
associated with early and effective T-cell responses. This successful immune 
response is characterized by relatively strong expansion of T-cells. These T-
cells are fully functional with respect to cytolytic capacity as reflected by 
granzyme, perforin secretion and/or cytokine production 94-102. 2) Transient 
immune control (Figure 5B); characterized by ensuing viral escape, possibly 
as a result of either immune mediated viral selection or tolerance/immune 
exhaustion. Immune pressure may drive the generation of virus variants in 
which relevant T- or B-cell epitopes are mutated. Epitopes are therefore no 
longer recognized by immune effector cells when they are presented on the 
surface of infected hepatocytes. During tolerance and/or immune exhaustion, 
immune modulatory mechanisms result in dysfunctional T- or B-cells, but with 
intact T- (or B-) cell receptor on the surface 103. 3) Chronic or persistent HCV 
infection (Figure 5C); can occur when T-cells are not fully differentiated into 
functional effector cells, late generation of neutralizing antibodies or immune 
exhaustion. 4) Hypothetical protection from chronic HCV infection by vaccine-
induced immune responses (Figure 5D); vaccine-induced neutralizing 
antibodies, prevent infection while functional HCV specific T-cells protect from 
chronic infection.   
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 Figure 5; Schematic overview of the kinetics of 
the adaptive immune responses during HCV 
infection. 
A) Viral clearance. Viral RNA (red line) is 
normally detected in blood within 1-2 weeks after 
exposure. The virus load will increase until the 
emergence of HCV specific CD4 (yellow line) 
and CD8 T-cell (green line) responses 4 to 8 
weeks after infection 96. Ideally, strain specific 
neutralizing antibodies (blue line) are present 
around the same time 120, 121. After viral 
elimination, antibody responses can either remain 
present or decrease to undetectable levels. 
Memory T-cells remain usually present and can 
be detected by in vitro assays B) Transient 
control. After the initial peak viremia (red line), 
T-cell responses emerge and virus load decreases 
but remains detectable in serum. CD8 T-cells 
(green line) remain detectable but CD4 T-cell 
(yellow line) responses decrease to low levels. 
There appears to be a constant battle between 
virus and the immune system. De novo escape 
variants are able to evade the T and B-cell 
responses but at the same time lose viral fitness. 
When effective T and B-cell responses contract 
because the correct epitopes are no longer present, 
the virus “mutates back” to a more fit variant and 
virus load may increase again. Thinner lines of 
the adaptive immune responses represent 
decreased functionality of CD4 (yellow), CD8 T-
cell (green) and antibodies (blue). C) Failed 
control leading to persistent infection; After the 
initial peak viremia, T-cell responses emerge and 
virus load decrease to lower levels but virus 
remains detectable in serum. T and B cells are 
functionally impaired or present in too low 
numbers to efficiently eliminate the virus. The 
virus remains present at steady state levels. 
Thinner lines of the adaptive immune responses 
represent decreased functionality of CD4 
(yellow), CD8 T-cell (green) and antibodies 
(blue). D) Vaccine induced protection model. 
Vaccine-induced broadly neutralizing antibodies 
are present at the time of exposure and prevent 
virus production by infected hepatocytes. The 
hepatocytes that are infected are successfully 
eliminated by cytolytic T-cells in the liver.  
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        Virus neutralizing antibodies 
Already in 1994, it was described that plasma components had an 
important role in protection of HCV infection 104. In a hallmark experiment by 
Farci et. al. 104, in vitro neutralizing capacity was determined by mixing 
infectious virus with heat inactivated plasma from the same patient and 
subsequently testing it for residual infectivity by inoculating the mixture into a 
naïve chimpanzee. Patient plasma collected 2 years after infection was able to 
prevent infection of the chimpanzee, while plasma collected 13 years after 
infection was not. At that time, there was no in vitro system available to confirm 
the presence of neutralizing antibodies. However, simultaneous appearance of 
envelope HCV specific antibodies in circulation 21 and mutations in the HVR of 
E2 of the virus 41, 105-107 substantiated the involvement of antibodies. This 
experiment not only demonstrated the protective capacity of neutralizing 
antibodies, but also showed the flexibility of the virus to escape immune 
pressure through mutation.  
HCV specific antibodies that are generated during the acute phase of the 
infection are mainly directed against linear epitopes within structural and non-
structural viral proteins. By contrast, neutralizing antibodies have been mapped 
to conformational epitopes within the E1 and E2 envelope proteins 108-114. 
While most neutralizing antibodies are strain specific 114-116, broadly 
neutralizing antibodies, antibodies that recognize epitopes that are highly 
conserved between HCV genotypes, have also been described for E2 115, 117, 
118.  
Specific targets for receptor binding have been identified in E2: CD81, 
SRB1 and coreceptors 119. Neutralizing antibodies directed against domain I 
and III of E2 interfere with binding to CD81, while neutralizing antibodies 
directed against HVR-1 disturb binding of E2 to SRB1.  
In humans, early induction of strain specific neutralizing antibodies was 
found to be associated with spontaneous recovery 120, 121. In most cases 
however, these antibodies are only generated during the chronic phase of the 
infection. At this stage, the virus has disseminated and viral clearance is more 
difficult to achieve. Nonetheless, these antibodies may exert immune pressure 
that could potentially lead to decreased viral fitness.  
The paradigm that neutralizing antibodies in chimpanzees play a less 
prominent role compared to humans, is mostly based on data collected by 
Logvinoff et. al. 121. In that experiment they used a molecular clone derived 
from patient H to infect chimpanzees. In chimpanzees, neutralizing antibodies 
were observed after 15 to 20 weeks. By contrast, in patient H these antibodies 
were already observed 7 weeks post infection. This experiment however did 
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not take into account that the virus may have adapted rapidly to its new host, 
and therefore was slightly different from the original H77 clone. This could have 
caused the delayed formation of H77-neutralizing antibodies. Better 
understanding of the kinetics and specificity of HCV neutralizing antibodies 
may eventually lead to improved vaccine candidates.  
 
T-cell responses 
Antibody-mediated depletion experiments in chimpanzees showed that 
depletion of CD8 T-cells caused prolonged virus replication, and HCV was only 
cleared after recovery of HCV-specific CD8 T-cells in the liver 46. On the other 
hand, CD4 T-cells were required for a complete control of HCV replication.122. 
Similarly, the association between HLA-class I and II molecules and HCV 
clearance emphasizes the role of both CD8 and CD4 T-cells (reviewed in 123). 
Dysfunctional CD8 or CD4 cells may lead to persistent HCV infection.  
Apart from viral escape, ineffective T-cell responses can also be a result 
of exhaustion 124-126. Exhausted T-cells are characterized by loss of CD127 
expression, decreased cytokine production or increased expression of 
inhibitory markers, like PD-1 and CTLA-4 (Figure 4). Moreover, negative 
immune modulators, like Tim-3, LAG-3, CD160 and 2B4, have been 
associated with exhausted HCV specific T-cells 124, 127, 128.  
Also active suppression of HCV-specific T-cell responses by regulatory T-
cells (Tregs) or immunosuppressive cytokines, like IL-10 and TGF-β, have 
been described 129. The contribution of each of these immuno-regulatory 
mechanisms during HCV persistence varies between individual patients, but 
also synergistic effects were observed 130. Blocking these inhibitory molecules, 
temporarily restored HCV specific T-cell responses and resulted in a transient 
drop in virus load 128, 131-133. Combining the recovery of functional T-cells by 
blocking T-cell inhibition with a vaccine that boosts T-cell responses, may 
therefore be an interesting therapeutic vaccine approach.  
 
Chimpanzees as a model for chronic HCV infection? 
To date, no case has been reported of a chimpanzee that developed 
fibrosis as a result of HCV infection. It is believed that intrinsic differences in 
IFN pathways may be, at least partly, responsible for this difference. It is 
therefore that chimpanzees are not the favorable animal model to study HCV-
related pathogenesis.  
It is tempting to draw a comparison with HIV infection in chimpanzees. 
Although chimpanzees can be infected with HIV, they do not develop AIDS. 
Recent reports however demonstrated that chimpanzees show signs of 
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immune activation comparable to what is found in HIV infected humans.  
In contrast to HCV, the origin of HIV is known. Via several cross-species 
transmissions, the simian variant of HIV, SIV, has adapted, and is now able to 
infect humans. The origin of HCV is currently not known 134. Yet, HCV-
homologues have been isolated from horses and possibly dogs 135, 136 but 
clinical manifestations are very different from HCV infections in humans. In 
addition, equidistant hepaciviruses have been described in rodent species 137. 
So far, only one HCV-like virus was isolated from a non-human primate. GBV-
B was first described in a laboratory-housed new world monkey, but the 
ultimate origin of this virus unknown 134, 138. Still, GBV-B is the only other 
hepacivirus that is known to induce immune-mediated pathology in the liver of 
a non-human primate. Persistent GBV-B infection is rare in a laboratory setting 
139, 140.  
To date, chimpanzees are still the only animal species in which persistent 
HCV infection can be studied. As discussed in detail in previous sections of 
this introduction, adaptive immune responses have been widely studied in 
order to dissect the differential immune responses between viral clearance and 
persistence. Although chimpanzees do not develop hepatic fibrosis, HCV 
infection in chimpanzees models non-progressive HCV infection in humans. 
Therefore, studying the consequences of chronic HCV infection in 
chimpanzees may contribute to improved understanding of HCV-induced 
disease and provide new insights necessary to develop and optimize 
therapeutic strategies.  
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ABSTRACT 
 
Broad T- and B-cell responses to multiple Hepatitis C Virus (HCV) 
antigens are observed early in individuals who control or clear HCV infection. 
The prevailing hypothesis has been that similar immune responses induced 
by prophylactic immunization would reduce acute virus replication and protect 
exposed individuals from chronic infection. Here we demonstrate that 
immunization of naïve chimpanzees with a multi-component HCV vaccine 
induced robust HCV-specific immune responses, and that all vaccinees 
exposed to heterologous chimpanzee-adapted HCV 1b J4 significantly 
reduced viral RNA in serum by 84%, and in liver by 99% as compared to 
controls (P=0.024 and 0.028 respectively). However, despite control of HCV in 
plasma and liver in the acute period, in the chronic phase three out of four 
vaccinated animals developed persistent infection.  
 
Analysis of expression levels of proinflammatory cytokines in serial 
hepatic biopsies failed to reveal an association with vaccine outcome. 
However, expression of IDO, CTLA-4 1 and PD-1 levels in liver correlated with 
clearance or chronicity. In conclusion, despite early control of virus load a 
virus associated tolerogenic-like state can develop in certain individuals 
independent of vaccination history. 
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INTRODUCTION  
 
Hepatitis C virus (HCV) is the major cause of chronic liver infection 
leading to liver cirrhosis, with an increased risk of hepatocellular carcinoma 2. 
Vaccines for the prevention of new HCV infections, or therapeutic 
immunization to facilitate viral clearance in the more than 170 million chronic 
carriers worldwide, would be of tremendous public health benefit 3. Following 
a period of acute viremia and elevated serum ALT activity, approximately 70% 
of infected individuals develop persistent HCV infection leading to a slowly 
progressive chronic hepatitis with the subsequent sequelae 4. The specific 
events leading to persistent HCV infection remain unclear, and it is apparent 
that there is a complex interaction between virus and host, in which both 
adaptive 5-11 and innate 12 responses 13 have been implicated, both influenced 
by the potentially tolerogenic liver environment 4, 14-16. Analysis of peripheral 
blood samples and, where possible, of liver biopsies from both humans and 
chimpanzees has revealed immune correlates of viral clearance implicating an 
important role for non structural protein 3 (NS3)-specific cellular immune 
responses in the control and clearance of HCV infection 6, 14, 17, 18. As 
prospective vaccine targets in addition to NS3, the more conserved core 
antigen, and the envelope glycoproteins E1 and E2 are potentially important, 
not only for protective T-cell immunity induced by the former 18-20, but also 
antibody responses against the envelope antigens 20-22, which may have 
neutralizing capacities able to control HCV viral loads as demonstrated 
recently in chimpanzees 11.  
Here we test the hypothesis that vaccine induced rigorous and multi-
specific B-, CD4+ and CD8+ T-cell responses would induce the control and 
consequently the clearance of HCV infection following exposure. As potential 
immune targets we utilized NS3 in combination of these three additional 
structural antigens in an HCV DNA prime, pox-virus boost vaccine strategy 
aimed at maximizing the breadth of adaptive B and T-cell responses. 
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MATERIALS & METHODS 
 
Animals.  
Six naïve mature chimpanzees (Pan troglodytes) were housed under 
conditions for optimal social and health care 23. All vaccine trial procedures 
were critically assessed for ethical care and use in accordance with 
international guidelines. Blood sampling and liver biopsies were performed as 
previously described 18. Body weight, temperature, hematology and 
biochemistry clinical values were monitored at regular monthly to bimonthly 
intervals. 
 
HCV vaccine vectors. 
Two DNA plasmids expressing the core-E1-E2 and NS3 of the HCV 
genotype 1b, J4 strain 24 were used for the priming immunizations. The NS3 
encoding plasmid was described previously 25. The CoreE1-E2 (aa 1-746) 
gene sequence was inserted into the gWiz plasmid (Gene Therapy System 
INC, San Diego) to create pgWizCE1E2 25. As the immunogenicity of NS3-4 
encoding DNA plasmids in primates was found to be of no additional benefit 
over the NS3 DNA 26 and unpublished data, the NS3 encoding DNA plasmid was 
selected. The empty plasmid, pgWiz, was used to immunize control animals. 
Recombinant  Modified Vaccinia Ankara (MVA) expressing core-E1-E2 
and NS3 gene sequences were constructed by transient host range selection 
27-29 using the plasmids pCMV-C980 and pCMV-N-729-3010, encoding for 
HCV-1b 24 structural (aa 1-830) and NS3 (aa 1028-1658) proteins. 
Recombinant viruses were amplified and purified by ultracentrifugation 
through sucrose 29. Non-recombinant MVA was used to immunize control 
animals. 
 
Peptides and recombinant proteins.  
Fifteen-mer peptides with overlaps of 7 amino acids covering the core, 
E1, E2 and NS3 sequences of genotype 1b, J4 strain 24 were purchased from 
Clonestar Biotech (Brno, Czech Republic). The peptides covering NS4 and 
NS5 proteins were 15-mers with 5 overlap, or 20-mer with 10 overlap for the 
aa positions 1875 to 2454, and were purchased from EMC microcollections 
GmbH (Tuebingen, Germany). Core polypeptide (aa 1-120 derived from HCV 
genotype 1a 30) fused to a His-tag was expressed in E. coli strain BL21 (DE3), 
and purified under denaturing conditions on a Ni-NTA agarose column 
(Qiagen). Sequences of NS3 helicase (aa 1192-1457), E1 (aa 192-326), and 
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E2 (aa 384-673) were derived from the HCV-1b strain. His-tagged NS3 was 
expressed in E. coli JM109 and purified on a Ni-NTA column. E1 and E2, 
deleted for their transmembrane domain, were cloned into pT-alpha vector.  
After transfection of CHO DHFR- cells, E1 or E2 were purified from 
supernatant on Ni-NTA agarose column. Analysis of the eluted protein 
fractions was performed by SDS-PAGE and Coomassie blue staining.  
 
Immunization and HCV exposure.  
The animals were immunized at weeks 0 and 6 with DNA plasmids 
encoding core-E1-E2 (left arm) and NS3 (right arm) or pgWIZ (both arms) at a 
dose of 2 mg per inoculum, equally divided intramuscularly and intradermally. 
Booster immunizations were given at weeks 14 and 20 with MVA encoding 
core-E1-E2 and NS3 or wildtype (1x109 pfu per inoculum, at the 
corresponding locations). At week 28, eight weeks following the last 
immunization, all animals were challenged intravenously with 25 CID50 of in 
vivo titrated HCV 1b J4 (generously provided by Robert H. Purcell, NIAID, 
NIH, Bethesda, MD), diluted in autologous pre-immune plasma. The vaccine 
and challenge HCV strains were both genotype 1b, differing in approximately 
5 % of total amino acids. 
 
Humoral immune responses.  
Anti-HCV antibody responses in sera were measured using microplate 
wells coated with HCV core (0.5 mg/ml), E1 (4 µg/ml), E2 (1 µg/ml) or NS3-
helicase proteins (0.5 mg/ml). ELISA was performed as described previously 
(Komurian-Pradel et al., in press). The capacity of the chimpanzee sera to 
neutralize HCV was analyzed using HCV pseudo-particles in infection assays 
on HuH-7 target cells as previously described 31. HCV pseudoparticles were 
generated as previously described using expression vectors encoding the viral 
components including E1E2 glycoproteins of strain CG1b 32. Control 
neutralizations were performed using pseudo-particles generated with 
glycoproteins derived from the feline endogenous retrovirus RD114 
(RD114pp). 
 
Cellular immune responses.  
HCV-specific lymphoproliferation was determined with peripheral blood 
mononuclear cells (PBMC) as described previously 18. Quantification of 
specific cytokine secreting cells was performed using IFNγ, interleukin 2 (IL-2) 
and interleukin 4 (IL-4) enzyme-linked immunospot (ELISPOT) assays 
according to the manufacturer’s instructions (U-Cytech, Utrecht, Netherlands) 
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and as described previously 18, using the core, E2 and NS3 recombinant 
proteins, and peptide pools covering E1 and NS3. Assays were performed in 
triplicate. An analysis of variance was performed on the log10-transformed 
data for each chimpanzee at each time-point. Means of antigen-stimulated 
wells were compared to the medium-alone wells using a Studentized range 
test. ICS was performed as described previously 33 by stimulating PBMCs 
(5x106/ml) with either Con-A, peptide pools (5 µg/ml of each peptide) or 
medium alone, and staining with FITC labeled anti-CD3 and PerCP labeled 
anti-CD8, PE labeled anti-IL-2 and APC labeled anti-IFNγ mAb (BD 
Pharmingen), allowing proper discrimination between CD3+ CD8+ responding 
cells from all other CD3+ cells The data obtained from the ICS assay were 
analyzed by using a test for differences between ratios, comparing the 
number of cytokine positive cells in the presence of the HCV antigen to the 
amount of cytokine positive cells in the medium control, with a two tailed test 
and alpha = 0.05. Only results with statistical significance are shown. 
 
Virus quantification and sequencing.  
For serum samples, HCV 5'NTR sequences were detected in a non-
quantitative nested real time polymerase chain reaction (RT-PCR) essentially 
as described by Krajden et al. 34. Independently, in another laboratory, all 
serum samples were quantified blindly for HCV RNA: RNA was extracted with 
the Nucleospin kit (Macherey Nagel) and eluted in RNAase free water. Sera 
were tested for a quantitative HCV RNA by real-time polymerase chain 
reaction (PCR) of the 5’ HCV non-coding region 35, 36. In addition, several 
serum samples were also blindly quantified for HCV RNA in a third laboratory, 
using the COBAS AMPLICORTM HCV MONITOR test (Roche Molecular 
Diagnostics) (data not shown). For liver biopsies, frozen tissue was disrupted 
and RNA extracted with the High Pure RNA Tissue kit (Roche). HCV RNA-
positive and -negative strand quantification in liver biopsies was carried out 
blindly by real-time PCR using molecular beacon detection 37. The NS3 region 
was targeted for amplification by nested-PCR. PCR products were directly 
sequenced by using the BigDye Terminator v1.1 cycle sequencing kit (Applied 
Biosystem) and ABI PRISM 3100 genetic analyzer (PE/Applied Biosystem). 
Sequence analysis was carried out with Vector NTI suite (Invitrogen). 
Quantification of expression of TGF-β, IFN-α, CD4, CD8, IL-10, IL-5, 
Interferon (IFN)γ, TNFα and CCR7 from liver tissue was performed by real-
time RT-PCR. RNA was extracted from the liver biopsies using the Stratagene 
Absolutely RNA RT-PCR miniprep kit. Real-time PCR was performed in SYBR 
Green PCR master mix (Applied Biosystems) containing human cDNA for 
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positive controls, for 40 cycles using an ABI 7700 Prism. Expression of PD-1, 
Foxp3, CTLA-4, IDO and Cox2 mRNA in liver was quantified as described 1. 
 
Statistical analysis.  
To compare the serum and liver HCV RNA in the four vaccinated 
versus the two control animal, two-tailed Student’s t-tests were performed on 
log10-transformed data to ensure normality, with alpha = 0.05, and P values 
calculated by exact methods, and given to two significant figures. When a 
sample was negative, a value of 1 (serum HCV RNA) or the sensitivity of the 
assay (liver HCV RNA) was assigned for facilitating data analysis. 
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RESULTS 
 
Induction of HCV-specific Th1 and Th2-cytokine responses 
DNA prime – MVA boost immunization induced strong Th1-cytokine 
responses against multiple antigens in all four vaccinated animals as 
determined by ELISPOT (Figure 1A-D). As expected, DNA priming induced 
low to undetectable HCV antigen specific responses, not exceeding 73 
cytokine-producing cells / 106 PBMCs. However, strong immune responses 
were induced after the first MVA boost immunization, reaching 2368 IFNγ 
producing cells / 106 PBMCs (Vac2), and 1250 IL-2 producing cells / 106 
PBMCs (Vac3). The IFNγ responses were 2 to 4 times higher than the IL-2 in 
Vac1, 2 and 3, while Vac4 elicited virtually no IL-2 responses. The analysis of  
individual responses to each vaccine antigen after the course of immunization 
showed that the IFNγ responses targeted all four vaccine antigens in each 
vaccinee, NS3 and E1 being consistently high, while strong IL-2 response 
were observed only against NS3 (Figure 1G).  
 
 
 
 
 
 
 
 
 (A-F) Vaccination and 
challenge schedule is shown 
at the top. Arrows correspond 
to the time-points of each 
immunization and to the 
HCV 1b J4 challenge. Shaded 
areas represent time-points 
from the challenge date 
onwards. Total response was 
calculated by summing 
responses against each HCV 
antigen (core recombinant 
protein, E1 peptide pool, E2 
and NS3 recombinant 
proteins). (G and H) 
Individual HCV-specific 
cytokine responses to the four 
vaccine antigens:  (G) prior to 
challenge (weeks 22-28), and 
(H) post HCV exposure 
(weeks 2-12 post exposure, 
acute phase).  The exact time 
points at which high 
responses were reached to 
each antigen could differ 
from 2 to 6 weeks between 
animals, therefore the highest 
response for each animal and 
each antigen over the 
indicated period is displayed. 
Figure 1; Time course and magnitude of HCV-specific IFNγ  and IL-2 T-cell responses 
by ELISPOT during immunization and after HCV challenge.  
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The induction of Th-2 type T-cell responses was assessed by 
measuring the IL-4 production in ELISPOT assays. Strong IL-4 responses 
were induced in Vac1, 2 and 3, ranging from 1115 (Vac1) to 2267 (Vac3) IL-4 
producing cells /106 PBMCs after one MVA administration (Figure 2A-D). In 
Vac4 however, the IL-4 response was lower, reaching only 473 IL-4 producing 
cells / 106 PBMCs after the first MVA injection, and was not sustained. Similar 
to the IL-2 responses, the IL-4 responses targeted mainly NS3, with 58 to 568 
IL-4 producing cells / 106 PBMCs prior to HCV exposure (Figure 2G). 
We also assessed the proliferative capacity of the HCV-specific T-cell 
responses (Figure 3). All vaccines elicited HCV-specific lymphoproliferative 
responses after DNA and MVA administration, Vac2 eliciting the highest 
response (Figure 3A-D). However, the responses observed in Vac3 and Vac4 
were transient, suggesting that the vaccine elicited poor T-cell memory in 
these two vaccinees. The antigen targeted by the vaccine was predominantly 
NS3 in all four animals (Figure 3G). 
 
Figure 2; Time course and 
magnitude of HCV-specific IL-
4 T-cell responses by 
ELISPOT during 
immunization and after HCV 
challenge. 
(A-F) The vaccination and 
challenge schedule is shown at 
the top. Arrows correspond to 
the time-points of each 
immunization and to the HCV 1b 
J4 challenge. Shaded areas 
represent time-points from the 
challenge date onwards. Total 
response was calculated by 
summing responses against each 
HCV antigen (G and H). 
Individual HCV-specific IL-4 
responses to the four vaccine 
antigens: (G) prior to 
challenge(weeks 22-28), and (H) 
post HCV exposure (weeks 2-
12). The exact time points at 
which high responses were 
reached to each antigen could 
differ from 2 to 6 weeks between 
animals, therefore the highest 
response for each animal and 
each antigen over the indicated 
period is displayed 
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Induction of HCV-specific CD8 T-cell responses 
The production of IFNγ in the ELISPOT assay to specific HCV with 
peptide pools provided first indication of the presence of HCV-specific CD8+ T 
cells. Our results showed that three out of four vaccinees had elicited strong 
NS3 peptide-specific IFNγ responses at two weeks after the first MVA 
injection, reaching up to 1785 IFNγ producing cells / 106 PBMCs in Vac3, 
while the IFNγ production in response to E1 peptides remained modest 
(Figure 4A-C). Only Vac4 elicited a poor IFNγ response to the E1 and NS3 
peptides (Figure 4D). The presence of CD8+ T-cell responses was confirmed 
using ICS with overlapping peptide pools covering the four antigens encoded 
in the vaccine. At week 22, CD8+ IFNγ responses to NS3 were confirmed in 
Vac1 and Vac3, reaching 0.16% of CD8+ cells in Vac1 (Figure 4G). This 
represented 323 IFNγ producing CD8+ cells / 106 lymphocytes, directly 
suggesting that the marked IFNγ production in the ELISPOT assay was 
largely generated by CD4+ T-cells. 
 
 
 
Figure 3; Time course and 
magnitude of HCV-specific 
lymphoproliferative T-cell 
responses during 
immunization and after HCV 
challenge.  
(A-F) The vaccination and 
challenge schedule is shown at 
the top. Arrows correspond to 
the time-points of each 
immunization and to the HCV 1b 
J4 challenge. Shaded areas 
represent time-points from the 
challenge date onwards. Total 
response was calculated by 
summing responses against each 
HCV antigen (G and H). 
Individual HCV-specific 
lymphoproliferation to the four 
vaccine antigens: (G) prior to 
challenge (weeks 22-28), and (H) 
post HCV exposure (weeks 2-
12). The exact time points at 
which high responses were 
reached to each antigen could 
differ from 2 to 6 weeks between 
animals, therefore the highest 
response for each animal and 
each antigen over the indicated 
period is displayed 
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These results showed that all vaccinees elicited consistent multi-
antigen and multi-functional specific T-cell responses as indicated by high 
numbers of cytokine producing cells, with a cytokine bias indicative of Th0-like 
responses, predominantly focused on NS3. 
 
 
Vaccine-induced HCV-specific B-cell responses  
The B-cell responses were analyzed by ELISA and by neutralization 
assays. The DNA prime alone was a poor inducer of antibody responses, but 
the prime-boost combination elicited high HCV-specific antibody titers in all 
four animals, peaking between 1,300 and 64,100 after the first MVA 
administration, but with no further increase after the second MVA 
immunization (Figure 5A). Although most of the antibody responses targeted 
as desired the envelope proteins E1 and E2 before (Figure 5B), or after 
challenge (Figure 5C), no neutralizing activity was detected in an HCV 1b 
pseudoparticle assay, either prior to, or after HCV challenge (data not shown). 
 
Figure 4; Time course and 
magnitude of E1 and NS3 peptide 
pool-specific IFN-γ  T-cell responses 
by ELISPOT and ICS during 
immunization and after HCV 
challenge.  
(A-F) The vaccination and challenge 
schedule is shown at the top. Arrows 
correspond to the time-points of each 
immunization and to the HCV 1b J4 
challenge. Shaded areas represent 
time-points from the challenge date 
onwards. The response to E1 was 
obtained by using one peptide pool 
covering the E1 sequence, and the 
total NS3 response was calculated by 
summing responses against the two 
peptide pools covering aa 1028 to 
1346 and aa 1340 to 1659 respectively 
(G and H). The individual HCV 
peptide-specific percentages of IFN-γ+, 
CD8+ responses were obtained by 
intracellular cytokine staining at the 
indicated time-points: (G) prior to 
challenge (week 22), and (H) after 
HCV exposure (week 34). 
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Vaccine-induced control of early virus load 
Eight weeks following the last immunization, all animals were 
challenged with HCV 1b J4. Over the first three months of follow up, the two 
vector control chimpanzees (Ctrl1 and Ctrl2) developed HCV viremia with 
peaks of serum HCV RNA of 778,125 and 766,000 copies / ml respectively 
(Figure 6A and B). Positive strand HCV RNA was detected in the liver (8,990 
and 3,550 copies / µg of total RNA), as well as minus-strand RNA, with 
positive / minus strand ratios of 1.4:1 and 2.7:1. In contrast to the control 
animals, all immunized animals maintained markedly lower virus loads in 
serum during the acute phase, as observed by the 74% reduction of peak 
viremia (P=0.030, peaks of 314,500 in Vac1, 74,775 in Vac2, 307,375 in Vac3 
and 242,250 copies/ml in Vac4, Figure 7A), and the 84% reduction in total 
serum viral loads during the first three months follow up (P=0.024 Figure 7B). 
Quantitation of HCV loads in the liver four weeks post exposure provided 
additional evidence that HCV replication was greatly reduced in all vaccinated 
animals. Positive HCV RNA strand production was reduced by at least 99% in 
the vaccinated group as compared to the controls (P=0.028). Moreover, HCV 
minus strand RNA was undetectable in all vaccinees (>99.7% reduction, 
 
 
Figure 5; Time course and magnitude of 
HCV-specific antibody responses during 
immunization and after HCV challenge.  
(A) The vaccination and challenge 
schedule is shown at the top. Arrows 
correspond to the time-points of each 
immunization and to the HCV 1b J4 
challenge. Shaded areas represent time-
points from the challenge date onwards. 
Total response was calculated by summing 
responses against each HCV antigen (core, 
E1, E2 and NS3). (B and C) Individual 
HCV-specific antibody titers to the four 
vaccine antigens: (B) and post HCV 
challenge (weeks 2-12) (C) are represented. 
The exact time points at which high 
responses were reached to each antigen 
could differ from 2 to 6 weeks between 
animals, therefore the highest response for 
each animal and each antigen over the 
indicated period is displayed 
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P=0.0003, Figure 6). These results demonstrate that HCV-specific vaccine-
induced adaptive immune responses controlled and markedly limited HCV 
replication in the first three months of infection. The most striking effect was 
observed in Vac2, whose peak viremia never exceeded 74,775 RNA 
copies/ml of plasma.  
 
 
 
 
Absence of protection against chronic infection  
The impact of immunization on the control of HCV virus load was 
observed in all four vaccinees during the period of primary viremia. However, 
these effects on viremia did not extend into the chronic phase when viral 
clearance in the vaccinated animals was anticipated. Ultimately, only one 
vaccinee (Vac1) successfully cleared HCV infection (Figure 6C). In contrast 
to Vac1, the three other immunized chimpanzees failed to clear the virus in 
spite of a markedly lower peak viremia than controls. Vac3 remained HCV-
positive at most time-points during follow-up (Figure 6E). Although no viral 
RNA was detected in the plasma of the remaining two immunized animals 
(Vac2 and Vac4) between weeks 9 and 18 post exposure using the 
 
 
Figure 6. Course of infection in 
control chimpanzees. 
Ctrl1 (A) and Ctrl2 (B), and in 
vaccinated chimpanzees Vac1 (C), 
Vac2 (D), Vac3 (E) and Vac4 (F). All 
animals were challenged at week 28 
following immunization (dashed 
vertical line). The liver enzyme ALT 
levels are represented as black lines, 
left Y-axis. Quantitative HCV-RNA 
levels are shown as shaded areas, right 
Y-axis. Nested HCV RNA PCR results 
on serum are indicated above each 
graph as: PCR  : negative and ❚: 
positive. Quantification of HCV RNA 
in liver was performed prior to HCV 
exposure and at weeks 4, 12, 28, 32, 36 
and 42 post exposure. Levels of HCV 
positive strand (Liver HCV +) and 
negative strand (Liver HCV –) are 
expressed as copies / µg total RNA, 
with - meaning below detection 
A B
C D
E F
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quantitative assay (detection limit 500 copies/ml), HCV RNA could be 
detected at several time-points (Figure 6D and F). In addition, by week 20 
post HCV exposure, viral RNA could again be quantitated at several time-
points in Vac2, Vac3 and Vac4, with titers ranging from 500 to 22,302 RNA 
copies / ml of plasma. Results were confirmed by an independent quantitative 
HCV RNA assay performed on other serum aliquots (COBAS, data not 
shown). No minus strand HCV RNA was detectable in liver biopsies from all 
vaccinees taken at weeks 28, 32, 36 and 42 post exposure, but positive 
strand RNA remained present in three of the four animals (Vac2, Vac3 and 
Vac4, Figure 6A-F). Different patterns were also observed between controls 
in the acute versus the chronic 
phase. While virus loads of the 
control animals during the acute 
viremic phase were markedly 
greater than those in the 
vaccinees, this was not the case 
in the chronic phase. Of the two 
control animals, Ctrl1 remained 
persistently infected, whereas in 
Ctrl2 HCV RNA levels declined 
and became negative by all 
assays (Figure 6A and B), 
suggesting that mechanisms 
other than adaptive immune 
responses contributed to viral 
clearance. Indeed, post HCV 
exposure both control animals 
developed weak T-cell immune 
responses to HCV, which 
decreased rapidly over time 
(Figures 1, 2 and 3). Specific 
CD8+ responses could not be 
detected in Ctrl2 while Ctrl1 
elicited a CD8+ response to NS5 
pp1 (Figure 4H). Immune 
responses induced by immunization were predominantly directed to NS3 and 
were associated with early control of infection in all four vaccinees, though 
subsequently only transient control was achieved in three animals. The animal 
that sustained complete viral control and clearance, Vac1, did generate multi-
 
 
 
 
 
 
Figure 7. Differences in virus loads in control 
versus vaccinated animals based on two 
different parameters 
A) a 74% reduction of acute phase peak viremia 
is observed when individual peak virus 
concentrations are compared, left two bars 
represent values in unvaccinated controls, right, 
bars corresponding to the four vaccinated 
animals. B) compiled area under the curve 
reveals a reduction of 84% in virus load in the 
four vaccinated animals. 
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functional T-cell responses (IFNγ and IL-2 and IL-4) to multiple HCV antigens. 
However, these were not necessarily of greater magnitude prior to, nor 
following HCV exposure compared to the other three vaccinees (Figures 1, 2 
and 3). However, Vac1 did elicit stronger CD8+ responses to NS3 prior to 
challenge (0.19% of CD8+ lymphocytes). Additionally, this animal mounted a 
strong CD8+ response to E2, peaking at 1.36% of CD8+ cells six weeks post 
exposure, (Figure 4H). These responses eventually decreased in Vac1 over 
time indicative of successful clearance, while Vac2 and Vac3 subsequently 
developed detectable NS3-specific CD8+ responses (from 0.45 to 0.77% of 
IFNγ secreting CD8+ T cells, Figure 4H) that were maintained up to the end of 
the follow up (data not shown). 
 
To investigate underlying causes of the discordance between the 
vaccine induced control in the acute phase, to the unpredicted causes of 
chronic persistence, we undertook an analysis of cytokines and immune 
regulatory molecules in hepatic tissue, Comparison between animals which 
cleared HCV with those which became persistently infected revealed no 
significant differences in the expression of TGF-β, IFNα, CD4 and CD8, IL-10, 
IL-5, IFNγ, TNFα, CCR7, FoxP3, CTLA-4 and Cox2 in liver biopsies before 
and after HCV challenge (data not shown). Strikingly, despite fluctuations in 
the acute phase, by week 12 post infection a consistent correlation of higher 
PD-1 expression in hepatic tissues was observed in animals which developed 
persistent infection versus lower levels in those which resolved infection (Vac1 
and Ctl2, Figure 8). Not only was this effect observed with PD-1 but also with 
levels of expression of IDO and CTLA-4 (data not shown 1), There is a close 
interaction between CTLA-4 and IDO, given CTLA-4’s ability to stimulate IDO 
activity which  ultimately favors development of tolerogenic dendritic cells 38  
Figure 8. Expression of PD-1 in hepatic tissues over time. 
 
 
Quantitative PCR levels of PD-1 from 
longitudinal liver biopsies from each of the 
study animals, from 4 weeks prior to 
infection, to 36 weeks, post-infection. All 
four animals which became chronically 
infected (open symbols) have elevated levels 
of PD-1 from week 12 onwards. (-r- = Vac 
2, -£- = Vac 3, -¯- = Vac 4, -- = Ctrl1) in 
contrast to lower levels in animals which 
cleared HCV infection ( = Vac 1, l = Ctrl 
2). Data presented relative to actin (not 
shown) and CD4 (above) show similar 
kinetics over time.  
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DISCUSSION 
 
With world-wide estimates of more than 170 million infected humans, 
chronically carrying HCV, the potential risk of transmission is great and the 
need for a prophylactic vaccine is apparent. Here, we report on a prophylactic 
HCV vaccine study aimed at inducing immune responses capable of (i) 
reducing acute phase viral load, and (ii) subsequently preventing persistent 
infection, and thus chronic liver disease. For this study we used a 
heterologous HCV 1b J4 isolate that has previously established chronic 
infection in all 7 naïve chimpanzees in which it had been used 18, 39-41. 
Following immunization we demonstrated that robust vaccine induced immune 
responses to multiple HCV antigens were possible. Upon exposure to the 
heterologous 1b strain there was a dramatic reduction of HCV replication in 
the early phase in all vaccinated individuals in vivo. Similar results were 
observed recently with a T-cell based vaccine against a 1a challenge 8. 
However, based on the characteristics of this 1b genotype to induce a high 
prevalence of persistent infection, we were able to demonstrate that the 
transition to chronic phase HCV viremia is not directly linked to early control. 
 
Early peak viral titers are a characteristic of this inoculum, occurring 
between 1 to 2.5 weeks post exposure 18, 39, 40. It has been suggested that T-
cell responses must be sustained for weeks or months beyond the point of 
apparent control of virus replication to prevent relapse and establishment of 
persistent infection 42, 43. In the absence of data concerning HCV-specific 
immune responses of vaccinated animals that were not exposed to HCV, we 
can only speculate that the relatively rapid decline of the HCV-specific 
immune responses post-infection may be due to a specific immune 
impairment by the virus itself. Indeed, impairment of adaptive immune 
responses in the presence of HCV infection in humans has been reported at 
both the level of dendritic and T-helper cells 44-47. Recently, several studies 
have reported that T-helper dependent CD8+ T-cell effector function is 
reduced in HCV infection (reduced proliferation, perforin and IFNγ 
expression), similar to observations in HIV infected individuals 48-52. In 
addition, while strong HCV specific humoral and CD4+ T-cell responses were 
induced in all vaccinees, vaccine-induced CD8+ T-cell responses detected by 
intracellular cytokine staining were rather weak in three of the four vaccinees. 
The strongest response was observed in the vaccinee with sustained viral 
clearance. In an effort to understand potential local and limiting effects in the 
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liver we measured mRNA expression of IFNγ, IL-5, IL-10, TNFα, CCR7 and 
TGF-b in hepatic biopsies of all study animals. This panel of cytokines 
unfortunately failed to reveal any correlation with effective viral clearance or 
persistence.  
There was little or no boost of the T-cell responses in the vaccinated 
chimpanzees following the second MVA boost or challenge. Over-stimulation 
or exhaustion of T-cell responses by MVA booster immunization seems only 
likely in the case of Vac4, as in this particular animal high levels of non-HCV 
background IFNγ were induced following MVA boosting which were 
maintained until shortly before challenge.  
 
Following acute HCV infection T-cell responses became poorly 
functional particularly in individuals which became chronically infected, which 
is reminiscent of immune exhaustion. Longitudinal liver biopsies revealed 
higher PD-1 expression in relationship to actin as well as CD4 expression in 
the four animals which became chronically infected in contrast to the lower 
levels in the two animals which cleared infection. These findings are 
supported by recent observations of elevated PD-1 expression in HCV 
infected persons 53 in which PD-1/PDL-1 receptor ligand blocking was 
reported to improve function of HCV specific CD8 T-cells. Our findings of 
elevated PD-1 in hepatic tissue provide mechanistic insight into HCV 
persistence as well as possible therapeutic and vaccine strategies. Findings of 
elevated levels of IDO and CTLA-4 expression from the same biopsies 
provided additional insights into underlying mechanisms for this impaired 
immune function 1. Increased IDO provokes tolerogenic-like effects when 
induced by pro-inflammatory cytokines such as IFNγ and TNFα 1, 38, 54. Both 
lines of evidence point towards the risk of driving an over zealous IFNγ CD8+ 
T-cell response that in particular may be counter productive if directed to 
promiscuous HCV epitopes that fail to impact sufficiently on viral fitness. Such 
rigorous but largely ineffective T-cell responses  may in fact drive or 
compound a tolerogenic environment in the liver. Detailed follow-up studies 
are currently underway to characterize the conserved or promiscuous nature 
of epitope-specific CD4+ and CD8+ T-cell responses and their MHC –
restricting molecules in these animals.    
 
The data presented here clearly demonstrate the potential of HCV 
vaccine candidates to elicit host immune responses capable of controlling 
HCV 1b viremia both in plasma as well as liver in the acute phase of infection. 
While these are important proof of principle findings with respect to HCV 
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vaccine development, they also point to the challenges ahead. Identifying 
conserved vaccine targets for CTL based vaccines that will provide efficacy in 
a large outbred population is a tall order. This is underscored by a cluster of 
recent reports 5, 9, 10 highlighting the potential for CTL escape by HCV in 
infected human cohorts 55. These data, together with growing evidence of 
HCV induced tolerance in hepatic sites provides new insight into the 
challenges, as well as potential strategies, for the induction of effective 
immunity to HCV. 
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ABSTRACT 
 
A single correlate of effective vaccine protection against chronic HCV 
infection has yet to be defined. In this study, we analyzed T-cell responses in 
four chimpanzees, immunized with core-E1-E2-NS3 and subsequently 
infected with HCV1b. Viral clearance was observed in one animal, while the 
other three became chronically infected. In the animal that cleared infection, 
NS3-specific CD8 T-cell responses were observed to be more potent in terms 
of frequency and polyfunctionality of cytokine producing cells. Unique to this 
animal was the presence of killing-competent CD8 T-cells, specific for 
NS31258-1272, being presented by the chimpanzee MHC class I molecule Patr-
A*03:01, and a high affinity recognition of this epitope. In the animals that 
became chronically infected, T-cells were able to produce cytokines against 
the same peptide but no cytolysis could be detected.  
 
In conclusion, in the animal that was able to clear HCV infection not 
only cytokine production was observed but also cytolytic potential against 
specific MHC class I/peptide-combinations.  
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INTRODUCTION 
 
Hepatitis C virus (HCV) infection is characterized by a high propensity 
for development of chronic infection, which typically manifests as 
asymptomatic for a long period of time. However, over decades the virus 
causes subtle, but cumulatively irreversible, hepatic damage. A vaccine that 
could prevent development of persistent HCV infection would therefore be of 
great clinical benefit.  
 
The chimpanzee is the only validated animal model of HCV infection 1, 
2. The dilemma that biomedical research in non-human primates, and 
chimpanzees in particular, is inevitably associated with low animal numbers 
and limiting statistical analysis, has been discussed elsewhere 3. 
Nevertheless, we believe that results from in depth immune-profiling of 
immunized chimpanzees may provide new insights into immune mechanisms 
operating in the early phase after infection and as such is important for 
optimal vaccine development in the future.  
 
Spontaneous HCV clearance has been associated with the presence of 
broad and strong T-cell responses in both humans and chimpanzees 4-7. 
Moreover, specific memory T-cell responses often correlate with early 
clearance after HCV reinfection 8-10. These data imply that T-cell-based 
vaccines may facilitate HCV clearance, protect from viral persistence and thus 
from HCV-related disease progression. For this reason, several HCV T-cell 
vaccine-candidates have been evaluated. Some of these vaccine-strategies 
induced strong T-cell responses however, no correlation was observed 
between either the magnitude or the breadth of vaccine-induced T-cell 
responses, and viral clearance. The lytic capacity of vaccine-induced CD8 T-
cells, in the context of MHC class-I presentation was not previously evaluated 
in relation to viral clearance. 
 
Previously, we reported partial control of an HCV 1b challenge after a 
DNA prime-MVA-boost vaccine strategy, targeting HCV core, E1, E2 and NS3 
in chimpanzees 11. In these animals, neither (neutralizing) antibody responses 
nor ex vivo cytokine production or proliferative responses were uniquely 
associated with control of HCV infection. Therefore, the current study aimed to 
identify potential mechanisms of protection via detailed functional 
characterization of the T-cell responses against the most dominantly 
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recognized antigen, NS3 11.We report that the animal that cleared infection 
had a high percentage of polyfunctional cytokine producing CD4 and CD8 T-
cells against NS3-peptides. Moreover, a strong cytolytic T-cell (CTL) response 
against epitope NS31258-1272 was identified, which was uniquely presented in 
the context of the chimpanzee MHC class I molecule Patr-A*03:01. 
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MATERIALS & METHODS 
 
Ethics statement 
This retrospective study was performed on cryopreserved PBMCs, 
isolated from animals that were part of an HCV vaccine-efficacy study 11. As 
previously described, the preceding study had been performed in six purpose 
bred, naive mature chimpanzees (Pan troglodytes) that were housed at the 
Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands, 
according to international guidelines for non-human primate care and use 
(The European Council Directive 86/609/EEC, and Convention ETS 123, 
including the revised Appendix A). The Institutional Animals Care and Use 
Committee (DEC-BPRC) approved study protocols (#426) according to strict 
international ethical and scientific standards and guidelines. The qualification 
of the members of this committee, including their independence from a 
research institute, is stated in the “Wet op de Dierproeven” (1996). The 
experiment can only be performed after a positive recommendation from this 
ethical committee. Permission for projects on non-human primates is 
requested in an animal ethical committee form. This form is discussed in the 
ethical committee and, if approved, a written permission is sent to the project 
leader and a copy to the director of the BPRC, who holds licence to perform 
animal experimentation. The project was monitored by a qualified 
independent veterinarian, specifically regarding the ethical issues of the 
projects.  
The animals were in good physical health with normal biochemical and 
hematological values. The animals were socially housed in a BSL3-facility 
with spacious cages, and were provided with commercial food pellets 
supplemented with appropriate treats. Drinking water was provided ad libitum. 
Environmental enrichment was provided daily and suffering of the animals 
was alleviated wherever possible. In 2002, the European Council banned the 
use of apes for biomedical research in Europe. Yet, this was decided after the 
initiation of the original vaccine-study described by Rollier et. al.  11. For this 
reason, the European Council approved continuation of this particular study. 
The following years, all chimpanzees that were housed at the BPRC were 
outplaced to public zoos or animal sanctuaries. Before 2001, the use of 
chimpanzees for biomedical research was highly restricted and regulated, it 
was not allowed to perform terminal experiments on these animals 12.  
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Peptide-pools 
For stimulation and expansion of HCV-specific cells, two different NS3-
peptide-pools were compiled: NS3vaccine was a mixture of 15-mer peptides with 
11 amino acids overlap, covering the NS3-sequence of the vaccine 
constructs; NS3challenge was a mixture of 15-mer peptides with 11 amino acids 
overlap covering the NS3-variants observed in the inoculum. Identification of 
NS3 epitopes within NS3 was first performed via the matrix setup 13 and 
confirmed in a second assay using individual peptides (peptide-sequences 
are listed in Table S1). 
 
In vitro expansion of NS3-specific T-cell lines 
Cells isolated before infection were expanded and tested for response 
against peptide-pool NS3vaccine, whereas cells isolated after challenge were 
tested against peptide-pool NS3challenge. PBMCs isolated at the day of 
challenge were stimulated in two separate cultures with either NS3vaccine or 
NS3challenge. After thawing, PBMCs were washed and resuspended in culture 
medium, R20 (RPMI, Invitrogen, CA, USA) supplemented with 20% FCS (MP 
medicals, Solon, OH, USA), pen/strep (100 U/ml/100 µg/ml) (Invitrogen) and 
L-glutamine (2mM) (Invitrogen)) and cultured at a final density of 10 million 
cells per ml in a 24 well culture plate (Greiner Bio-One). The cultures were 
initiated in R20 containing 5 ng/ml IL-7 (Peprotech) and NS3-peptide-pool (5 
µg/ml per peptide). After overnight incubation, 1 ml R20 containing IL-7 (10 
ng/ml) and IL-2 (Proleukin Chiron, final concentration 10 IU/ml) was added per 
well. Cultures were checked daily for general condition and depending on cell 
density, fresh R20 IL-2/IL-7 was added or cultures were split. After 12 days, 
the expanded cells were collected and resuspended in fresh R20 for further 
analysis.  
 
T-cell epitope mapping 
The cytokine production profile of HCV-specific T-cell lines was 
determined by intracellular cytokine staining (ICS) after restimulation with 
NS3-peptides. For T-cell epitope mapping 0.2 x 106 expanded cells were 
either restimulated with NS3-peptide-pool (1µg/ml/peptide) or without NS3-
peptide, in medium containing co-stimulatory aCD28 and aCD49d molecules 
(2µg each, BD-Biosciences) and 5% FCS (MP-Biomedicals). After 2 hrs, 
Brefeldin A (Golgiplug 1:1000, BD-Biosciences) was added and 16 hours later 
the surface markers were stained with a panel of fluorochrome labeled 
antibodies, containing CD3-PacificBlue (clone SP-34-2, (BD-Pharmingen), 
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CD14-PE-TexasRed (clone RMO52, BeckmanCoulter), CD20-PE-TexasRed 
(clone B9E9, BeckmanCoulter), CD4-PE-Cy7 (clone SK3, BD-Pharmingen) 
and CD8-APC-H7 (clone SK1, BD-Pharmingen). Stained cells were fixed and 
permeabilized (Cytofix/Cytoperm, BD Biosciences), followed by staining of 
accumulated intracellular cytokines with IFNγ-APC (clone B27, BD 
Pharmingen), IL-2-PE (clone MQ1-17H12, BD Pharmingen) and TNFα-FITC 
(clone MAb11, BD Pharmingen). Cell staining was analyzed on a FACSAria 
(BD Bioscience) and DIVA software Version 6.1.1. 
To evaluate antigen sensitivity, T-cell lines were restimulated with 
increasing concentrations of individual peptide ranging from 0.05 to 10 µg/ml 
before intracellular cytokine production was measured. 
  
MHC-class-I genotyping 
Animals were genotyped for their MHC-class-I repertoire as previously 
described 14 (Table 1).  
 
Table 1; MHC class I genotypes of the chimpanzees. 
 
Patr class I alleles 
 Patr-A Patr-B 
Vac1 A*03:01 A*04:04 B*02:01   B*03:01 
Vac2 A*06:01   A*04:01 B*01:01   B*03:01 
Vac3 A*09:01   -  $ B*01:01   B*02:01 
Vac4 A*09:01   A*0101 B*01:01   B*16:0101 
$ Vac3 is likely to be homozygous A*0901 
 
Non-radioactive cytotoxicity assay 
NS3-peptide-specific T-cell lines were tested for their capacity to kill 
peptide-loaded target cells, using a new non-radioactive cytotoxicity assay. In 
this assay, a panel of matched Patr MHC-class-I expressing transfectants, 
either constructed in 721.221 cells  (kindly provided by C. Walker, Center for 
Vaccines and Immunity, The Ohio State University) or K562 15 were used as 
target cells. In brief, 3 x 106 MHC-matched transfected target cells were 
labeled with 1 µM CFSE (CFSElow) (Fluka) in polypropylene tubes (Greiner 
Bio-One) and another 3 x 106 MHC-matched transfected target cells, 
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expressing the same class-I molecule were labeled with 8 µM CFSE 
(CFSEhigh). Subsequently, CFSElow cells were incubated with medium alone, 
whereas, CFSEhigh target cells were pulsed with HCV-peptide (8 µg/ml) for 2 
hrs at 37°C. Excess peptide was removed by washing before mixing CFSEhigh 
and CFSElow with 1 x 106 NS3-specific expanded T-cells (ET ratio 10:1) in a 
96 well plate (Greiner Bio-One). The mixed target and effector cells were 
cocultured for 16 hrs, after which CFSE staining  was analyzed using a 
FACSAria (BD Bioscience) and DIVA software Version 6.1.1. Specific lysis 
was calculated using the following formula; 
% specific lysis = 100-(((highpeptide*lowmock)/(lowpeptide * highmock))*100) 
and lysis was considered positive when exceeding 25%. 
 
Peptide-binding assay 
A cell-based peptide-binding-competition-assay was performed as 
previously described 15. In this assay, peptides are tested for binding to 
transfected cell lines expressing chimpanzee class-I molecules, while 
competing with a biotin-labeled reference-peptide. In a 96 wells plate, 100.000 
MHC class-I transfected K562 or 721.221 cells were incubated with 500nM of 
the biotinylated-indicator-peptide (in case of A*03:01 ATALECVYK was used, 
and in case of B*01:01 LSDMHLCSI, in which C indicates the position of the 
biotin-labeled cysteine) and 0.05 to 100 nM of the peptide of interest, for 
instance p59 (NS31258-1272), LGFGAYMSK or AATLGFGAY. Peptide 
KGGLRPRAG, predicted to have no or a very low binding affinity to MHC 
class I molecules based on the incorporation of glycines on the anchor 
positions, was used as control. After overnight incubation, excess peptide was 
removed by washing and indicator-peptide bound to cells was quantified using 
the DELFIA-system and the Victor3 1420 multilabel counter (Perkin Elmer). 
The binding affinity of the indicator peptide was verified using its unlabeled 
peptide as competitor, this is referred to as standardized competitor 15. 
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RESULTS 
 
Characterization of NS3 specific CD4 and CD8 T-cell cytokine responses 
We previously reported 11 an HCV-vaccine evaluation-study in 
chimpanzees, in which 4 out of 4 immunized animals became viremic shortly 
after challenge with HCV 1b J4. However, at a later stage, animal Vac1 
cleared HCV infection while the three other animals, Vac2, Vac3 and Vac4 
became chronically infected. As reported previously, IFNγ release, ex vivo 
lymphoproliferative responses, Th1/Th2 cytokine release patterns, and HCV-
specific antibodies were comparable amongst the four animals 11. NS3 was 
the immunodominant antigen in all four animals, while the responses against 
core, E1 and E2 were not only less intense, but also largely absent in Vac1, 
the animal which was protected against chronic infection. Therefore, 
functional analysis of the cellular responses was focused on the 
immunodominant NS3 antigen 11.  
 After 12 days of culturing in the presence of a pool of NS3 peptides, T-
cell lines were restimulated with individual peptides and analyzed for 
intracellular expression of IFNγ, IL-2 and TNFα using the gating strategy 
shown in Figure1.  
Figure 1; Gating strategy for the evaluation of cytokine production by CD4 and CD8 
cells.  
Cells from Vac1, two weeks after the last vaccine boost were stimulated with NS3vaccine and 
restimulated with either NS31258-1272 (p59) or medium alone. Cells within the lymphogate 
were selected, followed by selection of the CD3 positive, CD20/CD14 negative population, 
subsequently CD4 and CD8 positive cells were selected. Expression of IFNγ as a function of 
IL-2 or TNFα was plotted.	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Cells within the lymphocyte gate that were CD3 positive, and CD14 and 
CD20 negative were selected and subsequently IL-2, IFNγ and TNFα single, 
dual or triple cytokine expression was analyzed in the CD4 and CD8 T-cell 
subsets within the T-cell lines. Cytokine expression profiles varied per peptide 
as illustrated in Figure 1. For instance, only moderate cytokine induction was 
observed after peptide specific restimulation of expanded CD4 cells in Vac1. 
In contract, strong dual IFNγ and IL-2 expression was seen in expanded CD8 
T-cells restimulated with peptide 59 (NS31258-1272), while medium alone or 
peptide 64 (IRTGVRTITTGGPIT) did not induce cytokine production. In 
comparison, in Vac2 p59 only gave a marginal cytokine induction in expanded 
CD8 T-cells, while p64 induced moderate dual IFNγ/IL-2 and IFNγ/TNFα 
cytokine production (Figure 2). Instead, expanded CD4 T-cells in Vac2, 
showed stronger response towards p59.  
 
 
 
In this manner the responses against each individual NS3 peptide was 
investigated and the results are summarized in Figure 3 in the form of heat 
maps; showing the percentages of IFNγ producing CD4 (Figure 3A) and 
IFNγ/IL-2 dual cytokine producing CD8 (Figure 3B) T-cells in all four animals 
at all time points tested. 
	  
Figure 2; Evaluation of peptide-specific IL-2, IFNγ and TNFα expression in CD4 and 
CD8 T-cells.  
A representative example of the analysis performed in Vac1 (left panel) and Vac2 (right 
panel), two weeks after the final vaccine boost, is shown. PBMC were first expanded for a 
12 day period using a pool of all NS3 peptides, restimulated with individual peptides 
(medium alone, p59 or p64) and analyzed for induction of IFNγ, IL-2 and TNFα cytokine 
expression by expanded CD4 and expanded CD8 cells, using the gating strategy described 
in Figure 1. The numbers in the quadrants, represent the percentage of positive cells 
calculated from the parent-population. 
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In general, analysis of peptide responses by dual cytokine expression 
gives a clear-cut distinction between positive and negative responses, 
because of low background responses. However, for CD4 T-cells the number 
of dual cytokine expressing cells was often rather low, making it necessary to 
consider the total number of IFNγ cytokine producing cells. The peptide 
recognition profiles shown in Figures 3A and B indicate that some regions 
within the NS3 peptide sequence, indicated by red boxes, are broadly 
recognized amongst the animals. Other peptide specific responses were more 
restricted and only gave positive responses at some time points in one to two 
animals. No unique peptide response-pattern could be discerned for Vac1 that 
could explain vaccine induced viral clearance as compared to Vac2, 3, and 4. 
Moreover, no relation was observed between the number of peptides 
recognized and the course of infection (Table 2).  
Next, the sum of the % of cytokine producing cells induced by all 156 
individual peptides was calculated for expanded CD4 and CD8 lines. This total 
frequency of peptide-specific IFNγ -producing expanded CD4 T-cells was 
comparable between Vac1 and Vac2, but somewhat lower in Vac3 and Vac4 
(Figure 3C). After the last immunization (week -4), total peptide specific CD8 
T-cell responses were higher in Vac1 as compared to the other animals  
(Figure 3D). Triple cytokine production, i.e. simultaneous expression of IFNγ, 
IL-2 and TNFα by expanded CD8 cells, was also higher in Vac1 and for 
instance observed in 12.3% of the p59-specific expanded CD8 T-cells 4 
weeks prior to HCV infection, whereas this was less than 7% in Vac2, Vac3 
and Vac4 (Figure. 3E). 
 
Table 2; Number of NS3- peptides that induce IFNγ production by CD4 T-cells 
or IL-2/IFNγ dual cytokine production by CD8 T-cells. 
 
  TOTAL PRE POST 
CD4 Vac1 34 34 11 
 Vac2 55 42 36 
 Vac3 58 51 22 
 Vac4 38 19 25 
CD8 Vac1 22 20   8 
 Vac2 22 20   6 
 Vac3 35 22 27 
 Vac4 44 27 25 
PRE, pre challenge. POST, post challenge 
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Figure 3; Heat map of NS3-peptide-specific T-cell responses in four immunized 
chimpanzees at different study time points. (A) Percentage of expanded CD4 T-cells 
producing I IFNγ upon restimulation with individual peptides, subdivided into three 
categories; i.e. low response (light green; 0.001%-0.1% specific IFNγ production), 
intermediate (green; 0.1-1% specific response), high (dark green; > 1% specific response). (B) 
Percentage of expanded CD8 T-cells showing IL-2/IFNγ double cytokine production upon 
restimulation with individual peptide, subdivided into three categories; i.e. low response (light 
blue; 0.01%-0.1% specific IFNγ production), intermediate (blue; 0.1-1% specific response), 
high (dark blue; > 1% specific response). White areas indicate where no responses were 
detected. The red boxes highlight areas within NS3 that are broadly recognized. Per animal 6 
time points of analysis are shown lined up beneath each other; -12) Two weeks following the 
1st MVA boost, cells stimulated with NS3vaccine, -4) Four weeks following 2nd MVA boost, 
cells stimulated with NS3vaccine , 0) Day of HCV infection, stimulation with NS3vaccine,  0) Day 
of HCV infection, stimulation with NS3challenge,  and 4 and 36 weeks after challenge, 
stimulation with NS3challenge. The individual peptides tested are indicated at the top of the map 
by the numbers 1 to 156. The red boxes represent broadly recognized regions within NS3.  
Total frequency (all peptide responses combined) of (C) IFNγ production by expanded CD4 
T-cells and (D) IFNγ/IL2 dual cytokine production by expanded CD8 T-cells per animal. (E) 
Frequency of p59 specific triple positive IL2/TNFα/IFNγ producing CD8 T-cells. The 
numbers on the X-axis represent the study week, relative to time of challenge. 
*Despite several attempts, frozen cells from Vac1 from 4 weeks following HCV infection did 
not respond to either NS3vaccine or NS3challenge peptide stimulation and no expansion could be 
achieved @Due to a high IFNγ background. specifiv responses could not be detected. 
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In conclusion, we observed increased number of NS3 specific cytokine 
producing expanded CD8 T-cells after the last immunization, and especially 
more triple IFNγ, IL-2 and TNFα cytokine producing cells in the animal that 
cleared the virus, relative to those animals that became chronically infected. 
 
Cytolytic capacity of NS3 p59 specific CD8 T-cells in Vac1 
Next, NS3-peptide-specific cells were evaluated for their capacity to kill 
peptide-loaded target cells. Similar to standard 51chromium release assays, T-
cells were expanded prior to analysis 6, 16. The expanded T-cells were tested 
for their lytic capacity for all individual peptides that were found to induce IL-
2/IFNγ dual expression in expanded CD8 cells (Figure 2B) and was tested 
against a panel of MHC matched target cells 15 (Table 1).  
 
Figure 4A illustrates specific killing of p59-pulsed CFSEhigh relative to 
unpulsed CFSElow Patr-A*03:01 target cells, using expanded T-cells from 
Vac1, isolated 10 weeks after HCV challenge. As a control, no difference in 
ratio of the area under the curve was observed if both the CFSEhigh and CFSE 
low Patr-A*03:01 targets were unpulsed (Figure 4C), precluding non-specific 
toxicity due to labeling with higher CFSE concentration. Killing of target cells 
was only observed for particular peptide-MHC class I combinations. As shown 
in Figures 4B and D, neither unpulsed nor p59-pulsed Patr-B*02:01 targets 
were lysed by expanded cells from Vac1. Amongst all peptides tested, i.e. 24, 
22 and 35 in Vac1, Vac2 and Vac3 respectively, highly efficient killing was 
only observed against p59 in Vac1 and only when this peptide was presented 
by Patr-A*03:01 (Figure 4E to G). Only the peptides partly overlapping with 
p59 gave some lysis, while none of the other MHC class-I-peptide-
combinations exceeded 25% of specific killing. Due to the limited number of 
cells after expansion, Vac4 could not be tested.  
 
Collectively, the data show that although stimulation with p59 can 
induce some level of cytokine production in all vaccinees, a p59-mediated 
cytolytic capacity was only observed in Vac1. 
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NS3p59(aa1258-1272) binds with high affinity to Patr-A*03:01. 
Peptide binding to MHC-class I is determined by the anchor-residues 
fitting into the B- and the F-pocket of the relevant allotype for most MHC 
class-I-molecules. Usually MHC class I molecules bind nonamer peptides, in 
which the p2-position of the peptide anchors into the B-pocket and the p9-
position of the peptide anchors into the F-pocket. Peptide 59, which was 
observed to initiate cytolysis when presented in the context of Patr-A*03:01, 
was scanned using the NetMHCpan version 2.8 prediction algorithm 17 
against the MHC class I molecules present in the studied cohort (Table 1). It is 
known that peptides that bind, or are predicted to bind to MHC class I 
molecules with an affinity < 500 nm are potential T-cell epitopes 18-20. In p59 
four potential nonamer peptides are present, AATLGFGAY, ATLGFGAYM, 
TLGFGAYMS, and LGFGAYMSK. The only combination that was predicted to 
bind with an affinity < 500 nm was LGFGAYMSK in the context of Patr-
A*03:01. A cell-based peptide binding competition assay was performed to 
test the binding-affinity of p59, and the nonamer peptides AATLGFGAY and 
LGFGAYMSK to Patr-A*03:01 and as control to Patr-B*01:01. The peptide 
binding motif of Patr-A*03:01 is defined as X(STA)XXXXXX(RK) and for  Patr-
B*01:01 as (X(ST)XXXXXX(IL) 15, 21. Figure 5 shows that all three NS3 
peptides have a high binding affinity to Patr-A*03:01, with IC50 values between 
0.03 to 0.2 µM, which is higher compared to the control peptide (IC50=8.2 µM) 
and the standardized competitor peptide of Patr-A*03:01 with IC50=1.5 µM 15. 
Figure 4; Cytolytic 
killing of CFSE-loaded 
target cells. 
(A) Specific lysis of 
NS31258-1272-pulsed Patr-
A*03:01 target cells (red 
peak) in comparison with 
unpulsed Patr-A*03:01 
target cells (yellow peak) 
by NS3-peptide-pool 
expanded PBMC from 
Vac1 isolated 10 weeks 
after HCV 1bJ4 challenge (blue peak). (B) No specific lysis of NS31258-1272-pulsed Patr-
B*02:01 target cells. (C) and (D) Control experiments showing no killing of unpulsed Patr-
A*03:01 or Patr-B*02:01 target cells. (E,F,G) Percentage of lysis for all MHC class-I-
peptide-combinations tested in Vac1, Vac2, Vac3 respectively.  
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Peptide LGFGAYMSK was found to have the highest binding affinity to Patr-
A*03:01. In contrast, only low binding affinity was observed for p59 in the 
context of Patr-B*01:01 as compared to its standardized competitor (IC50=1.0 
µM), whereas for the two nonamer peptides, no amenable regression curves 
could be drawn suggesting low or no binding affinity (not shown).  
 
 
T-cells of Vac1 respond at lower peptide concentration 
Antigen specific responses not only depend on the presentation of 
peptides by MHC class I molecules but also on the binding of the 
peptide/MHC complex to the T-cell-receptor (TCR). Therefore, we tested 
whether the response-threshold of CD4 and CD8 T-cell lines from Vac1 
differed from Vac2 and Vac3. To this end, NS3-specific expanded T-cells, 
isolated 4 weeks prior to HCV infection, were expanded from PBMCs, 
restimulated with different concentrations of NS31258-1272 ranging from 0.05 to 
10 µg/ml, and stained for intracellular IL-2 and IFNγ.. Expanded CD8 T-cells 
from Vac1 were found to respond at a peptide concentration as low as 0.05 
µg/ml whereas, at least, 20 times more peptide was required for CD8 T-cells 
from Vac2 and Vac3 (Figure 6). For IFNγ production by expanded CD4 T-
cells the difference is even more striking. Here, we could hardly detect p59-
specific IFNγ producing CD4 T-cells in Vac2 and Vac3 while these cells are 
abundantly present in Vac1. 
Figure 5; Dose-inhibition curves for 
selected NS3-peptides to Patr-A*03:01 
Binding affinity of selected NS3-peptides 
to Patr-A*03:01, established by peptide 
binding competition assay. Patr-A*0301 
cells were incubated with increasing 
concentrations of NS3 p59 (top left), 
LGFGAYMSK (LGF, top right), 
AATLGFGAY (AAT, bottom left), or 
KGGLRPRAG (control, bottom right) in 
the presence of biotin-labeled indicator 
peptide.  
Binding of indicator peptide was quantified by incubation with europium labeled 
streptavidin. Indicated is reduction in percentage of europium positive cells relative to cells 
incubated with indicator-peptide only. The indicated IC50 values (µM) are derived from the 
regression curves of three independent experiments in the case of p59, LGF and AAT, and 
of two individual experiments in the case of KGG. The IC50 values were estimated using 
non-linear least-squares regression with the “R” platform for statistical computing. 
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Figure 6; Antigen sensitivity of p59 specific cytokine induction. 
NS3-expanded T-cells from Vac1, Vac2 and Vac3, from 4 weeks prior to HCV challenge, 
were restimulated with a concentration range of p59 and evaluated for induction of IL-2/ 
IFNγ expressing CD8 T-cells (left graph) and IFNγ expressing CD4 T-cells (right graph). 
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DISCUSSION 
 
The chimpanzee is the closest living relative of man and the only 
validated animal model for HCV infection. The evolutionary proximity of both 
species is reflected by close genetic and immunological similarity. For these 
reasons the chimpanzee provides an exquisite animal model, in which 
immune responses against HCV vaccines and the effect on deliberate 
infection can be investigated in an experimental setting 2. Here, we report of 
an in depth profiling of CD4 and CD8 T-cell responses in four chimpanzees, 
which were immunized with an experimental vaccine for HCV and 
subsequently challenged with HCV 1b J4 11. 
 
While all four animals became infected, only the Patr-A*03:01 positive 
animal was able to clear HCV infection. Detailed mapping of CD4 and CD8 T-
cell cytokine responses, and the analysis of their cytolytic potential, revealed 
that expanded T-cells of the vaccinee which effectively cleared HCV infection 
displayed: a) a higher frequency of peptide-specific IL-2/IFNγ dual cytokine 
producing CD8 T-cells; b) peptide-specific TNFα production in CD8 T-cells; c) 
cytolytic capacity against peptide-loaded target cells; d) cytokine induction at a 
low antigen concentration for the cytolysis-inducing peptide. Remarkably, the 
cytolysis-inducing peptide p59 was found to bind strongly to Patr-A*03:01, 
which was only present in Vac1. Using the NetMHCpan algorithm, it was 
predicted that peptide LGFGAYMSK, one of the nonamer peptides present in 
the 15-mer p59, would show the strongest binding to Patr-A*03:01. Peptide 
LGFGAYMSK was also predicted to bind to the MHC class I molecules Patr-
A*01:01, A*04:01, A*04:04, and A*09:01, present in all of the studied animals, 
but only with intermediate affinity between 0.9 and 5 µM. These data are in 
agreement with the differences in cytokine responses and cytolyses reported 
in expanded T-cells here and could indicate a particular affinity threshold is 
necessary for a peptide to induce adequate immune responses for combating 
HCV. The strong binding of the 15-mer p59 to Patr-A*03:01 is somewhat 
unexpected, as generally nonamer peptides bind to MHC class I molecules. 
Nonetheless, in humans it has been shown that particular MHC class I 
molecules are capable of binding longer peptides with bulged structures 22, 23. 
Stimulation assays would give information about the biological relevance of 
the binding experiments. However, the limited number of cells stored from 
these animals, preclude performing such assays. 
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Unlike ex vivo detection of CTL in humans, detection of these cells in 
chimpanzees can often only be achieved after amplification of antigen specific 
responses 6, 16. Obviously, in vitro expansion of T-cells from frozen PBMC has 
its limitations. Antigen presenting cells may be affected by the 
freezing/thawing process resulting in –partly hampered- antigen presentation. 
Furthermore, the addition of cytokines and peptides may skew the immune 
system differently as compared to the in vivo situation.  
 
To determine the degranulating capacity of T-cells, CD107a stainings 
were performed on T-cell lines. However, the results of these assays were 
unclear and no conclusion could be drawn from it, basically because of the 
lack of a proper negative control.  
 
Unlike in the intracellular cytokine staining assays, where the difference 
between cells restimulated with peptide or medium alone was very clear, no 
clear difference could be observed when CD107a was used. Probably the 
expansion-protocol used here does agree with antigen specific CD107a 
staining. Unfortunately, the number of stored cells from these animals is 
limited and assays like this require too many cells to repeat the assays. 
 And although we cannot exclude that upon further amplification of antigen 
specific responses, CTL responses might also be detectable in the other 
animals, our data suggest that they are of lower magnitude.  
 
To study the possibility of viral escape from immune pressure as a 
cause of development of chronicity in Vac2, Vac3 and Vac4, analysis of viral 
sequences was performed and compared with the inoculum sequence (data 
not shown). Only a limited number of amino acid substitutions were detected 
in the areas that overlap with cytokine-inducing peptides. There was however 
no evidence for mutational escape in the immunodominant p59 in any of the 
animals. 
 
This study highlights a potential role for CD8 mediated cytolytic 
responses as a discriminatory factor between viral clearance and the 
development of chronic infection in HCV vaccinated subjects and underscores 
that this parameter is to be considered as an important immunological readout 
in future vaccine trials. Indeed, studying peptide binding and CD8 cytolytic 
responses could complement the other contributing immune mechanisms 
previously described 11, 24, 25.  
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It should be noted that the reported data were obtained from peripheral 
blood and not from the site of HCV-induced inflammation, the liver. For ethical 
reasons and animal welfare, the number of liver biopsies taken during the 
study, was limited and not sufficient for the comprehensive analysis as 
presented in this manuscript. Nevertheless, a direct comparison of CD8 T-cell 
function between liver and peripheral blood in chimpanzees during HCV 
infection, showed in essence that the cells in the circulation reflect the 
situation in the liver 26, 27.  
 
The data presented here, are in line with the finding that self-limiting 
HCV infection in humans is associated with the presence of HLA-B*57 and 
HLA-B*27 restricted CD8 T-cell responses 28, 29. Chimpanzee Patr-A*03:01 
and Patr-B*01:01 have almost identical B-pocket residues as compared to 
HLA-B*57. Moreover, peptide binding studies have shown that both Patr-
molecules may potentially bind HLA-B*57 or HLA-B*27 15 
 
In conclusion, we observed that in contrast to peptide-specific cytokine 
production, the induction of an effective CD8 T-cell effector function elicited in 
the context of peptide presentation by appropriate class-I molecules appeared 
to be associated with clearance of infection. 
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ABSTRACT.  
 
 Accumulating evidence indicates that neutralizing antibodies play an 
important role in protection from chronic Hepatitis C Virus (HCV) infection. 
Efforts to elicit such responses by immunization with intact heterodimeric 
E1E2 envelope proteins have met with limited success. To determine if 
antigenic sites, which are not exposed by the combined E1E2 heterodimer 
structure, are capable of eliciting neutralizing antibody responses, we 
expressed and purified each as separate recombinant proteins E1, and E2 
from which the immunodominant hypervariable region (HVR-1) was deleted. 
Immunization of chimpanzees with either E1 or E2 alone induced antigen 
specific T-helper cytokines of similar magnitude. Unexpectedly the capacity to 
neutralize HCV was observed in E1 but not in animals immunized with E2 
devoid of HVR-1. Furthermore, in vivo only E1 vaccinated animals exposed to 
the heterologous HCV-1b inoculum cleared HCV infection. 
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INTRODUCTION 
 
The Hepatitis C Virus (HCV) envelope glycoproteins, E1 and E2, are 
heterodimerically exposed on the surface of the virion and play a crucial role 
in receptor binding, viral fusion and entry of HCV 1. Combined, E1E2 
heterodimers have long been considered and evaluated as candidate HCV 
vaccine antigens, primarily, but not exclusively for the induction of neutralizing 
antibodies 2. Due to the different functions of the E1E2 heterodimer it is safe 
to assume that it will undergo conformational changes during the virus life 
cycle 3. The E2 molecule in this complex is known to bind specifically to cell-
surface molecules such as CD81, SR-B1, Claudin-1 and others 1, 4. However, 
both in E1 and E2 structural homologies to fusion mediating proteins of 
related viral families have been described 5. E2 also possesses a major 
determinant of isolate specific neutralizing antibodies located near its N-
terminus called the hypervariable region (HVR-1). However, due to its 
immunodominance and the consequential selective pressure on this region, it 
rapidly accumulates non-synonymous mutations making it hypervariable 
which is an undesirable attribute for a candidate vaccine antigen. In contrast, 
the role of E1 in HCV infection and immunity is still unclear, yet several 
antibodies directed against E1 were found to prevent cell entry 6, 7.  
 
We rationalized that by removing the HVR-1 from E2, and separating 
the two components of the heterodimer, that novel structural features might be 
revealed, creating new targets for the induction of broad neutralizing 
antibodies. To test this hypothesis, chimpanzees were immunized with either 
recombinant E2 protein with the HVR-1 deleted, or the intact recombinant E1 
protein alone. To determine if the vaccine induced antibody responses were 
sufficient to protect from persistent HCV infection, all animals were exposed to 
a 1b inoculum, which has the propensity to cause chronic infection. By 18 
weeks the two E1 immunized animals had cleared HCV infection, while RNA 
viremia persisted in the two E2 immunized animals and the control animal. 
Vaccine induced protection from persistent HCV infection correlated with E1 
induced neutralizing antibodies, demonstrating a previously unrecognized role 
for E1 subunit in immunization. 
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MATERIALS & METHODS 
 
Animals 
This study was critically reviewed and approved and undertaken by the 
institute’s animal ethical committee and performed in accordance with Dutch 
law and international guidelines for the use of animals in research (BPRC 
IACUC ID #253) in consultation and prior to amended Dutch legislation. Five 
mature, captive bred chimpanzees (Pan troglodytes verus), naive for 
retroviruses and hepatitis viruses, were socially housed and monitored 
multiple times per day by experienced veterinary staff (BPRC, Rijswijk, The 
Netherlands).  
Throughout the study, animals were checked twice daily for general 
behavior, appetite and stool consistency. Body weight, rectal temperature and 
hematology and clinical chemistry were assessed during each sedation for 
immunization, blood collection or liver biopsy. Serum and peripheral blood 
mononuclear cells (PBMCs) were isolated from heparinized blood samples 
collected using aseptic techniques as previously described 8.  
 
HCV immunogens and assay antigens 
Recombinant HCV envelope proteins E1s (aa192 to aa326) and 
E2∆HVR-1 (E2 aa412 to aa715 with deletion of HVR-1 aa384 to aa411) were 
used for immunizations and in the cellular assays. Both proteins were derived 
from the European HCV 1b BE11 strain and were expressed by recombinant 
vaccinia virus transfected Vero cells, purity of all proteins was estimated to be 
>95% by SDS-PAGE 9. For immunization, E1 and E2 proteins were 
formulated with Alum (Alhydrogel, Superfos Biosector, Denmark), 1.3% 
Al(OH)3 in buffered phosphate solution and diluted with physiological saline to 
a final protein concentration of 50 µg/ml and 0.13% Al(OH)3. Although both 
the vaccine proteins as well as the challenge virus were derived from 
genotype HCV 1b, the challenge was considered heterologous since in E1 
7%, and in E2 approximately 11% of the amino acid residues were different 
between the vaccine and challenge sequence. 
 
To analyze virus-induced immune responses after challenge, HCV NS3 
(NS3 1071 to 1084 and 1181 to 1465), an E. coli fusion protein based on a 
HCV 1b isolate (BE8309), was used.  
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Experimental Design, immunizations and HCV exposure 
Chimpanzee E1-Ma and E1-Yo were immunized with 50µg E1, while 
E2-Jo and E2-Ka received 50µg E2 recombinant protein. One animal, Ctrl-Hu, 
served as a challenge control and did not receive any HCV immunogen or 
adjuvant before challenge. 
Animals were given intramuscular (I.M.) immunizations in the biceps at 
weeks 0, 3, 6, 9, 12 and 15 at a dose of 50µg protein per ml diluted Alum 
(Figure 1). At week 18, the animals were intravenously (I.V.) exposed to 100 
CID of an in vitro titrated HCV 1b inoculum J4.91’01, diluted in saline.  
 
Humoral responses 
Vaccine specific antibody titers were determined by limiting dilution 
ELISA 8 or INNO-LIA HCV (Innogenetics, Ghent , Belgium). 
HCV neutralizing capacity of longitudinal serum samples was determined 
before and during the immunization period at weeks 7 and 17 and at week 
107, which is 89 weeks following infection. The assay was performed as 
previously described 10-12 with HCVpp expressing E1 and E2 envelope 
glycoproteins of the isolates CG (J) (AF333324) and UKN1B 12.6 (AY734975)  
 
Virus quantification 
Quantification of HCV RNA in serum was monitored using Amplicor 
(Roche Diagnostics, Basel, Switzerland) 13.  
 
Cellular immune responses. 
The number of HCV specific PBMCs was determined by 
lymphoproliferation and ELISPOT assay at regular time points during the 
immunization period and after experimental HCV exposure as previously 
described 8. 
 
Analysis of  HCV E1 And E2 sequence diversity 
Viral RNA was isolated at weeks 1, 3, 6, 12, 31, 36 and 41 weeks after 
challenge for as long as the virus was detectable in serum, making use of the 
QIAamp Viral RNA Mini Spin protocol (Qiagen Benelux B.V., Venlo, The 
Netherlands). DNA synthesis and outer PCR was performed in one step using 
the Qiagen One Step RT-PCR kit (Qiagen Benelux B.v., Venlo, The 
Netherlands), followed by a conventional nested PCR. The following primer 
sets were used to sequence E1; outer primer set HCPr638 (5'CTG TCY TGY 
TTG ACC RTC CCA GC3' (nt 544 to 566 when aligned to H77) and HCPr639 
(5'CCC GTC AAC GCC GGC RAA GAG TAR C3' nt 1149 to 1125) inner 
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primer set HCPr640 (5'GTY TGA CCA YCC CAG CTT CCG CT3' nt 551 to 
573) and HCPr641 (5'TCA ACG CCG GCR AAR AGT ARC RYC AC3' nt 1145 
to 1120). To completely cover the E2 region, the following 3 primer sets were 
used, fragment I; outer primer HCPr642 (5'TGG CGC TAC TCT TTG CCG 
GCG TTG A3' nt 1121 to 1145) and HCPr643 (5'AGG CAC CTA GGT GTC 
AAC CA3' nt 1844 to 1825); inner PCR HCPr644 (5'CGG CGT TGA CGG 
GGC GAC CTA3' nt 1137 to 1157) and HCPr645 (5'CCC GAG CCA CAT TTT 
GTG TA3' nt 1820 to 1801) Fragment II; outer HCPr691 (5’GTG TGY GGY 
CCA GTG TAY TG3’ nt 1510 to 1529) and HCPr692 (5’CCA CTC YGT YGT 
RGA CAG YA3’ nt 2037 to 2018); inner HCPr693 (5’GAY GTG RTG CTY CTY 
AAC AA3’ nt 1609 to1628) and HCPr694 (5’TCC TCC AAG TYR CAR CGC 
TC3’ nt 1988 to 1969). Fragment III; outer HCPr646 (5'TGA TCT GCC CCA 
CGG ACT GC3' nt 1757 to 1776) and HCPr647 (5'TCC CGG TCC AAG GCG 
TAA GC3' nt 2459 to 2440); inner primers HCPr648 (5'ACG GAC TGC TTC 
CGG AAG CA3' nt 1768 to 1787) and HCPr649 (5'GGC GTA AGC TCG TGG 
TGG TA3' nt 2448 to 2429) 
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RESULTS 
 
Vaccine Specific Antibody Responses  
  The induction of vaccine specific antibodies in serum was determined 
by ELISA. As shown in Figure 1, all four vaccinees developed envelope 
specific antibodies with similar magnitude and kinetics, increasing following 
each immunization and peaking 14 to 17 weeks following the first 
immunization. After experimental HCV exposure at week 18, HCV specific 
antibody responses gradually declined, yet persisted at low levels until the 
end of the study. Similar declines have been noted previously by us and 
others as a frequent sequelae of HCV infection in chimpanzees. Antibody 
formation directly after experimental infection is low and often falling below the 
detection limits of standard ELISA assays 14, 15. In the control animal HCV 
specific antibodies were only observed after challenge (data not shown). 
 
Induction of HCV specific T-cell responses by immunization 
Induction of cellular immune responses against the vaccine proteins 
(E1 or E2) as well as an HCV protein not included in the vaccine (NS3) were 
assessed by lymphocyte proliferation and ELISpot analysis. As shown in 
Figure 2, both E1 immunized animals and the two E2 immunized animals 
developed vaccine- induced IL4 secreting cells (140 IL4 sfu/106 PBMCs in E1-
Ma, 44 IL4 sfu/106 in E1-Yo, 217 IL4 sfu/106 in E2-Ka and 106 IL4 sfu/106 in 
E2-Jo). Instead, the number of vaccine induced IFNγ secreting cells was 
much lower in all four animals (<10 sfu/106 PBMCs in each animal). These 
data implied a Th2-dominant immune response, which correlated with high 
vaccine induced antibody levels in serum at the time point of challenge. As 
Figure 1; Humoral responses.  
A) Vaccine specific antibody titers over time, 
i.e. E1-specific antibodies were measured in 
E1-Ma and E1-Yo, and E2-specific antibodies 
in serum from E2-Ka and E2-Jo. Time points 
of immunizations are indicated by grey arrows 
under the X-axis and the time point of 
challenge by a black arrow. The shaded area 
represents the post challenge follow up 
period. B) Evaluation of cross reactivity. 
Serum samples collected at weeks 0, 13, 14, 
15 and 16 (separate bars) were tested for 
binding to E1 and E2 with standard ELISA  
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expected only weak cellular immune responses were observed against the 
non-vaccine viral protein NS3 following HCV exposure in all 5 animals. 
 
 
 
 
 
 
 
Magnitude over time 
of IL4 and IFNγ 
cytokine responses of 
individual animals 
were measured against 
recombinant proteins 
HCV E1 (black bars), 
E2 (grey bars) and 
NS3 (white bars). 
Responses are shown 
for the two E1 protein 
immunized animals 
E1-Ma and E1-Yo, the 
two E2 protein 
immunized animals 
E2-Ka and E2-Jo and 
the naive control 
animal Ctrl-Hu. 
Immunizations were 
given at weeks 0, 3, 6, 
9, 12 and 15 followed 
by HCV exposure at 
week 18. The shaded 
area represents the 
post challenge follow 
up period. Shown are 
the numbers of antigen 
specific spot forming 
cells per million 
PBMCs minus the 
background (mean of 
triplicate medium 
controls). 
Figure 2; HCV-specific IL4 and IFNγ responses 
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Expectedly, NS3 specific responses were IFNγ biased while the 
envelope specific responses preserved their Th2-like characteristics. T-cell 
responses were further substantiated by lymphoproliferation and L-2 ELIspot 
(Figure 3). Although, E2-Jo was only immunized with recombinant E2 protein 
and not with E1, in vitro stimulation of PBMCs with E1 also induced cytokine 
production. This cross-reaction between the two envelope proteins was also 
observed in the humoral response  (Figure 1B). Serum samples collected at 
weeks 0, 13, 14, 15 and 16 from E2-Jo were found to have some reactivity 
against E1, which was low compared to the E2 binding. Neither E1 nor E2 
specific T-cell responses were observed prior to challenge in Ctrl-Hu.  
 
 
 
Magnitude over 
time of 
lymphproliferation 
and IL2 cytokine 
responses of 
individual animals 
were measured 
against 
recombinant 
proteins HCV E1 
(black bars), E2 
(grey bars) and 
NS3 (white bars). 
Responses are 
shown for the two 
E1 protein 
immunized animals 
E1-Ma and E1-Yo, 
the two E2 protein 
immunized animals 
E2-Ka and E2-Jo 
and the naive 
control animal Ctrl-
Hu. Immunizations 
were given at 
weeks 0, 3, 6, 9,  
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Figure 3; HCV-specific lymphoproliferation and IL2 responses. 
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Neutralizing capacity of vaccine-induced antibodies 
To determine if the antibodies 
induced by the vaccine proteins, E1 or 
E2, were functional in neutralizing HCV, 
pseudoparticle assays (HCVpp) were 
performed on serum obtained before and 
7, 17 and 107 weeks following initial 
immunization. The HCVpp were 
pseudotyped with E1E2 glycoproteins 
derived from strain UKN1B 12.6, which 
has a closely related amino acid 
sequence to the vaccine strain, or CG (J), 
an isolate most similar to the challenge 
inoculum 16 As a control, the glycoprotein 
from RD114, the cat endogenous virus, 
was used. Figure 4 displays the 
percentage of target cells infected by 
HCVpp, and the inhibition of infection by 
serum from vaccinees obtained at 
different time points. Comparison of the 
percentage of infection between the 
immunized animals and the control 
animal Ctrl-Hu, showed more efficient 
inhibition by sera obtained from the E1 
immunized animals than by sera from the 
E2 immunized animals. At week 7 both of 
the E1-immunized animals developed 
antibodies that strongly inhibited CG (J) 
HCVpp infection (p<0.01 Two Way 
ANOVA), while no inhibition was 
observed by sera from the two E2 
immunized animals. This CG (J) 
neutralization was also observed, but at a 
somewhat reduced level, at week 17 
during the pause between immunization 
and viral exposure. In both E1 immunized 
animals, significant neutralization 
(p<0.01) was also observed against 
Figure 4; Neutralizing 
antibodies. 
Serum samples collected 
before immunization and at 
weeks 7, 17 and 107 were 
tested for the inhibition of 
infection of Huh-7 target 
cells by HCVpp. Serum was 
tested against CG (J) and 
UKN1B 12.6 HCV isolate 
envelopes, while RD114, a 
cat endogenous virus 
derived envelope, served as 
a control. Results are 
expressed as percentage of 
infected cells Plotted in the 
graphs are the results of two 
independent assays, both 
performed in duplicate. * 
reduction of percentage of 
infected cells as compared 
to the control animal  
(p<0.01). 
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HCVpp exposing the UKN1B 12.6 envelope both at week 7 and 17. As 
expected, persistent HCV infection induced neutralizing antibodies inhibiting 
HCVpp infection with both CG (J) as well as UKN1B 12.6 isolates (week 107), 
Figure 4. Vaccine induced levels of neutralization declined in the absence of 
HCV in E1-Ma and E1-Yo  
 
Neutralizing antibody titers correlate with 
clearance of infection. 
Three weeks after the final protein 
immunization, efficacy against viral challenge 
was evaluated by intravenous exposure to 
100 CID HCV 1b J4.91’01. All four vaccinees 
and the naive control animal became acutely 
infected. A peak virus load between 1 and 5 
x105 IU ml-1 was reached 1 to 6 weeks after 
challenge in all animals except E2-Ka, where 
the peak viremia was 1 log lower (Figure 5A). 
Subsequently, the virus load decreased to 
levels between 103 and 104 IU ml-1 in the 
control and the two E2 immunized animals. 
Instead, in the two E1 immunized animals 
virus became undetectable in serum and liver 
biopsies by quantitative PCR 18 weeks after 
challenge. Furthermore, liver enzyme levels, 
ALT and γGT returned to pre-challenge 
values in these two animals (Figure 5B and 
Figure 5C). In contrast to the E1 immunized 
animals, all others remained persistently 
infected and retained slightly elevated liver 
γGT (Figure 5C) (p=0.039, two tailed 
Student’s t-test).  
 
No evidence for selective immune pressure directed against envelope 
regions 
To rule out that development of chronic infection in the E2 vaccinated 
animals was either due to an ineffective E2 induced vaccine response, or due 
to viral evolution and vaccine escape we performed longitudinal sequence 
analysis of the E1 and E2 regions of the predominant viral variants in plasma. 
Furthermore we compared these sequences to the challenge inoculum 
 
Figure 5; Viral load and 
liver enzymes. 
Shown is; A) the plasma 
viral load (copies ml-): B) 
ALT levels (IU ml-) and C) 
γGT (U ml-) in individual 
animals observed over time 
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J4.91’01 as well as a parental virus isolate from which it was derived HC-
J4/91 (D10750) 17. As shown in Figure 6, all the non-synonymous mutations 
relative to the inoculum aligned. In the acute phase only one amino acid 
residue change was observed in the E1 region (G232A or G232D), and three 
in the E2 region (F438L, A466V and V496I). These changes seem to be 
unrelated to the vaccination strategy, as they are observed in all animals 
irrespective of the antigen they were immunized with.  
 
 In the chronic phase of infection in the animals not immunized with E1, 
three de novo mutations occurred in putative E1 epitopes (V219M,  T256A 
and V301M) and two in E2 (H434Q and T444A). Surprisingly, all residues 
which became established during the acute phase reverted to the residue 
found in the original inoculum. Interestingly, with the exception of position 301 
in the E1 region (valine in E2-Jo and methionine in the other animals), the 
dominant viral variants (in both E1 an E2 regions) that emerged at the end of 
the study were found to be identical in the three animals that became 
persistently infected.  
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Figure 6; sequence analysis 
Sequence alignments from the peripheral blood of the envelope regions E1 and E2 from the 
indicated animals following persistent viremia (viral escape or evasion). Nucleotides are 
represented by standard single letter codes, dashes indicate identity with the reference 
sequence HC-J4/91, substitutions or mutations are represented by single letter codes. 
Sequences were derived from time points after virus escaped the immune responses. 
Samples from the following time points were used to isolate viral sequences, Ctrl-Hu 41 
weeks, E1-Ma  6 weeks, E1-Yo 12 weeks, E2-Ka 31 weeks and E2-Jo 41 weeks (last time-
points from which amplification of sequences was routine) after HCV exposure 
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DISCUSSION 
 
The partial characterization of the immune correlates of clearance of 
HCV infection and the identification of the targeted viral antigens, facilitated 
the rational development of a vaccine for the prevention of chronic HCV 
infection 8, 18, 19. HCV vaccine studies directed at the induction of virus 
neutralizing antibodies have focused either on the use of the E1E2 
heterodimer, or the E2 protein alone 2, 15, 20, 21. However, two lines of evidence 
have suggested a role for E1. Firstly, broadly neutralizing human monoclonal 
antibodies to the E1 glycoprotein have been identified 6, 7. Secondly, 
functional analysis has identified several membrane active regions in E1 (as 
well as E2) involved in virus-cell membrane fusion 5.  
 
Here we tested the hypothesis that the independent use of HCV E1 
subunit as a vaccine immunogen would be capable of inducing neutralizing 
antibodies and facilitating protection from HCV infection. Interestingly, 
although immunization with E1 was successful in inducing neutralizing 
antibodies, these did not have a directly of blunting the acute viral peak after a 
relatively high dose, intravenous HCV exposure. Ultimately, E1-neutralizing 
antibodies, together with recruited T-helper responses appear to have 
facilitated HCV 1b clearance. However, additional mechanisms such as 
antibody dependant cellular cytotoxicity (ADCC), recruited innate responses in 
the liver or late induction of CTL activity may have contributed to clearance.  
 
Although antibodies were also present in the serum of the E2 
immunized animals, these antibodies lacked the ability to neutralize HCV and 
the virus persisted in these animals. It could be speculated that the E2 protein 
devoid of its HVR-1 was misfolded and incapable of inducing NAbs. However, 
comparison of E2 proteins with and without HVR-1 for reactivity with a range 
of patient sera showed no clear differences, suggesting that the 
conformational structure of the E2 protein lacking the HVR-1 as used in this 
study was antigenically intact (data not shown). 
 
While the immune responses observed in the E1 immunized animals 
were restricted to the vaccine-component, chimpanzee E2-Jo, did not only 
respond to E2 but also to E1 in both cellular as well as humoral immune 
assays. Although this observation is somewhat unexpected, it must be noted 
that shared immunoreactivity between the two envelope glycoproteins was 
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reported previously 22 and may be elicited in animals that carry the 
appropriate MHC makeup. 
 
The majority of the HCV vaccine efficacy studies in chimpanzees were 
performed before the development of suitable HCV neutralization assays 
therefore only limited data have been available on the correlation of HCV 
neutralization and vaccine efficacy. Furthermore, in the majority of HCV 
protein vaccine efficacy studies to date, E1 and E2 were administered as 
heterodimer 21 and as the HCVpp also express E1 and E2, it is impossible to 
determine the role of the separate envelope components. This is the first 
study to demonstrate a direct correlation with vaccine induced E1-neutralizing 
antibodies and early clearance of HCV infection. Earlier studies have focused 
on E2 as the lead vaccine target given the observations of E2-binding 
inhibition assays and the characterization of several E2 specific virus 
neutralizing mAb 23, 24. The E2 antigen used in this study was devoid of the 
HVR-1 and therefore the outcome does not allow direct comparison with 
earlier protein vaccine efficacy studies. Our efforts to focus the immune 
response to the more conserved regions  of E2 failed as the antibodies 
generated with this strategy did not inhibit infection with HCVpp. The lack of 
the HVR-1 may possibly have reduced binding to one of the scavenger 
receptor class B type 1 (SR-B1) regions 11, 25. Since SR-B1 also mediates 
HCV uptake and cross-presentation by dendritic cells in humans 26, this may 
have resulted in suboptimal antigen presentation and the formation of lower 
affinity antibodies with reduced neutralizing capacity, despite induction of high 
T-cell and binding antibody responses. 
 
Following immunization, all vaccinees developed an antigen specific 
Th-2 dominant immune response directed towards the vaccine components 
as shown by increased lymphoproliferation, the high number of HCV specific 
IL4 secreting cells and by the formation of HCV specific antibodies before 
challenge. The degree of protection observed against this heterologous 1b 
variant is different than the complete protection obtained with E1E2 
heterodimers against HCV-1a challenge of chimpanzees 15. However, our 
data concur with the outcome of re-exposure to HCV in humans and 
chimpanzees, where viral clearance is observed much later, after the acute 
phase 2.Athough vaccine mediated formation of viral escape variants is of 
great concern , this was not observed in this study. 
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This proof of principle study reveals the previously unrecognized 
importance of E1 alone as a candidate HCV vaccine antigen. Moreover these 
findings suggest that further insights into the structure-function relationship of 
the E1E2 heterodimer are required. Improved understanding of the dynamics 
and structural changes upon receptor binding and membrane fusion may 
reveal conserved domains which could be exploited as neutralizing antibody 
targets for immunization. 
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ABSTRACT 
  
In humans, clearance of hepatitis C virus (HCV) infection is associated 
with genetic variation near the IL-28B gene and the induction of interferon-
stimulated genes, like IP-10. Also in chimpanzees spontaneous clearance of 
HCV is observed. To study whether similar correlations exist in these animals, 
a direct comparison of IP-10 and IL-28B polymorphism between chimpanzees 
and patients was performed.  
All chimpanzees studied were monomorphic for the human IL-28B 
SNPs which are associated with spontaneous and treatment induced HCV 
clearance in humans. As a result, these particular SNPs cannot be used for 
clinical association studies in chimpanzees. Although these human SNPs 
were absent in chimpanzees, gene variation in this region was present 
however, no correlation was observed between different SNP-genotypes and 
HCV outcome. Strikingly, IP-10 levels in chimpanzees correlated with HCV-
RNA load and γGT, while such correlations were not observed in humans. 
The correlation between IP-10, γGT and virus load in chimpanzees was not 
found in patients and may be due to the lack of lifestyle-related confounding 
factors in chimpanzees.  
Direct comparison of IP-10 and IL-28B polymorphism between 
chimpanzees and patients in relation to HCV infection, illustrates that the IFN-
pathways are important during HCV infection in both species. 
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INTRODUCTION 
 
Worldwide, an estimated 170 million people are chronically infected 
with the hepatitis C virus (HCV) 1 and are therefore at risk to develop liver 
diseases, like cirrhosis and hepatocellular carcinoma. Upon infection with 
HCV, only a minority of individuals can clear the virus spontaneously, while 
the majority of patients become chronically infected 2, 3. In recent years, an 
important role for host factors has been documented in determining the 
progression towards chronicity of HCV as well as prediction of therapy-
induced clearance of HCV 4-10. Genetic variation on chromosome 19, within an 
intergenic region upstream of the IL-28B gene, encoding for the IFN lambda 3 
protein (IFNλ3) correlates with both spontaneous as well as treatment-
induced clearance 6, 8. Furthermore, low plasma levels of interferon-gamma-
inducible protein 10 (IP-10) prior to therapy predict treatment-induced 
clearance of HCV infection 7, 11-13 but whether these two factors interrelate is 
currently under intense debate. However, this is highly relevant since both 
parameters directly interfere with antiviral IFN-pathways. 
 
Chimpanzees are not only the closest living evolutionary relatives of 
humans but also the only validated animal model to study HCV infection. 
Similar to humans, HCV in chimpanzees can either lead to a self-limiting 
infection or to viral persistence, and also in the chimpanzee, antigen specific 
cellular immune responses are believed to be important 14-16. In patients, low 
pre-treatment IP-10 levels in serum and strong upregulation of IFN-stimulated 
genes (ISGs) during treatment in the liver were shown to correlate with 
successful IFNα based therapy 7, 9, 11, 12, 17. However, in contrast to humans, 
standard IFNα-based therapy failed to reduce serum HCV RNA levels in 
chronically infected chimpanzees 18, and therefore mechanisms leading to 
treatment-induced sustained virological response (SVR) cannot be studied in 
these animals. The lack of clinical response to IFNα in chimpanzees was 
suggested to be similar to that in patients nonresponsive to therapy: a 
maximum induction of ISGs by HCV itself, rather than by treatment with 
exogenous IFNα 18.  
 
Interestingly, also a weak association between the preferred IL-28B 
genotypes and low serum IP-10 baseline levels in patients chronically infected 
with HCV was recently reported 11, 19. This suggests an interaction between 
IP-10 and IFNλ during the course of HCV infection in humans 12. However, at 
present, a clear understanding of the mechanisms and their potential role in 
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viral clearance is lacking. In this study, we aimed to evaluate and compare IP-
10 and polymorphism near the IL-28B gene in chimpanzees and humans in 
relation to HCV infection to obtain better insight in the potential association 
between the two host factors in HCV infection.  
We show that, however chimpanzees do not possess the same human 
SNPs near the IL-28B gene, allelic variation is present in this region in 
chimpanzees. No association was observed between IL-28B polymorphism 
and the course of HCV infection in chimpanzees. Furthermore, we report a 
positive correlation between peripheral levels of IP-10 and HCV RNA as well 
as γGT levels in chimpanzees, but not in patients. These findings demonstrate 
differences between HCV-infected chimpanzees and patients, which may 
impact pathophysiologic processes in the liver. 
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MATERIALS & METHODS 
 
Study population 
To study the potential roles of IP-10 and polymorphisms during HCV 
infection in chimpanzees, we examined these parameters using the unique 
repository of chimpanzee DNA and serum samples of the Biomedical Primate 
Research Centre (BPRC). This database contains surplus material from blood 
samples collected routine health check purposes by both the BPRC as well as 
third party owners of chimpanzees. The work described here, was designed 
around the availability of the samples thus, no samples were collected from 
chimpanzees for the purpose of this work. Table 1 summarizes the relevant 
characteristics of the chimpanzee cohort included in this study. The animals 
were divided into different groups based on their HCV status: 1) “high viral 
load”: animals who were experimentally infected with HCV and virus load 
consistently higher than 200,000 IU/ml, where 200,000 is the median virus 
load of the animals in the study; 2) “low viral load”: animals who were 
experimentally infected with HCV and viral load consistently lower than 
200,000 IU/ml; 3) “cleared”: animals who were experimentally infected with 
HCV and resolved infection 4) “naive“: non–infected animals that serve as 
healthy controls. In addition, DNA samples of 44 animals were screened for 
the presence of genetic variation near the IL28B gene. In total 63 
chimpanzees were included in the analysis of the IL-28B region of which 11 
animals were not part of the BPRC breeding. 
 
Blood samples were obtained from patients with chronic HCV infection 
visiting the outpatient clinic of the Erasmus Medical Center (see Table 2). 
Patients were infected with either HCV genotype 1 (n=37), genotype 2 (n=3), 
genotype 3 (n=13), genotype 4 (n=4) or genotype 6 (n=1). Patients co-
infected with human immunodeficiency virus, hepatitis A virus, hepatitis B 
virus or hepatitis D virus were excluded from the study. The protocol was 
approved by the Medical Ethics Committee of the Erasmus Medical Center 
and all patients gave their written informed consent. In line with the 
chimpanzee cohort, the patients were divided into different groups based on 
their HCV status: 1) “high virus load”: virus load consistently higher than 
500,000 IU/ml, where 500,000 is the median virus load of all patients in this 
study; 2) “low virus load”: patients with virus load consistently lower than 
500,000 IU/ml.  
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Determination of HCV load and liver enzymes 
Quantification of HCV RNA levels was assessed using the Cobas 
Amplicor HCV monitor test (Roche Diagnostics, Branchburg) according to the 
instructions of the manufacturer. The levels of γGT, ALT and AST were 
determined in serum using the COBAS Integra 400 plus analysis system.  
 
IL-28B gene associated polymorphisms in chimpanzees 
To determine the genotype of the rs8099917 and rs12979860, genomic 
DNA was isolated from either chimpanzee PBMC or whole blood 20 and the 
nucleotide sequence was determined by PCR amplification followed by direct 
sequencing. To assess the genotype of rs8099917, a previously described set 
of PCR primers was used 21, while a new set of primers was designed for the 
amplification of a fragment of 209 bp containing rs12979860 (IL-28-860-F2 5’-
GGACAAGCGGCGCTTATCG-3’ and IL-28-860-R2 5’-GGCTCCAGGTCGGG 
GCG-3’). To amplify the fragments of interest, 1 µg of genomic DNA, 0.5 µM 
of each PCR primer, 0.2 mM dNTP each, 1.5 mM MgCl2 and 1 unit of 
Platinum Taq DNA polymerase (Invitrogen, Paisley, Scotland) were mixed in 
the appropriate PCR buffer in a total volume of 50 µl. The PCR conditions 
were: 1 cycle of denaturation at 94 ºC for 2 min, 30 cycles of denaturation at 
94 ºC for 30 s, annealing at 61 ºC for 30 s and extension of 68 ºC for 30 s, 
followed by a final extension for 7 min at 68 ºC. PCR fragments were purified, 
using the GenJETTM Gel Extraction Kit (Fermentas, St. Leon-Rot, Germany) 
according to the manufacturer’s protocol. The nucleotide sequence of the 
PCR fragments was determined using the ABI Prism BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, USA). 0.2 µM of PCR 
primer, 1 µl of BigDye Terminator-mix and 5x sequencing dilution buffer in a 
total volume of 10 µl and sequenced directly on an ABI 3130XL genetic 
analyzer (Applied Biosystems, Foster City, USA). The data was analyzed 
using MacVector™ version 12.0.2 (MacVector, Inc Cambridge, UK). 
Sequences observed for rs12979860 were deposited in the EMBL database 
and received the accession numbers HE599784 and HE599785. 
The genotype of the IL28B associated SNPs in patient blood were 
determined using competitive allele-specific PCR (KASP; KBioscience 
Hoddesdon, UK).   
 
Serum levels of IP-10, IL-29 and IL-28A/B  
The concentrations of IP-10, IL-29 and IL-28A/B in serum were 
determined using commercially available kits. The levels of IP-10 in patient- 
and chimpanzee sera were measured using the Quantikine Kit (R&D 
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Systems, Abingdon, UK; sensitivity of assay: 2 pg/ml).  The concentration of 
IL-29 and IL-28A/B in chimpanzee sera was measured using VeriKine-DIY 
Human Interferon Lambda immunoassays specific for IL-29 or for the 
combination of IL-28A/B (both from PBL InterferonSource, NY, USA). The 
assays were performed according to the manufacturer’s instructions, and the 
detection limits for both immunoassays were 62.5 pg/ml. IL-29 ELISA results 
were confirmed by the human IL-29 ELISA Ready-SET-Go!® kit (e-
Bioscience, San Diego, USA,  detection limit for this assay was 8 pg/ml). 
 
Statistics 
Statistical analysis was performed using Graphpad Prism 5.0 
(GraphPad Software, Inc., La Jolla, USA). To test if a significant correlation 
exists between two quantitative variables, the correlation coefficient r2 is 
calculated as a measure of variation of 2 variables. In addition, to test whether 
this correlation was significant, a t-test was performed. A two tailed T-test was 
used to determine statistical difference of liver-enzymes between patients and 
chimpanzees.  
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RESULTS 
 
No evidence found for the human SNPs associated with HCV clearance 
in chimpanzees 
In humans, spontaneous as well as treatment-induced clearance was 
found to be associated with a series of SNPs upstream of the IL-28B gene 4-6, 
8, 10. To assess whether clearance of HCV in chimpanzees is associated with 
the same SNPs, genotype analysis of chimpanzee DNA was performed for 
rs8099917 and rs12979860.  
The SNP rs8099917 consistently showed thymidine at this position on 
both chromosomes, indicating that all animals tested were homozygous 
rs8099917-TT carriers. In humans rs8099917-T is the preferred allele 
associated with HCV clearance. In addition, the chimpanzees were also 
genotyped for the rs12979860 SNP, and again no evidence was found for 
variance at this position. All animals tested had homozygous rs12979860-TT 
genotypes. In humans, the rs12979860-T allele is the so-called risk-allele 
associated with an increased risk for viral persistence. Thus, both IL-28B 
associated human SNPs are not present in chimpanzees. 
 
Chimpanzees possess a unique sequence near the IL-28B gene 
Since rs8099917 and rs12979860 genotyping was performed by 
sequencing, the neighboring nucleotide sequences are also known, allowing 
us to compare this region with documented human genome sequences 
(National Institutes of Health, Bethesda, USA). Two different haplotypes were 
observed near rs12979860, HE599784 and HE599785. Notable was the 
strong uneven distribution: 62 out of 63 animals were heterozygous, carrying 
both HE599784 and HE599785. Only one animal was found to be 
homozygous for HE599785. These data suggest that an as yet unknown 
balancing selection may be operative on this region. 
 
No detectable IFNλ in serum from chimpanzees 
In humans carrying the rs12979860-TT genotype, significant lower 
serum levels of IFNλ were documented in chronically infected patients as 
compared to patients with resolved infections 19, 22. To investigate whether this 
difference could also be observed in chimpanzees, ELISA was performed on 
sera from chronically infected animals and animals that cleared the infection. 
Using commercially available immunoassays designed to detect human IL-
28A/B and IL-29, we were unable to detect IFNλ in sera from any of the 
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chimpanzees tested, neither in animals chronically infected with HCV nor 
animals that spontaneously cleared the infection. In the same assays, IL-
28A/B and IL-29 could be detected in sera from patients with chronic HCV 
infection (data not shown; detection limit of the assays: 62.5 pg/ml and 8 
pg/ml, respectively).  
 
IP-10 levels in serum correlate with viral load in HCV infected 
chimpanzees, but not in humans 
To investigate whether the IP-10 levels in serum were associated with 
viral clearance, we compared IP-10 levels of chronically infected animals with 
a high HCV load (>200,000 IU/ml), low HCV load (<200,000 IU/ml), 
chimpanzees that had resolved HCV infection early after experimental 
exposure, and a group of HCV-naïve, non-exposed chimpanzees. As shown 
in Figure 1A, the IP-10 levels in sera of animals with a high viral load were 
significantly higher relative to animals in the other groups. The serum IP-10 
levels of animals with low viremia, animals that resolved the infection and 
Figure 1; Correlation between 
HCV viremia and IP-10 in 
serum in chimpanzees 
Box-whisker plots indicate the 
interquartile range and the 
median (horizontal line) of IP-
10 concentrations in serum from 
animals of the different groups; 
“high HCV load” where the 
virus load of individual animal 
is higher as compared to median 
value of 200,000 IU/ml; “low 
HCV load” where the virus load 
of individual animal is lower as 
compared to the median value 
of 200,000 IU/ml; HCV 
resolvers and naïve, non-
exposed (A). Box-whisker plots  
 indicate the interquartile range and the median (horizontal line) of IP-10 
concentrations in serum of humans and chimpanzees with high HCV load (> median 
virus load) and low HCV load (< median virus load) (B) and IP-10 concentrations 
plotted against HCV-RNA load in serum from chimpanzees and humans (C). A 
significant correlation between the two parameters is defined as r2>0.85 and p<0.05 
where “r2” is a measure for correlation and “p” is a measure for the quality if this 
correlation. 
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HCV-naïve animals were relatively low and comparable between these 
groups. 
 Earlier studies in chronically infected patients demonstrated an 
association between viral load and IP-10 levels in serum 23, 24. Therefore, we 
evaluated whether this correlation also existed in chimpanzees. As shown in 
Figure 1B, at a low viral load, the IP-10 levels were similar in humans and 
chimpanzees. In contrast, serum IP-10 levels were higher in chimpanzees 
with a high viral load relative to human patients with similar high viral loads. A 
strong correlation between serum IP-10 concentration and viral load was 
observed in chronically infected chimpanzees. In contrast to chimpanzees, 
neither a correlation was observed in the overall group of patients chronically 
infected with HCV (Figure 1C), nor when this group was divided into 
subgroups according to their rs12979860 genotype (data not shown). 
  
Serum IP-10 concentrations correlate with γGT in HCV infected 
chimpanzees, but not in humans 
In patients, the 
concentration of the serum 
aminotransferase ALT is 
used as indicator of active 
damaging processes in the 
liver during chronic HCV 
infection. However, in 
chimpanzees, γGT tends to 
be more increased rather 
than ALT. We therefore 
assessed whether IP-10 
levels in blood correlated 
with the liver enzymes γGT, 
ALT and AST in chronically 
HCV infected chimpanzees 
and patients. As shown in 
Figure 2A, in chimpanzees 
the serum levels of IP-10 
strongly correlated with γGT 
(r2=0.91 and p<0.0001), 
while no correlation was 
observed between IP-10 and 
Figure 2; Relation between IP-10 levels 
and aminotransferases in serum 
Relation between IP-10 and liver enzymes 
γGT, ALT and AST from HCV-infected 
individual chimpanzees  (A) and HCV-
infected patients (B) A significant 
correlation between the two parameters is 
defined as r2>0.85 and p<0.05 where “r2” is 
a measure for correlation and “p” is a 
measure for the quality if this correlation.  
 
 
	   IL-­‐28B/IP-­‐10	  IN	  CHIMPANZEES	  	   	  135	  
 
either ALT (r2=0.58; p=0.0007) or AST 
(r2=0.17; p=0.11). In contrast, in HCV 
infected patients, nocorrelations were 
observed between serum IP-10 and the 
aminotransferases (Figure 2B). Direct 
comparison of the levels of ALT and AST 
in serum of patients and chimpanzees 
demonstrated that only moderate ALT 
values were observed in chimpanzees, 
whereas 4 out of 58 patients exceeded 
an ALT value of 200 U/ml which is more 
then 4 times the maximum reference 
value for healthy humans and 
chimpanzees (Figure 3). Similarly, also 
AST levels were only moderately 
increased in chimpanzees, whereas 11 
patients exceeded the maximum 
reference value by threefold. In contrast, 
serum γGT levels were found to be 
substantially elevated in some individuals 
from both species: in 3 out of 16 
chimpanzees and 7 out of 60 patients, 
the γGT levels exceeded 200 U/ml, which 
is more then 5 times its reference value 
in healthy humans and chimpanzees. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3; γGT, ALT and AST 
in humans and chimpanzees 
chronically infected with HCV 
Interquartile range and the median 
(horizontal line) of gGT, ALT and 
AST in U/ml in chimpanzees and 
patients chronically infected with 
HCV. 
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DISCUSSION 
  
In humans, HCV clearance is associated with specific IL-28B gene 
polymorphisms as well as the levels of specific ISG, such as IP-10 4, 5, 7, 8, 10, 
13. It has been suggested that these pathways are associated with one 
another in humans 11, 19 although the interrelating mechanism is still unknown. 
The work presented here was designed to assess whether a potential 
correlation between IFNλ and polymorphism near the IL-28B gene can be 
studied in chimpanzees. 
  
In humans, genetic variation near the IL-28B gene is associated with 
spontaneous as well as treatment-induced clearance of HCV 4, 5, 8, 10. In 
chimpanzees, we found no evidence for these human SNPs and therefore it is 
unlikely that these specific SNPs play a role during HCV infection in 
chimpanzees. Instead, all animals tested were found to be homozygous 
carriers for rs12979860-TT and rs8099917-TT, which is in line with recently 
reported data of chimpanzees from another primate center 25. A potential 
explanation may be that HCV is regarded as a human disease as no 
documentation is available on wild chimpanzees infected with HCV. In that 
respect different evolutionary selective pressure may have caused differences 
in innate responses between both species. 
  
Since the documented SNPs, rs12979860 and rs8099917 are located 
in an intergenic region rather than within gene-encoding regions of the DNA, 
there may be a link between the region where the SNPs are located and 
another, yet unspecified gene. Given the fact that humans and chimpanzees 
share a common ancestor, the chimpanzee sequence likely represents the 
ancestral genotypes. This is in line with the finding that Central and Western 
African human populations carry the rs12979860-TT genotype at high 
frequency 10.  
 
Even though humans and chimpanzees show 98.8% identity at the 
DNA level 26, many SNPs identified in humans are not necessarily present in 
chimpanzees. Although no evidence was found in chimpanzees for the two 
SNPs with documented relevance during HCV infection in humans, additional 
polymorphism near the IL-28B gene was detected. In the animals tested, a 
remarkable level of heterozygous carriers was observed, this may suggest a 
balancing selection being operative on this region. Our findings cannot be 
explained by the breeding strategy as concluded on the basis of variation in 
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the mtDNA 27, and because it was also observed in animals from outside the 
BPRC breeding colony. The underlying mechanism responsible for this 
heterogeneity to assure a genetically diverse population is unknown.  
 
In serum from chimpanzees no IFNλ was detected, and therefore no 
conclusion could be drawn from its effect on the outcome of HCV infection in 
chimpanzees. IFNλ has been measured in chimpanzees before using human 
detection reagents 25. Given the rapid normalization of IFNλ levels in 
chimpanzees shortly after infection, it is expected that IFNλ is too low to 
detect during the chronic phase of infection. Lower IFNλ levels in 
chimpanzees could not be explained by a different copy number of the IFNλ-
encoding genes as both in humans as well as chimpanzees only one copy of 
each of the IL-29/IL28A and IL-28B genes was observed (human and 
chimpanzee database supported by National Institutes of Health, Bethesda, 
USA). 
 In patients chronically infected with HCV, low baseline IP-10 levels are 
predictive for successful treatment-induced clearance 7. Our data show that 
IP-10 levels are higher in chronically infected chimpanzees relative to 
patients. This finding is in line with the suggestion that HCV infection causes 
stronger upregulation of ISGs in chimpanzees as compared to humans 18. 
Furthermore, based on data from a limited number of animals with high HCV-
RNA levels, it was suggested that the failure of chimpanzees to respond 
successfully to IFN-based antiviral treatment was due to high baseline 
activation of the IFN-system. Based on our data it is to be expected that 
peripheral IP-10 levels from the animals in the Lanford-study are high. Given 
the documented correlation between high IP-10 and limited treatment success 
in humans, it is tempting to speculate that chimpanzees with a high HCV load 
and subsequently high baseline IP-10 levels in serum are indeed equivalent to 
human non-responders to IFN-based therapy. However, this implies that 
animals with lower IP-10 may respond to IFN-based therapy.  
 
As humans and chimpanzees do not to show the same variation near 
the IL-28B gene, we were not able to confirm the earlier documented 
association between IL-28B variation and γGT levels in humans 17. We did 
however find a correlation between γGT, IP-10 and virus load. This may 
imply, interrelating mechanisms play a role in both humans and chimpanzees, 
but that species-specific factors may contribute to biochemical differences 
between both species.  
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 Our data show that although chimpanzees do not possess the SNP 
near the IL-28B gene that are associated with HCV outcome in humans, 
chimpanzees do show genetic variation in this region. Furthermore, we found 
a positive correlation between IP-10 and viral load as well as γGT in 
chimpanzees, which was not found in patients. This difference may reflect the 
heterogeneous characteristics of HCV induced reactions in the liver of both 
species. The correlation between IP-10, virus load and γGT may reflect the 
lack of confounding factors in chimpanzees, since heavy alcohol intake, 
diabetes and obesity are known to influence the progression of hepatitis C 
virus infection in humans, but not in chimpanzees.  
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TABLES 
 
Table 1 
Characteristics of chimpanzee population 
         genotype  yrs pi HCV load  IP-10    ALT  AST  γGT  
High virus load  
n=8 1 4 505000  2247  91 34 204  
  (4-21) (207000-1080000)(547-5956) (39-162) (20-54) (30-558)  
 
Low virus load  
n=6 1 3 31908  274  58 33 33 
  (2-4) (649-95500) (209-359) (46-82) (18-46) (20-55) 
Cleared HCV infection 
n=6 1 4.5 0  143    
  (3-10)   (71-131) 
 
Naïve HCV 
n=10   0  414 
     (146-1834) 
 
Relevant characteristics of the chimpanzee population studied, the HCV-
genotype, the time since HCV exposure, HCV-RNA load (IU/ml), IP-10 (pg/ml) 
levels in peripheral blood, the liver enzymes ALT (U/ml), AST (U/ml) and γGT 
(U/ml). Shown are the average values and the minimal and maximal values. 
 
Table 2 
Overview of the characteristics of the patient population, chronically 
infected with HCV 
patient ID       genotype HCV load   IP-10   ALT  AST  γGT  
High virus load  
n=30 1,2, 3 and 6  7827576  540  135 80 87  
   (585185-42100000) (67-2000) (17-444) (25-251) (16-347) 
 
Low virus load  
n=27 1, 3 and  4 255115   281  84 64 70 
   (15-2114180)  (66-902)  (20-263) (24-255) (9-205) 
 
Relevant characteristics of chronic HCV patients studied: HCV genotype, 
HCV-RNA load (IU/ml), IP-10 (pg/ml) levels in peripheral blood, the liver 
enzymes ALT (U/ml), AST (U/ml) and γGT (U/ml). Shown are the average 
values and the minimal and maximal values.
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ABSTRACT 
 
Increased levels of soluble C14 (sCD14) in serum may either be the 
consequence of increased microbial translocation or diminished clearance of 
bacterial products by hepatic dysfunction. During HIV/SIV infection sCD14 is 
up-regulated as a consequence of pathological disruption of the gut epithelial 
barrier resulting in increased microbial translocation. Also in HCV infected 
patients with advanced liver fibrosis, increased levels of sCD14 have been 
reported. Since the liver plays an important role in clearance of translocated 
bacteria, fibrosis may negatively affect clearance and thus contribute to higher 
sCD14 levels. We have tested the hypothesis that increased levels of sCD14 
in blood, during chronic HCV infection, can occur in the absence of hepatic 
fibrosis and microbial translocation.  
 
In chimpanzees and human patients, sCD14 was quantified as a 
marker for systemic microbial exposure, and intestinal fatty acid binding 
protein (I-FABP) as a marker for gut perturbation. In addition, LPS-binding-
protein, EndoCab, sIL-2R and IL-6 were analysed.  
HCV infected patients with advanced liver fibrosis exhibit increased 
levels of sCD14. In the majority of these patients up-regulation of CD14 
could not be explained by microbial translocation, as shown by normal levels 
of endocyte necrosis. This finding was confirmed in HCV infected 
chimpanzees. Also in these animals, up-regulated sCD14 levels were 
observed in the absence of I-FABP. In addition, as chimpanzees do not 
develop hepatic fibrosis, sCD14 elevation cannot be explained by impaired 
hepatic clearance of microbial products. These data support the hypothesis 
that replicating HCV can cause up-regulation of sCD14 production. 
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INTRODUCTION 
 
 Soluble CD14 (sCD14) levels in blood and microbial translocation are 
often used to describe the same pathological process. However, this is not 
entirely correct. Microbial translocation is the process of leakage of microbial 
products from the gastrointestinal tract to extra-intestinal locations like 
mesenteric lymph nodes, peripheral blood or the liver. Increased exposure to 
microbial products 
then leads to 
increased levels of 
sCD14 in the blood. 
However, increased 
levels of sCD14 may 
also be a 
consequence of 
diminished clearance 
of bacterial products 
by hepatic 
dysfunction. Hence, a 
more precise term for 
sCD14 up-regulation 
would be ‘microbial 
exposure’ as 
schematically 
explained in Figure 1.  
 
 
In HIV infected humans, increased levels of sCD14 in serum 
have been described in relation to disease progression 1, 2. sCD14 up-
regulation was associated with increased levels of intestinal-fatty-acid-
protein (I-FABP), which is released during endocytic cell death 1, 2. As a 
consequence of enterocyte death, the integrity of the gut epithelial barrier is 
lost, which gives rise to increased microbial translocation. Sustained 
increased microbial translocation and subsequent microbial exposure, may 
result in chronic systemic immune activation, ultimately leading to immune 
exhaustion and loss of immune function 3. 
 
In HCV infection, elevated sCD14 levels are associated with hepatic 
fibrosis 4, 5 and HCV seroconversion 6 but not with increased levels of LPS-
microbial))
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Clearance)
)
microbial)
exposure)
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HIV&disease&progression&
microbial))
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Figure 1; Schematic model of the term microbial 
exposure.   
Systemic microbial exposure is determined by the balance 
between microbial translocation and hepatic clearance. 
During HIV infection perturbation of the gut causes more 
microbial products to enter the blood. During HCV infection 
translocation is innitialy not affected and increased microbial 
exposure is caused by decreased hepatic clearance hepatic 
clearance. 
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binding protein (LBP) 6. Although it is assumed that portal hypertension 
negatively affects the capacity of the liver to clear residues from translocated 
bacteria, the exact mechanism is still unknown 7. Here, we tested the 
hypothesis that HCV-induced sCD14 up-regulation can occur in the absence 
increased microbial translocation and hepatic fibrosis. 
 
In order to address the effect of HCV infection and liver fibrosis on 
sCD14 levels, we have included chimpanzees into the study. Chimpanzees 
are the only validated animal model to study HCV infection. Like humans, 
infection of chimpanzees can either lead to a spontaneously resolved 
infection or the animals become persistently infected. Unlike in humans, 
hepatic fibrosis as a result of HCV infection has not been documented in 
chimpanzees 8. Previously, we reported on the correlation between the 
soluble activation marker interferon gamma inducible protein 10 (IP-10) and 
HCV load in chimpanzees 9. These data indicate that immune activation 
does take place in the absence of immune-pathology in HCV-infected 
chimpanzees. Therefore, HCV infected chimpanzees offer the unique 
opportunity to investigate whether systemic microbial exposure and immune 
activation can occur in the absence of liver fibrosis. 
 
Several assays have been described to quantify microbial 
translocation, systemic microbial exposure and immune activation in 
peripheral blood. Lipopolysaccharide (LPS), a glycolipid of the outer cell wall 
of gram-negative bacteria, elicits an inflammatory reaction via TLR4 
triggering that is required when bacterial products are present in peripheral 
blood. However, direct quantification of LPS in stored peripheral blood is 
technically complicated and data are unreliable when samples have been in 
contact with polypropylene 10. Since all samples used in this study had been 
stored in polypropylene ampoules, quantification of LPS was not the 
preferred technique. Therefore, a panel of surrogate markers was used for 
quantification of systemic microbial exposure. LPS-binding protein (LBP) is 
predominantly produced by hepatocytes and in order to initiate monocyte 
activation, LBP chaperones LPS to membrane CD14 (mCD14) and TLR4. 
To prevent monocyte overstimulation, sCD14 is being produced in the liver. 
Similar to mCD14, sCD14 can bind the LPS-LBP-complex. However, sCD14 
is a non-signaling molecule, a so-called decoy receptor. Both LBP and 
sCD14 can be measured in blood and are indirect but widely-used markers 
for LPS-induced monocyte activation and systemic microbial exposure 6, 11-
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13. In addition, quantification of EndoCab, antibodies that are directed against 
the core antigen of LPS 6, 13, was used.  
Enterocytes are part of the intestinal mucosa. When the mucosa is 
damaged, intestinal fatty acid protein (I-FABP) is released by enterocytes in 
peripheral blood. I-FAPB is used as an indicator for damage to the gut 
mucosa 4, 13 and is a measure for microbial translocation. Immune activation 
was quantified by measurement of soluble IL-2R (sIL-2R or sCD25) and IL-6 
levels as described earlier 4, 13.  
 
To aim of this study was to investigate whether microbial exposure 
during chronic HCV infection is a consequence of increased microbial 
translocation or from reduced microbial clearance due to fibrosis. In humans 
with advanced fibrosis, increased microbial exposure was observed as 
shown by elevated levels of sCD14. This was however not associated with 
increased levels of I-FABP, indicating that sCD14 was not a result of 
increased microbial translocation. To assess if hepatic fibrosis was the 
cause of increased microbial exposure, sCD14 levels were determined in 
chimpanzees as a model for HCV infection without fibrosis. Also in 
chimpanzees increased microbial exposure was observed, indicating that 
liver fibrosis is not the sole cause of sCD14 up-regulation. By contrast, in 
HIV/SIV-infected chimpanzees, up-regulation of sCD14 was caused by 
microbial translocation as shown by the higher I-FABP levels. 
152	  	   	   CHAPTER	  3.2	  
 
MATERIALS & METHODS 
 
Bio-repository 
Samples were collected from chronic HCV patients visiting the 
outpatient clinic of the Erasmus MC, Rotterdam, and stored at -80°C. 
Relevant clinical and virological details of the individual patients are 
presented in Table 1. The institutional ethical review board of the Erasmus 
MC approved the protocols, and informed consent was obtained from all 
individuals. Stage of liver fibrosis was determined by METAVIR score on 
core needle biopsies, and HCV RNA load was determined with COBAS 
Taqman assay. Patient samples were divided into two groups patients with 
little or no fibrosis (F0/F1), and patients with advanced fibrosis (F3/F4). 
 
Samples from chimpanzees used in this study were collected for 
reasons of health and welfare management or obtained from the BPRC 
repository. Plasma and serum samples were stored in polypropylene tubes 
(Greiner Bio-One) analyzed in parallel no difference was observed between 
the two sample types (data not shown).  
Liver tissue samples were collected post mortem. As chimpanzees 
have never been euthanized in the setting of experimental work conducted 
at the Biomedical Primate Research Centre (BPRC), liver material was 
collected from animals that had died from natural causes. Based on the HCV 
status, chimpanzees were divided into different groups: 1) ‘‘naïve”: non–
infected animals (n=7) serving as healthy controls: 2) Acute (n=10), <6 
weeks after experimental HCV infection; 3) ‘‘low virus load’’: HCV infected 
animals (n=5) with a virus load consistently lower than 250,000 IU/ml; 4) 
‘‘high viral load’’: HCV infected animals (n=5) with a virus load consistently 
higher than 250,000 IU/ml; 5) ‘HIV/SIV’; (n=19) chimpanzees that were 
infected with HIV and/or SIV for more than 4 years. 
All HCV chimpanzees were experimentally infected with HCV 
genotype 1 and HCV RNA load was determined with a ROCHE HCV 
Taqman assay. Relevant parameters of patients and chimpanzees are 
summarized in Table 1. 
 
Assessment of liver fibrosis 
Liver tissue was fixed in 10% formalin, processed by conventional 
methods and embedded in paraffin. Four micrometer sections were prepared 
and stained with hematoxylin and eosin using standard procedures. 
Subsequently, sections were microscopically examined by an experienced 
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pathologist for signs of hepatic fibrosis like disruption of liver parenchyma 
architecture, extension of fibers, formation of large fibrous septa, pseudolobe 
separation, collagen deposition and the presence of inflammatory cells.  
 
Quantification of systemic bacterial exposure and immune activation.  
 Commercially available ELISA kits were used to quantify the levels of 
sCD14 (R&D Systems, Minneapolis, MN, USA), I-FABP, LBP and EndoCab 
(all from Hycult Biotech, Plymouth Meeting, PA, USA), IL-6 (Ucytech, 
Utrecht, The Netherlands) and sIL-2R (eBioscience, Inc, San Diego, CA, 
USA) in stored plasma or serum. All tests were performed according to the 
manufacturer’s guidelines. The assays were performed in duplicate and data 
were analyzed using ADAMSEL software (BPRC, Rijswijk, The 
Netherlands).  
 
Statistical analysis 
To determine if there were significant differences between the 
different study groups, either unpaired parametric or non-parametric tests 
were performed (Prism 6.0.). Statistical significant differences were defined 
as p<0.05.  
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RESULTS 
 
No signs of liver fibrosis in chimpanzees 
In the hepatic tissue from adult chimpanzees, >10 years after HCV 
genotype 1 infection, only minor lymphocyte infiltrates were found, mainly 
located around the portal ducts but also dispersed throughout the liver. No 
signs of vascular construction were observed and the hepatic bile ducts were 
regularly shaped. Furthermore, no steatosis was observed. The data 
suggest that no fibrosis was present in the livers of chimpanzees. 
 
Increased sCD14 is associated with HIV and HCV infection  
In patients with advanced fibrosis (F3/F4), the levels of sCD14 were 
significantly higher (p=0.021) compared to healthy controls, median 4774 
ng/ml (ranging from 2624 to 6785 ng/ml) and 1712 ng/ml (ranging from 1084 
to 7328 ng/ml), respectively (Figure 2A). Chimpanzees overall had lower 
sCD14 levels compared to humans (Figure 2B). Yet, a modest but 
significant difference was observed between naïve and HCV infected 
chimpanzees with a high virus load (p=0.032) and with HIV/SIV infected 
chimpanzees (p=0.0014). No association was observed with acute HCV 
infection in chimpanzees or with low 
virus load.    
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Figure 2; Soluble CD14 expression in 
peripheral blood in humans and 
chimpanzees.  
sCD14 levels in plasma/serum was 
analyzed in (A) negative healthy human 
controls,  patients with fibrosis stage F0 
or F1 and patients with advanced fibrosis, 
stage F3 or F4. (B) Naïve chimpanzees, 
HCV infected animals with consistently 
high virus load and HIV/SIV infected 
chimpanzees The boxes indicate the 
median with 25th and 75th percentile, and 
the whiskers the minimum and maximum 
values. P-values were calculated using 
unpaired two-tailed t-tests, 
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Signs of disrupted gut barrier integrity after HIV not HCV infection  
To investigate if elevated sCD14 was caused by disruption of gut 
epithelial cells, I-FABP was quantified. No association was observed 
between I-FABP and fibrosis in HCV infected patients (Figure 3). Also in 
HCV infected chimpanzees the gut epithelial barrier remained intact as 
shown by the low levels of I-FABP on serum.  
 By contrast, increased levels of I-FABP were detected in HIV/SIV 
infected chimpanzees compared to chimpanzees with high HCV load 
(p<0.0001), chimpanzees with low HCV load (p<0.0001), and animals with 
acute HCV infection (p=0.009). Due to two outliers, no significant difference 
was reached between the naïve animals and HIV/SIV infected animals. 
 
Figure 3; I-FABP 
levels in peripheral 
blood I-FABP in 
human negative, 
F0/F1 and F3/F4) 
(open dots) and 
chimpanzees (naïve, 
acute HCV infection, 
low HCV load, high 
HCV load and 
HIV/SIV) (black dots). Lines represent the mean values. P-values were calculated using the 
non-parametric, unpaired, two tailed t-tests  
 
 
Increased LBP in HIV infected chimpanzees 
In addition to I-FABP, also EndoCab and LBP have been reported to 
correlate with microbial translocation and HIV disease progression 2. To 
investigate if these markers are associated with HCV infection, their levels in 
serum were quantified. No correlation was found between hepatic fibrosis 
and EndoCab and the development of fibrosis (Figure 4A) or LBP (Figure 
4B). Similarly, no difference was observed between levels of EndoCab or 
LBP in HCV infected chimpanzees (Figure 4A and 4B). By contrast, a 
modest increase was observed in LBP in serum from HIV/SIV infected 
chimpanzees compared to naïve animals (p=0.034) (Figure 4B). This 
observation is in line with the up-regulated sCD14 in HIV/SIV infected 
chimpanzees.  
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No evidence for systemic immune activation in HCV-infected 
chimpanzees 
To assess if HCV infection led to increased systemic immune 
activation, IL-6 and sIL-2R levels were determined. No differences in IL-6 
and sIL-2R levels were found between healthy controls and patients  No 
evidence was found for up-regulated IL-6 or sIL-2R  HCV or HIV/SIV infected 
chimpanzees (data not shown).  
 
Figure 4; Levels op biomarkers in peripheral blood 
Levels of EndoCab (A), LBP (B), in humans (open dots) and chimpanzees (black dots). 
Analyzed were HCV negative human controls, chronic HCV carriers with F0/F1, and 
patients with F3/F4. Naïve chimpanzees were compared to animals with acute HCV 
infection, chronic HCV infection with low virus load, chronic HCV infection with high virus 
load and HIV.SIV infection. Lines represent the mean values. P-values were calculated 
using a non-parametric, unpaired, two tailed t-tests. 
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DISCUSSION 
 
In concordance with literature 8, no indication was found for hepatic 
fibrosis in HCV infected chimpanzees by histological examination of liver 
sections.  
 
Our data show an association between increased sCD14 levels and 
advanced hepatic fibrosis in humans. These data are in accordance with 
data published by Sandler et al. 4. Elevated levels of sCD14 are indicative for 
increased systemic bacterial exposure, which can be caused by increased 
microbial translocation from the gut, or by reduced clearance of bacterial 
products by the liver. As described earlier, in a fraction of the HCV patients 
with advanced hepatic fibrosis, evidence for loss of gut epithelial barrier 
integrity was found 4. Also in our study cohort, some individual patients 
showed elevated I-FABP levels. These data suggest that severe fibrosis may 
corroborate sCD14 up-regulation by microbial translocation. This is in line 
with the observation that I-FABP levels were not increased in HCV infected 
chimpanzees, who typically do not develop fibrosis.  
 
As shown by the elevated sCD14 levels in chimpanzees with high 
HCV load, sCD14 can also be up-regulated during HCV infection in the 
absence of fibroses and increased microbial translocation. Ex vivo studies 
have shown that human hepatocytes produce sCD14 14. However, studies in 
the chimeric mouse model demonstrated that HCV infection does not 
promote sCD14 production by human hepatocytes 15. Hence, this does not 
exclude that other cells in the liver, like monocytes or epithelial cells, may be 
responsible for sCD14 up-regulation in response to HCV infection 14.  
 
Excessive microbial translocation is seen as a characteristic AIDS in 
humans and is not observed in non-pathogenic SIV infections in sooty 
mangabeys or African green monkeys 16. Although HIV does generally not 
cause AIDS in chimpanzees, some cases of pathogenic infections with HIV 
in chimpanzees have been reported 17-19. In the HIV/SIV-infected animals 
tested here, modest but significantly higher levels of sCD14 were observed 
in HIV/SIV infected chimpanzees compared to naïve animals. In addition, 
higher levels of I-FABP were found in these animals. This indicates that 
increased levels of sCD14 after HIV/SIV-infection are caused microbial 
translocation as a result of endocyte apoptosis. Without AIDS-like disease in 
these chimpanzees, the loss of epithelial integrity in the gut is similar to what 
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is seen in HIV patients progressing to AIDS, and macaques infected with 
pathogenic SIV-strains 2, 12, 20. Th17 cells in the gut mucosa are the primary 
target cells for HIV and SIV in humans and macaques 21, 22. Depletion of 
these cells are thought to lead to imbalanced regulation and impaired 
epithelial barrier function 23. It would therefore be interesting to study 
whether Th17 cells are targeted by HIV or SIV in chimpanzees. In this light, 
the lack of association between HCV infection and microbial translocation is 
not surprising. In contrast to HIV, primary target cells of HCV are located in 
the liver and not in the area where microbial translocation takes place. There 
is evidence for the presence of HCV proteins in enterocytes, albeit this is not 
accompanied by inflammatory responses 24 and therefore, pathophysiologic 
changes in the mucosal barrier are not likely to occur. 
 
The sCD14 levels in chimpanzees are much lower compared to 
humans. We acknowledge that the sCD14 levels detected in healthy control 
animals are different from the levels that were recently reported by 
Greenwood et al 25. This difference may be explained by the individual 
animals that were included. In our experiments, the relatively low levels of 
sCD14 were confirmed by low levels of LBP. Even upon HIV/SIV infection, 
up-regulation of sCD14 and LBP was only marginally in chimpanzees. At 
present, we have no clear explanation for this. It has been described that 
baseline levels of microbial translocation vary between species and the 
environment in which one lives 26, 27. This may indicate that the innate 
immune system in chimpanzees is less susceptible to activation by bacterial 
products compared to humans. However, we have previously shown that 
monocyte-derived dendritic cells in chimpanzees are susceptible to LPS 
stimulation 28. On the other hand, pre-exposure to LPS may lead to tolerance 
to subsequent LPS stimulation 29.  
 
IL-6 and IL-2R in peripheral blood was variably up-regulated in 
humans, independent from HCV infection or hepatic fibrosis. In addition, 
these markers were poorly expressed and not up-regulated during HIV or 
HCV infection. This suggests that IL-6 and IL-2R are not the appropriate 
markers to study HCV-induced activation. Alternatively, other activation 
markers, like IDO 30 and IP-10 9.  have been described in HCV-infected 
chimpanzees. As expression of IP-10 correlated with HCV virus load in 
chimpanzees, with γGT, ALT and liver fibrosis  in humans 9. These markers 
may be more appropriate to study HCV induced immune activation. 
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In conclusion, HCV infected patients with advanced liver fibrosis 
exhibit increased levels of sCD14. In the majority of these patients up-
regulation of CD14 cannot be explained by microbial translocation, as shown 
by normal levels of endocyte necrosis. This finding was confirmed in HCV 
infected chimpanzees. Also in these animals, up-regulated sCD14 levels 
were observed in the absence of I-FABP. In addition, as chimpanzees do not 
develop hepatic fibrosis, sCD14 elevation cannot be explained by impaired 
hepatic clearance of microbial products. These data support the hypothesis 
that replicating HCV can cause up-regulation of sCD14 production. 
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Table 1 
 
Chimpanzees; High HCV load (gt* 1) 
weeks pi†   VL‡((IU/ml)  γGT§ AST‖ ALT#  
Ph-05  1144     506,000  160.6 24.5 108.0 
To-05  988     250,000  480.0 50.7 177.5 
Fe-05  520     384,000    65.5 26.4   91.9 
Ma-05  520   1,160,000  157.1 61.1 148.7 
Pe-05  1144     740,000  531.2 19.9   78.6 
 
Chimpanzees; Low HCV load (gt* 1)       
weeks pi†   VL‡ ((IU/ml)  §GT§ AST‖ ALT# 
Ir-06  162           650  14.3 38.1 21.1 
Fu-06  310      33,400  33.2 86.5 66.3 
Jo-00  343    202,000  83.7 55.1 52.2 
Hu-06  30      73,700  37.2 26.0 51.5 
Ka-00  29    133,000  72.8 92.0 68.0 
        
Chimpanzees; Acute 
weeks pi†  VL‡ ((IU/ml)  γGT§ AST‖ ALT#  
Iri-03  1     79,950  26.5 52.7 73.0 
Ju-03  1   314,500  33.1 22.3 55.9 
Ke-03  1   125,125  54.2 18.7 51.3 
To-03  1     74,775  35.1 26.6 46.5 
Wi-03  1   307,375  21.6 19.2 55.7 
Fau-00  3       5,000   38.0 NDh 54.0 
Li-00  3          500  29.0 NDh 44.0 
Fua-00  5     10,000  58.0 NDh 50.0 
Hu-00  2   100,000  24.0 16 54.0 
Fua-00  2      10,000  36.0 NDh 25.0 
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Table 1 continue 
 
Chimpanzees; Healthy controls 
weeks pi† VL‡ ((IU/ml)  γGT§ AST‖ ALT# 
Ir-03a      0  31.0 59.6 58.3 
Ke-03     0  37.7 13.4 32.9 
Ju-03     0  28.4 20.5 47.6 
An-92     0  NDg NDg NDg 
Re-92     0  NDg NDg NDg 
Fr-03     0  NDg NDg NDg  
Os-95     0  NDg NDg NDg 
 
Patients; Low fibrosis         
weeks pi† VLc ((IU/ml)  γGT§ AST‖ ALT# 
X-104           5,960  53 38 41 
X-182              226  15 19 10 
X-150         55,600  16 25 27 
X-756           6,730  20 35 62 
X-748         23,500  19 57 109 
X-033        475,000  59 156 54 
X-577       569,000  35 82 121 
X-160       591,000  18 28 38 
X-168    1,180,000  42 41 45 
X-672    1,290,000  133 34 34 
X-785    1,310,000  23 45 78 
X-436       475,000  97 34 21 
X-428       387,000  189 84 137 
X-116       287,000  23 29 18 
X-078       237,000  37 42 52 
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Table 1 continue 
 
Patients; High fibrosis 
weeks pi†  VLc ((IU/ml)  γGT§ AST‖ ALT#  
X-153       362,000  67 51 77 
X-551       272,000  78 85 46 
X-481       362,000  119 46 60 
X-722       535,000  109 51 100 
X-345       544,000  103 107 98 
X-317       587,000  352 250 200 
X-779       972,000  253 150 253 
X-774     1,090,000  22 45 47 
X-227     1,560,000  48 63 80 
X-553     1,930,000  231 27 43 
Table 1; Individual characteristics  
*gt, HCV genotype, b pi, weeks post experimental HCV infection, c VL, HCV load 
(copies/ml), d γGT, gamma glutamyl transpeptidase levels in blood, e AST, aspartate 
aminotransferase, f ALT, aspartate aminotransferase g ND, not determined
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ABSTRACT 
 
In humans, CD16 and CD56 are used to identify functionally distinct NK 
subsets. Due to ubiquitous CD56 expression, this marker cannot be used to 
distinguish between NK cell subsets in chimpanzees. Therefore functional 
analysis of distinct NK subsets during HCV infection has never been 
performed in these animals. In the present study an alternative strategy was 
used to identify four distinct NK subsets on the basis of the expression of 
CD16 and CD94. The expression of activating and inhibiting surface receptors 
showed that these subsets resemble human NK subsets. CD107 expression 
was used to determine degranulation of the different subsets in naïve and 
HCV infected chimpanzees.  
In HCV infected chimpanzees increased spontaneous cytotoxicity was 
observed in CD94high/dimCD16pos and CD94lowCD16pos subsets. By contrast, 
increased NCR mediated degranulation in the CD94dimCD16neg subset was 
demonstrated after NKp30 and NKp44 triggering. Our findings suggest that 
spontaneous and NCR mediated cytotoxicity are effector functions of distinct 
NK subsets in HCV infected chimpanzees. 
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INTRODUCTION 
 
NK cells are important immune cells in the first line of defense to 
several viral infections. NK cells have ambiguous functions: they have the 
ability to lyse infected target cells without prior activation, and they exert 
regulatory functions by modulating downstream adaptive immune responses 1, 
2. NK cell activation is regulated via activating and inhibiting natural 
cytotoxicity receptors (NCRs). Many studies have reported on dysbalanced 
NCR expression on NK cells in HCV infected humans 3-13, but the results are 
contradictory with regard to which NCRs are associated with functional 
changes after HCV infection.  
 
On the basis of the expression of CD56 and CD16, different NK cell 
subsets can be identified in human peripheral blood 1, 14-16. The NK subsets 
have different functional properties: CD56dimCD16pos are predominantly 
cytotoxic against antibody opsonized target cells 1, whereas CD56bright NK 
cells show less cytolytic activity and predominantly produce cytokines 17-19. 
However, others have shown that both subsets can produce IFNγ, albeit with 
different kinetics 20.  
 
The chimpanzee is the only validated animal model for the 
characterization of innate and adaptive immune responses during HCV 
infection 21-23. Similar to humans, chimpanzees either clear HCV shortly after 
infection or become persistently infected. Since acute HCV infection is 
generally not accompanied with clinical signs, early interactions between virus 
and host are difficult to study in humans. An animal model circumvents these 
challenges, and enables experimental infection under controlled conditions 
with regard to HCV genotype, dose and route of infection. Although 
microarray analysis of an HCV infected chimpanzee has shown up-regulation 
of NK-associated genes 24, chimpanzee NK cell functions after HCV infection 
have been poorly studied. The aim of the current study was therefore to test 
the hypothesis that cytotoxic capacity of the NK subsets is different between 
naïve and HCV infected chimpanzees.  
 
Phenotypical and functional analyses of chimpanzee NK subsets are 
complicated by ubiquitous CD56 expression on NK cells. Therefore, CD56 
cannot be used to distinguish different NK subsets in chimpanzees 25, 26. To 
be able to study NCR mediated cytolysis on different NK subsets in 
chimpanzees, we use here a new strategy that identifies distinct NK 
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subpopulations on the basis of CD94 and CD16 expression. Surface 
expression of CD94 identifies a functional intermediate between human 
CD56bright and CD56dim NK-cell subsets 17. We report that on the basis of 
CD94 and CD16 coexpression 4 subsets of CD3-CD14- chimpanzee 
lymphocytes can be distinguished. All four subpopulations have a unique 
NCR expression pattern, which confirms their NK cell identity.  
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MATERIALS & METHODS 
Phenotypic analysis of NK cells 
Peripheral blood mononuclear cells (PBMCs) from naïve and HCV (n=15) 
infected chimpanzees were used. HCV chimpanzees (n=15) had been 
experimentally infected with HCV genotype 1a or 1b and HCV RNA load was 
determined with Roche Cobas Amplicor 27. Virus load in serum of the animals 
varied between 6667 and >850,000 IU/ml. All chimpanzees had alanine-
aminotransferase (ALT) values within normal limits for chimpanzees (1-140 U/l), 
except one animal who had an ALT of 149 U/L .PBMCs were isolated 4 weeks to 
20 years after HCV infection. The original studies from which cell specimens used 
in the current study had been archived, were reviewed and approved by the BPRC 
animal experimental committee. PBMCs were isolated from heparinized blood 
(Vacurette, Greiner Bio-One) by standard density gradient centrifugation (Lympho 
Separation Medium, MP Biomedicals, OH, USA) and subsequently frozen in 
DMSO with 20% fetal calf serum (Life Technologies). 
 
Phenotypic analysis of NK cells 
Archived PBMC samples were thawed using standard procedures. 
Multiparameter flow cytometric analysis was used for phenotypical analysis of the 
cells. To distinguish between live and dead cells, cells were stained with the 
fixable Live/Dead marker (Life Technologies). Next, CD107-APC (clone H4A3, BD 
Biosciences) was added and after incubation, cells were stained for the surface 
markers CD3-PerCP (clone SP34.2, BD Biosciences), CD8-AmCyam (clone SK1, 
BD Biosciences), CD14-ECD (clone RMO52), CD94-FitC (clone HP-3D9), CD16-
APC-H7 (clone 3G8, BD Biosciences), NKp30-PE (clone Z25, Beckman Coulter), 
NKp44-PE (clone Z231, Beckman Coulter), NKp46-PE (clone BAB281, Beckman 
Coulter), NKG2A-PE (clone Z199, Beckman Coulter), NKG2D-PE (clone ON72, 
Beckman Coulter), DNAM-PE (clone DX11, R&D Systems). After washing, the 
cells were fixed and permeabilized with perm/fix buffer (BD Biosciences) and 
intracellular cytokines was stained with IFNγ-AF700 (clone B27, BD Biosciences) 
and TNFα-PE-Cy7 (clone MAb11, BD Biosciences). After overnight fixation in 2% 
paraformaldelhyde solution, cells were measured on an LSRII FACS machine (BD 
Biosciences). Cells were analyzed with FlowJo software (version 9.8.5, Tristar; 
Ashland, Oregon, USA).  
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Reversed ADCC assay 
Reversed ADCC assay was performed as previously described 3. Fcγ-
receptor carrying P815 mastocytoma cells (kindly provided by prof Laman) 
were used as target cells, and K562 myeloma cells were used as positive 
controls. In brief, 0.1*106 PBMCs were resuspended in medium (RPMI 1640 
medium (Life Technologies) supplemented with 10% foetal calf serum (Life 
Technologies), 2 mM L-glutamine (Life Technologies), 100 U/ml penicillin (Life 
Technologies), 0.1 µg/ml streptomycin, (Life Technologies), 0.1 µg/ml IL-21 
(PeproTech, Rocky Hill, NJ, USA) and 200 IU IL-2 (Proleukin, Chiron, 
Emeryville, CA, USA)) and co-cultured with target cells (E:T ratio 1). Cultures 
were set up with or without IgG monoclonal antibodies specific for NKp30 
(clone Az20), NKp44 (clone Z231), NKp46 (clone Bab281), NKG2A (clone 
Z199), NKG2D (clone BAT221) and DNAM (clone F22), all kindly provided by 
prof. L Moretta, Instituto Giannina Gaslini, Genova, Italy. After 3 hrs 
incubation, cells were stained as described above.  
 
Statistical analysis 
Statistical analyses were performed using the unpaired t-test in Graph-
Pad Prism software, p value ≤0.05 was considered significant.. 
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RESULTS 
 
Four different NK subsets in chimpanzees. 
Multiparameter flow cytometric analysis was used to identify different 
subsets. Viable large granular cells, negative for the expression of CD3 were 
selected for further analysis (Figure 1). Next, CD14 negative cells were 
analyzed for the expression of CD16 and CD94. Four distinct populations 
were distinguished: CD94dimCD16neg, CD94highCD16neg, CD94high/dimCD16high 
and CD94lowCD16high cells. 
 
 
 
 
Figure 2A shows the differential expression of the NCRs NKp30, 
NKp44, NKp46, NKG2A, NKG2D and DNAM in the four populations. Little or 
no NKp30 and NKp44 expression was observed on any of the four subsets 
directly after thawing, while expression of NGK2D was restricted to the CD16 
negative populations. The inhibitory receptor NKG2A was abundantly 
expressed on the surface of the CD94dimCD16neg, CD94highCD16neg and 
CD94high/dimCD16high cells, but not on CD94lowCD16high cells. The low 
expression of NKG2A may raise doubts on whether this subpopulation 
comprises indeed NK cells, but intermediate expression of levels NKp46 and 
DNAM were found. In addition, the expression of NKp46 and NKG2D shows a 
statistically significant up-regulation after culturing the cells in the presence of 
IL-2 and IL-21 prior to FACS analysis (p<0.0001 and p=0.0025, respectively)  
Figure 1; Multiparameter flow 
cytometric analysis of NK 
subsets. 
(A) Gating strategy; large 
granular cells were analyzed for 
the expression of CD3. CD3neg 
cells were selected while CD14pos 
monocytes were excluded from 
further analysis. Next, CD94 
expression was plotted against 
CD16 and gates were placed to 
identify CD94dimCD16neg, 
CD94highCD16neg, 
CD94high/dimCD16high and 
CD94lowCD16high subsets.  
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(Figure 2B). Based on these data we conclude that the 
CD94lowCD16high fraction represents an NK subset. 
 
 The phenotypical analysis strongly suggests that CD94dimCD16neg, 
CD94highCD16neg, CD94high/dimCD16high and CD94lowCD16high represent NK 
subsets in the chimpanzee. Next, we investigated the impact of HCV infection 
on NCR expression by these subsets. Compared to naïve chimpanzees, HCV 
infected animals showed disparate deviations in NCR expression 
(Supplementary Figure 1). In the CD94dimCD16neg subset we observed 
significant up-regulation of the expression of NKp46, whereas expression of 
NKG2D and DNAM was down-regulated. The CD94highCD16neg subset 
showed increased levels of NKp46 and lower levels of DNAM. In the two 
CD16high populations, the effect of HCV infection was less pronounced with 
small differences in NKp30, NKp44 and NKp46 expression.  
 
 
Figure 2; Frequency of 
NCR expression on 
chimpanzee-NK subsets.  
(A) The frequency of 
NKp30, NKp44, NKp46, 
NKG2A, NKG2D and 
DNAM expressing cells 
was calculated as the 
percentage of 
CD94dimCD16neg (upper left) 
CD94highCD16neg (upper 
right), CD94high/dimCD16high 
(lower left) and 
CD94lowCD16high (lower 
right). (B) cytokine-
induced up-regulation of 
NKp46 (left graph) and 
NKG2D (right graph) in 
CD94lowCD16high.  
The dots represent the individual chimpanzees tested. Statistical significant 
differences are indicated by * (p value between 0.05 and 0.001, ** (p value between 
0.001 and 0.0001) and *** (p≤0.0001). For every group, the bars represent the mean 
value and the standard deviation. Statistical significant differences are indicated and 
considered significant when p<0.05. 
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Increased CD107 expression in CD94lowCD16high subset in HCV infected 
chimpanzees 
Next, we determined intracellular CD107 levels in the different subsets 
as a validated marker for cytolytic capacity. In healthy controls, 
CD94dimCD16neg and CD94highCD16neg subsets expressed lower levels CD107 
compared to CD94high/dimCD16high and CD94lowCD16high (Figure 3A). In HCV 
infected chimpanzees also higher CD107 expression was observed in the 
CD94high/dimCD16high and CD94lowCD16high subsets (Figure 3B). When CD107 
expression was compared between naïve and HCV infected animals, 
significantly higher expression was observed in the CD94lowCD16high subset, 
 Figure 3; Frequency of CD107 expression on NK subsets from naïve and HCV infected chimpanzees. 
The frequency of CD107 was calculated as the percentage CD107 expressing cells 
within the CD94dimCD16neg, CD94highCD16neg, CD94high/dimCD16high and 
CD94lowCD16high subsets in (A) naïve and (B) HCV infected chimpanzees. (C) 
frequency of CD107 within the CD94lowCD16high subset in naïve (open circles) and 
HCV infected (black dots) chimpanzees. The dots represent the individual 
chimpanzees tested. Statistical significant differences are indicated as * (p value 
between 0.05 and 0.001, ** (p value between 0.001 and 0.0001) and *** (p≤0.0001). 
For every group, the bars represent the mean value and the standard deviation 
180	  	  	  	  	  	   	   	   	   	   	  CHAPTER	  3.3	  
	  
but not in CD94dimCD16neg, CD94highCD16neg or CD94hig h/dimCD16high cells 
(Figure 3C). Together, these data suggest that in chimpanzees CD16high NK 
cells likely play a more prominent role Fcγ-mediated cytotoxic responses than 
CD16neg NK cells.  
 
 
 
HCV promotes reversed ADCC in CD94dimCD16neg cells 
For the investigation of NCR-mediated responses, reversed ADCC 
assays were performed. All four subsets displayed increased CD107 
expression in response to NCR-specific IgG monoclonal antibodies (Figure 
4), but their response to individual NCR triggering differed. Overall the 
response of the CD94lowCD16high subset to NCR triggering was weaker 
compared to the other subsets. Especially, NKp46 triggering induced 
disparate degranulation in the individual subsets. While the CD94highCD16neg 
subset showed strong elevation of CD107 expression after NKp46 triggering, 
CD94lowCD16high failed to respond. When comparing reversed ADCC activity 
between naïve chimpanzees and HCV infected animals, only few differences 
were observed. In HCV infected animals, the CD94dimCD16neg subset 
promoted higher degranulation after NKp30 and NKp44 triggering as 
compared to cells obtained from naive chimpanzees. These data suggest that 
HCV infection does not impair ADCC activity in chimpanzees.  
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Figure 4; CD107 induction by reversed ADCC assay. 
The frequency of CD107 expressing cells was calculated as the percentage of 
CD94dimCD16neg (upper left), CD94highCD16neg (upper right), CD94high/dimCD16high 
(lower left) and CD94lowCD16high (lower right) in naïve (open bars) HCV infected 
chimpanzees (black bars) after 3 hours culture with specific IgG-antibodies binding 
NKp30, NKp44, NKp46, NKG2A, NKG2D and DNAM. For every group, 
spontaneous CD107 induction was subtracted. The bars represent the mean value and 
the standard deviation. Statistical significant differences are indicated as * (p value 
between 0.05 and 0.001), ** (p value between 0.001 and 0.0001) and *** 
(p≤0.0001).  
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DISCUSSION 
 
The aim of this research was to develop a convenient strategy for 
phenotypical characterization of functionally distinct NK subsets. In humans 
CD16 and CD56 are used to identify functionally distinct NK subsets. As the 
ubiquitous high expression of CD56 precludes usage of this marker, an 
alternative strategy was used to separate the CD3negCD14neg cells into 
different subsets: CD94dimCD16neg, CD94highCD16neg, CD94high/dimCD16high and 
CD94lowCD16high cells.  
In humans and non-human primates, the vast majority of the functional NK 
cells express NKG2A on their surface. NKG2A expression on the 
CD94dimCD16neg, CD94highCD16neg and CD94high/dimCD16high subsets confirms 
that these subpopulations are indeed NK cells. The lack of NKG2A expression 
raised doubts on whether the CD94lowCD16high subset indeed represents NK 
cells. However, in humans NKG2A is normally expressed on CD56bright and 
CD56dim NK cells. Others have reported on a CD56–CD16– NK cell subset in 
non-human primates 28, 29; this NK subset has no known counterpart in 
humans. However, both Pereira et al 28 and Reeves et al 29 defined NK cells 
as CD3–CD8αα+CD20−/dimNKG2A+, thus including NKG2A in the selection 
criteria. Therefore, it is unclear whether also NKG2A- NK cells exist. Given the 
fact that surface expression of CD94 identifies intermediate NK stages 17, it is 
tempting to speculate that the CD94lowCD16high subset represents an NK 
subset that is more differentiated compared to the human CD56dim subset. 
This is in line with the loss of NKG2A on the surface of fully differentiated NK 
cells 30. 
 
The variable surface expression of the different NCRs on the distinct 
NK subsets suggests functional heterogeneity between chimpanzee NK 
subsets. Indeed, intracellular CD107 staining indicated that cytolytic capacity 
was stronger in the CD94high/dimCD16high and CD94lowCD16high subsets 
compared to the CD94dimCD16neg and CD94highCD16neg subsets. This is in line 
with studies in humans, which showed that cytolytic effector function of NK 
cells is strongly associated with the expression of CD16 15, 16. By contrast, 
NCR-mediated CD107 expression was poorly induced in the CD94lowCD16high 
subset. Reversed ADCC does not depend on CD16 expression but on the 
triggering of the NCR on the NK cell. However, these results should be 
interpreted with caution since the outcome of the experiment is highly 
dependent on the binding affinity of the anti-NCR antibody to the NCR. When 
the binding affinity of the Fc-tail of the antibody to the Fc-gamma receptor on 
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the target cell exceeds the affinity of the NCR-epitope on the NCR on the NK 
cell, the assay measures ADCC and not reversed ADCC activity. In that case 
the CD107 expression should be interpreted as background in the assay. 
Collectively, it is tempting to speculate that CD94dimCD16neg, 
CD94highCD16neg, CD94high/dimCD16high and CD94lowCD16high resemble human 
CD56dim, CD56high/dim, CD56negCD16high and CD16high-fully differentiated NK 
cells, respectively.  
 
When comparing the cytolytic capacity of the different NK subsets 
between naïve and HCV infected chimpanzees, we found increased CD107 
expression in CD94lowCD16high in HCV infected animals. In humans, others 
have demonstrated an association between increased killing capacity of 
CD56pos NK cells and protection from HCV infection 31. In chimpanzees, this 
specific NK subset could  not be studied but the functional resemblance may 
suggest that CD56pos cells are the human counterpart of CD94highCD16neg in 
chimpanzees. In the animals studied, no increase of CD107 expression was 
observed in the CD94highCD16neg cells and this may explain why the virus 
persisted and the animals became chronically infected.  
 
Differences in NCR expression on the different subsets were observed 
between naïve and HCV infected chimpanzees. These differences were 
however not translated into altered NCR-mediated cytotoxicity. In the 
chimpanzees tested, increased NKp30 and NKp44 mediated cytolysis of 
CD94dimCD16neg cells was demonstrated. This contrasts with the decreased 
NCR mediated target cell killing by peripheral NK cells observed by others 5. 
In addition, we found no evidence for increased usage of NKG2D receptor 
pathways 8, as NKG2D was down-regulated on the CD94dimCD16neg and 
CD94highCD16negsubsets in HCV infected animals. Decreased levels of 
NKG2D have been described in the livers of patients chronically infected HCV 
6. Similar observations by Pembroke et al 6, we observed that NKG2D down-
regulation was accompanied by increased spontaneous degranulation. 
However, blood NK cells, but not liver NK cells, were studied in chimpanzees, 
and decreased expression of NKG2D was only observed in the 
CD94dimCD16neg and CD94highCD16neg subsets, whereas spontaneous 
cytolysis was an effector function of the CD94high/dimCD16high and 
CD94lowCD16high subsets. The same authors described that enhanced NKp46 
mediated killing is associated with liver pathology. In chimpanzees, NKp46 
was also up-regulated, but only in the CD94dimCD16neg, CD94highCD16neg, and 
CD94lowCD16high subsets. Unlike humans, our chimpanzees did not develop 
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fibrosis in the liver after HCV infection. However, they did show signs of liver 
inflammation 32. In this respect, it would be interesting to investigate 
intrahepatic NK cells for the expression of NKp46 and cytolytic capacity.  
 
In chimpanzees, discordant results were observed between NCR 
expression and NCR mediated CD107 expression. In the CD94dimCD16neg, 
CD94highCD16neg and CD94high/dimCD16high subsets high NKG2A expression 
was observed. However, NKG2A triggering failed to induce CD107 
expression. By contrast, low NKG2A expression was detected on the surface 
of CD94lowCD16high cells, but the cells showed only modest NKG2A mediated 
CD107 expression. In contrast to earlier published data, where NKG2A was 
found up-regulated on NK cells from individuals with chronic HCV 12, the 
results presented here show increased NKG2A-induced cytotoxicity in both 
naïve as well as HCV infected chimpanzees. The NKG2-family is well 
conserved between different primate species but exhibit polymorphism that 
affect the binding of monoclonal antibodies 33. The antibody that was used in 
the experiments described here is Z199. In humans, Z199 binds to NKG2A 
and NKG2E. By contrast, in rhesus macaques Z199 binds to NKG2A and 
NKG2C 34. The exact binding pattern of this monoclonal antibody in 
chimpanzees has not been investigated. While the NKG2A/CD94 complex 
delivers an inhibitory signal, the NKG2C/CD94 and NKG2E/CD94 deliver 
activating signals upon ligand binding. In this light, the NK cells in the 
CD94lowCD16high subset that respond to Z199 engagement with CD107 
expression may not be inhibiting NKG2A cells, but also include activating 
NKG2C NK cells.  
 
In conclusion, the present study provides a new strategy that enables 
evaluation of different NK subsets in chimpanzees. Furthermore, it shows that 
spontaneous and NCR mediated cytotoxicity are effector functions of distinct 
NK subsets in HCV infected chimpanzees.  
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SUPPLEMENTARY FIGURE 
 
 
Supplementary Figure 1; Frequency of NCR expression on NK subsets from 
naïve and HCV infected chimpanzees.  
The frequency of NKp30, NKp44, NKp46, NKG2A, NKG2D and DNAM expressing 
cells was calculated as the percentage of CD94dimCD16neg (upper left) 
CD94highCD16neg (upper right) CD94high/dimCD16high (lower left) and CD94lowCD16high 
(lower right) in naïve (open circles) and HCV infected chimpanzees (black dots). At 
the bottom of each graph the MFI is indicated in italic. The dots represent the 
individual chimpanzees tested. Statistical significant differences are indicated as * (p 
value between 0.05 and 0.001, ** (p value between 0.001 and 0.0001) and *** 
(p≤0.0001). For every group, the bars represent the mean value and the standard 
deviation. Statistical significant differences are indicated and considered significant 
when p<0.05. 
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GENERAL DISCUSSION 
 
Chimpanzees have been the most important animal model in the study 
of HCV 1-3. Chimpanzees have played a key role in the discovery of the virus 
and characterization of HCV-induced adaptive immune responses. More 
recently, chimpanzees have improved our understanding of vaccine-induced 
protection and the consequences of viral persistence 4. The latter were 
broadly discussed in the previous chapters of this thesis. The general 
discussion will therefore focus on the overall role of the chimpanzee as an 
animal model, and on new challenges in controlling the HCV epidemic.  
 
The end of an era, changing gears. 
In 2002, the Dutch Government prohibited the use of great apes for 
biomedical research. Since then, all chimpanzees that were housed at the 
BPRC have been relocated to either Zoos or a sanctuary. By then, the ethical 
debate on using chimpanzees had started in the USA. In 2013, it was agreed 
that research on NIH-owned or -supported chimpanzees was no longer 
allowed. Also, a number of pharmaceutical companies, including MSD, signed 
an agreement declaring they will no longer use chimpanzees in their research 
programs. Still, in the USA, a colony of 50 chimpanzees will be kept for future 
research. Any new research proposal involving chimpanzees, will be 
evaluated by ‘the chimpanzee research use panel’, before the NIH makes a 
decision about funding. Approval will only be given for exceptional research 
subjects. HCV is one of the viruses on the list of exceptions.  
 
Shortly after the public debate started on the ban of the use of 
chimpanzees for research purposes, in vitro models to study HCV became 
sparsely available. Critics may believe this timing is not a coincidence, but 
many documented attempts are available showing the hurdles that were 
overcome before in vitro culture systems were a fact. Even today, it is not 
possible to isolate HCV from any given patient, and replicate that virus in vitro. 
Only one successful attempt has been described, JFH-1 5. JFH-1 was isolated 
from a patient with fulminant hepatitis and full length HCV RNA was 
transfected into Huh-7 cells. Nowadays, JFH-1 is widely used and chimeric 
viruses, combining JFH-1 and other HCV genotypes and subtypes, have been 
generated (reviewed in 6). 
 
The progress made in the development of these in vitro systems 
resulted in better understanding of the HCV lifecycle and virus-host 
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interactions. It is safe to say that these cell culture-based techniques have 
directly initiated the development and screening of direct-acting antiviral drugs 
(DAA). DAAs are compounds that specifically target nonstructural proteins of 
HCV and disrupt virus replication. Currently, DAAs can be divided in four 
classes, NS3/4A protease inhibitors, NS5A inhibitors, NS5B nucleoside and 
NS5B non-nucleoside inhibitors. The year 2011 is considered a turning point 
in the treatment of chronic HCV infection. In that year telaprevir 7 and 
boceprevir 8 received regulatory approval, and since then, other compounds 
have followed 9. 
 
Immense improvement of HCV management options 
Since the introduction of the first DAAs, new generation drugs have 
been developed, evaluated and approved. Unlike HIV treatment, which only 
controls infection and must be taken for the rest of a patient’s life, HCV 
treatment aims at the elimination of the virus. To determine the most effective 
treatment approach, extensive pre-therapeutic diagnostics are required. This 
includes the determination of liver disease severity, HCV RNA quantification, 
genotype and subtype assessment. The full medical history of a patient is 
important as coinfection with hepatitis B virus, HIV are comorbidities that 
increase progression of liver disease and adaptation of treatment protocol 
may be required. Also other non-liver related disorders may require 
modification of treatment. Approximately 90% of the patients can now be 
successfully treated 10.  
 
The success of the new treatment options has led to new concerns. 
DAA-therapies are much more expensive than IFNα/RBV-treatment and not 
every HCV-infected patient can be treated immediately, therefore prioritization 
is necessary. To determine the impact of treatment with respect to medical 
costs and how society benefits from quality-adjusted-life-years, everal cost-
effectiveness-studies have been performed. 11-13. The multiparametric nature 
of these types of analysis make it difficult to compare the results but they are 
used to create decision models for HCV management. In Europe, ‘the EASL 
Recommendations on Treatment of Hepatitis’ 10 describes the clinical 
decision-making process for optimal HCV management. In November 2015, 
subcutaneous injection of PegIFN-α2a, PegIFN-α2b and the orally 
administered Ribavirin, Sofosbuvir, Simeprevir, Daclatasvir, Ledipasvir, 
Paritaprevir, Ombitasvir, Ritonavir and Dasabuvir were available and 
combined in various regimen. The current challenge in the development of 
new drugs lies in the care of difficult to treat patient groups, like patients 
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infected with genotype 3, or more advanced fibrosis stages, renal 
impairment/hemodialysis, HIV coinfections, decompensated cirrhosis and 
post-transplant patients. Also the development of new pan-genotypic agents 
is of great interest. 
 
 
Are DAAs the holy grail for controlling HCV epidemic? 
The reverse side of recent developments, like the second generation 
DAAs and ethical debate on using chimpanzees, is that HCV vaccine 
development has nearly come to an end. The new drugs shifted a vaccine 
further down the list of priorities. However, when we look at the developments 
in the HIV-field, this may change in the near future.  
 
Initially, antiviral therapy gave HIV infection the status of chronic 
disease instead of a deadly disease. Years after the introduction of HAART, it 
is obvious that treatment is a major step forward, but it will not put a halt to the 
HIV epidemic. On one hand, long-term use of antiviral drugs exerts 
continuous selective pressure on the virus and may eventually lead to viral 
resistance. On the other hand, every day 5600 people 14 are newly infected 
with HIV. The majority of these people live in Africa and do not have access to 
a proper health care system and antiviral therapy is out of reach. Therefore, 
immunizing high-risk individuals in endemic areas, is currently seen as the 
best option to stop the HIV epidemic.  
 
Similar circumstances apply to the HCV epidemic. It is without question 
that DAAs are a great improvement in patient care and HCV management in 
the developed parts of the world but it requires a large financial investment. 
Cost effectiveness of treatment with the new agents depends on many factors 
and also involves agreement between the pharmaceutical industries, local 
authorities and public health care services 15. The price tag for treatment in 
China, where 200 to 450 million people are infected 16 is different from Egypt, 
with 8-10% the highest HCV prevalence in the world. But for both 
governments the costs are contingencies that initially require a large 
investment 17. This implies that the new generation of drugs may not be 
available to patients in developing countries, or in countries with relative low 
prevalence.  
Additionally, the primary goal of treating chronic HCV infection is to eliminate 
the virus and to reduce the risk of development of hepatocellular carcinoma 
(HCC). But the association between drug-induced viral clearance HCV 
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disease regression is controversial. Several studies have reported that drug-
induced clearance is associated with reduced liver fibrosis 18-20 and decreased 
incidence of HCC· 21-26. However, others have reported on the development of 
HCC after viral clearance 27-32. These studies indicate that viral clearance 
does not warrant prevention of disease progression. A recent meta-analysis 
from 25 observational studies showed a 10% reduced risk of developing HCC 
compared between patients with and without SVR 33, 6.7 % in patients without 
cirrhosis and 22 % in patients with cirrhosis. The mechanism behind 
progressive liver disease after therapy-induced viral clearance is currently not 
understood. Possibly, HCV remains present in the liver at very low levels and 
local replication is responsible for disease progression. This is in line with the 
observation of HCV-specific CD8 T cells in the liver of a successfully treated 
chimpanzee 34 and intrahepatic Tregs in patients 4 years after HCV clearance 
35.  
Another concern is the development of viral resistance. Although there 
are basic differences between HIV and HCV, similar mechanisms have been 
reported to contribute to viral resistance as a result of antiviral therapy. 
Control of virus replication can be achieved by interfering with the function of 
the accessory, nonstructural proteins. This selective pressure may cause 
adaptation of the virus resulting in the formation of escape variants. Viral 
resistance has already been reported to protease inhibitors 36-38. On the 
positive side, mutations induced by selective pressure, can lead to a reduction 
in viral fitness. It was demonstrated that immune pressure induced changes of 
non-structural regions can be lethal to the virus 39 and potentially limit viral 
persistence. Still, the potential development of antiviral resistance is of great 
concern that may interfere with controlling the HCV epidemic.  
 
Back to the drawing board 
An affordable vaccine that is able to prevent primary infection or 
reinfection of people in high-risk groups, or cure chronic HCV infection would 
therefore be of benefit.  
Reinfection studies in humans and chimpanzees have shown that 
previously cleared HCV infection does not confer life long immunity 40-43. It can 
however reduce the development of persistent HCV infection. Based on this, 
several prophylactic vaccine efficacy experiments were performed in 
chimpanzees 44-58 
Relevant information regarding vaccine components, strategy, 
adjuvants, genotype of the vaccine-components and the challenge virus, and 
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the challenge outcome are summarized in Table 1 and reviewed by 
Verstrepen et al 4. In summary, these studies have shown that HCV vaccine 
efficacy is a case of trial and error. Protection from infection is rare 44, 55 but 
vaccine-induced responses may protect from viral persistence 45-56, 58, 59. More 
importantly, HCV vaccine experiments have revealed new insights in potential 
mechanisms that are involved in vaccine-induced protection from chronic HCV 
infection. For instance, it was found that recombinant E1/E2 envelope proteins 
can elicit antibody responses that may protect from heterologous infection 44. 
This is not surprising, as E2 has been described to contain several 
neutralizing epitopes that potentially block binding to CD81, SRB1 and 
coreceptors 60. Because these HCV-envelope protein vaccines were based on 
the E1/E2 heterodimer and the role of the individual glycoproteins could not 
be determined. Only recently, E1 and E2ΔHVR-1gp (E2 lacking the HVR-1) 
were evaluated separately 47. In two animals immunized with gpE1, HCV 
neutralizing antibodies were induced. Both animals were able to resolve HCV 
infection shortly after a heterologous HCV-1b challenge. In contrast, the two 
E2ΔHVR-1 immunized animals showed no neutralizing capacity and, despite 
the presence of E2 specific cellular responses, both animals became 
chronically infected. This study showed for the first time that E1 neutralization 
can be achieved by vaccination. This may imply that blocking E1 epitopes 
interferes with proper gpE1/E2 folding and sheds new light on the role of E1 
as an immunogen in HCV vaccines. 
 
Many HCV vaccine approaches that aim to induce T-cell responses, 
like virus-like particles and multicomponent prime-boost modalities, have been 
evaluated (Table 1). Overall broad and strong vaccine induced T-cell 
responses were associated with better perspectives but did not warrant 
protection from infection. In our DNA/MVA experiment, four animals were 
immunized with HCVcore-E1-E2 and HCV-NS3 plasmids and MVA 
expressing HCVcore-E1-E2 and HCV-NS3. Strong and broad T- and B-cell 
responses were reported 53. However, despite strong humoral responses, no 
virus neutralizing capacity was found and after challenge with HCV-1b, all four 
animals showed acute viremia. Only one animal was able to control virus 
replication to undetectable levels. The other three animals became chronically 
infected. The vaccine induced vigorous T-cell responses as reflected by 
strong proliferation and HCV specific IFNγ, IL-2 and IL-4 responses. 
Retrospectively, vaccine induced T-cell responses were analyzed in more 
detail. It was found that, although the vaccine elicited NS3 specific cytokine 
producing CD4 and CD8 T-cells in all four vaccinees, only in the chimpanzee 
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that cleared HCV infection, CD8 T-cells were found to have cytolytic capacity 
61. Interestingly, the animals that became chronically infected had higher 
mRNA expression levels of exhaustion markers PD-1, CTLA-4 and IDO in the 
liver, suggesting the induction of T-cells with regulatory functions that might 
have prevented formation of a cytotoxic T-cell response 53 
 
The induction of functional cytolytic T-cells by vaccines did not warrant 
protection from infection as shown by Folgori 56 and chapter 2.1 of this thesis. 
On the positive side, we have shown that cytolytic T-cells may protect from 
viral persistence (this thesis chapter 2.2). This is an important finding as the 
induction of killing competent T-cells was only achieved in the animal with the 
appropriate MHC class I molecule to present the viral peptide to the T-cell. 
This finding implies that peptides that are selected after screening of the HCV 
genome for conserved CTL-epitopes, and have a high binding capacity to 
MHC class I molecules, may be used as vaccine immunogens. To be able to 
protect at population levels, rather than individual level, several peptides 
covering different HCV genotypes and class I molecules, should be included 
in a vaccine. Similar synthetic peptide approaches are currently under 
investigation for malaria 62, HIV 63 and human papillomavirus 64. 
 
Hypothetically, this result may also be an opening towards a 
therapeutic HCV vaccine-approach, similar to strategies that are currently 
investigated in end stage melanoma patients 65. Using the same strategy in 
HCV infected patients would imply the following: First, the patient is typed for 
its MHC class I and the presence and variability of CTL and neutralizing 
antibody epitopes. Next, functional CTL and plasma cells are isolated from the 
patient. After in vitro expansion, high numbers of autologous CTL are infused 
into the patient to kill infected hepatocytes. At the same time, a high dose of 
autologous neutralizing antibodies is produced and the plasma cells are 
administered to prevent infection of new cells.  
  
In summary, these experiments have provided evidence for the central 
role of neutralizing antibodies in obtaining protection from HCV infection. On 
the other hand, most vaccine candidates that induce cellular immune 
responses do not protect from infection but lead to reduced viremia in the 
acute phase of the infection and reduce the risk of viral persistence. The 
current challenge is to translate this newly acquired knowledge into an 
efficient prophylactic or therapeutic HCV vaccine with improved efficacy.  
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Surrogate model, the next best thing? 
Due to further restrictions on the use of chimpanzees for biomedical 
research, future evaluation of new vaccine candidates in these animals will be 
limited. In recent years, strong effort was made in the development of a small, 
fully immunocompetent, animal model that supports HCV replication. So far a 
wide range of rodent models is available 6, 66. All these models have great 
value in specific HCV research fields, but lack at least one of the important 
features that are required to study HCV vaccine efficacy.  
 
Like SIV is used to study HIV infection in humans 67, HCV may also 
benefit from a surrogate model. Although the experimental infection of bank 
voles with a newly discovered hepacivirus is promising 68, a rodent model may 
have its limitations, partly because innate immunity is differently regulated in 
rodents compared to humans 69. GBV-B in common marmosets is a promising 
candidate in non-human primates. Worldwide, several experiments have been 
performed to characterize the infection of GBV-B in marmosets. With the 
report on persistent GBV-B infection in the presence of immune mediated liver 
pathogenesis and fibrosis 70, 71, GBV-B may have the potential to become the 
new non-human primate model to study HCV infection. In addition, common 
marmosets are already broadly used in biomedical research in the fields of 
autoimmune- and infectious diseases 72, 73. This implies that both innate as 
well as the adaptive immune system of these new world monkeys resembles 
the human system. With common mamosets being scientifically accepted 
models for various types of disorders, more specific diagnostic tools become 
available to investigate immune responses in these animals 73. A non-human 
primate model to study HCV infection would be of great value, in addition to 
the rodent models that are currently available.  
A recent report that primary hepatocytes from rhesus macaques are 
permissive for HCV replication, and that particle production can be enhanced 
by suppression of antiviral signaling pathways, is an exciting breakthrough 74. 
This development indicates that rodent models alone, do not suffice when 
aiming at the dissection of the complex interplay between the immune system, 
HCV pathogenesis, lentiviral coinfection and vaccine development. 
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Misconceptions in HCV research in chimpanzees. 
Investigating human diseases in an animal model, especially non-
human primates and chimpanzees, often leads to debate on ethical 
considerations versus translational value. Without a doubt, the preferable 
species to study HCV infection is humans, however it is not possible to control 
conditions, like time point, genotype and dose of infection. Only a well-
designed and properly conducted animal-experiment allows standardization of 
these variables. This does however imply intrinsic differences between the 
natural host and the experimental model. The role of the chimpanzee, in 
dissecting the adaptive immune responses during acute and chronic HCV 
infection, is indisputable. The value of chimpanzees in investigating other 
immune mechanisms, like immune-mediated pathology during is HCV 
infection, is however less well-recognized. The final paragraphs of this thesis 
are used to discuss some of the misconceptions that are commonly held 
about HCV research in chimpanzees. 
 
An often-used point of criticism is that chimpanzees do not develop 
hepatic fibrosis and are therefore not good models to study immune-mediated 
pathology. However, it is well recognized that some humans do not progress 
to fibrosis, while others rapidly develop significant fibrosis 75. In fact, male sex, 
duration of infection, acquisition of infection at >40 years of age, long term 
excessive alcohol consumption, long-term immunosuppression in case of HIV 
coinfection or organ transplantation and coinfection with hepatitis B virus are 
typical determinants for HCV-induced fibrosis. Some of these factors do not 
apply in the controlled laboratory settings that are associated with chimpanzee 
research. Typically, healthy, young-adult animals are selected for this type of 
research and maybe even more important, alcohol and other toxic substances 
that are either cleared by or metabolized in the liver, are not part of their daily 
diet. Therefore, it is tempting to speculate that chimpanzees resemble human 
non-progressors.  
 
No doubt, innate immune responses are differently regulated between 
chimpanzees and humans. Qualitative analysis of LPS induced immune 
responses have shown many similarities in regulatory pathways but also 
differences between humans, rhesus macaques and chimpanzees 76. 
Microbial translocation is not restricted to the gut, but also takes place in other 
mucosal surfaces, like the skin, lungs, eyes, nose, mouth, throat and parts of 
the reproductive organs. Obviously, chimpanzees have lower hygiene 
standards compared to humans, and It is therefore expected that the bacterial 
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burden in peripheral blood is higher and sCD14 levels are more up-regulated 
in these animals. However, our experiments have shown lower levels of 
sCD14 in chimpanzees. In addition, it was observed that in chimpanzees, 
monocytes express lower levels, or even no CD14, on their surface. Although 
highly speculative, this may be a direct result of the divergent evolution of 
human and chimpanzee species. In line with this finding is the lower 
expression of NKp30 and CD56 on the surface of chimpanzee NK cells. Our 
data has shown that chimpanzees do respond to LPS. Similar to HIV infected 
humans, chimpanzees show signs of gut perturbation with up-regulated levels 
of sCD14, LPB and IL-6. The overall response observed in chimpanzees was 
lower compared to humans and it would be interesting to investigate if the 
human system is overreacting or if there is dampening of the immune system 
in chimpanzees 77. 
 
It was described that chimpanzees do not respond to IFNα-based 
therapy 78. This was explained by stronger up-regulation of intrinsic IFN 
pathways by HCV infection in chimpanzees compared to humans. In patients 
chronically infected with HCV, low baseline IP-10 levels are predictive for 
successful treatment-induced clearance 79 Indeed, we observed much higher 
levels of IP-10 in some of the chronically infected chimpanzees. In 
approximately 50% of the animals, up-regulation of IP-10 levels was 
comparable to humans, suggesting that chimpanzees are more similar in this 
respect than earlier concluded. Lanford et. at. 78 concluded that chimpanzees 
overall, resemble human non-responders to IFN-based antiviral treatment. 
However, they analyzed only a limited number of chimpanzees and at least 
two of these animals had a high virus load. Based on our finding that virus 
load correlated with peripheral IP-10 levels, it is to be expected that IP-10 
levels in these animals are high. It is therefore tempting to speculate that 
chimpanzees with a high HCV load, and subsequent high baseline IP-10 
levels, are indeed equivalent to human non-responders to IFN-based therapy. 
However, this implies that animals with lower IP-10 levels may respond to 
IFN-based therapy. Unfortunately, this was never tested in chimpanzees.  
 
Another often suggested difference is that spontaneous clearance is 
more often observed in chimpanzees compared to humans and therefore 
chimpanzees are not comparable to humans. For decades it was estimated 
that approximately 80% of the people who contract HCV, become chronically 
infected. However, improved screening programs show that this is 
overestimated. Recently WHO has adjusted the percentage of HCV-
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persistence to 55 to 85%. This is in line with the finding of HCV specific 
cellular immune responses in seronegative individuals, implying loss of HCV-
specific antibodies after viral clearance can occur in humans 80-83  
On the other hand, there may be a good explanation for the firm 
believe that chimpanzees clear HCV infection more often compared to 
humans.  Humans and chimpanzees share a common ancestor who lived 
approximately 5 million years ago. After the split of the hominoids, both 
species evolved separate from one another. This implies that both species 
encountered different –lethal- pathogens. One of the theories is based on 
evidence for a selective sweep in chimpanzees, which led to a reduction of 
the MHC class I repertoire 84. The allotypes that were preserved after the 
selective sweep are enriched for binding peptides that are commonly 
presented by HLA-B27 and HLA-B57, the alleles that are associated with 
protective HCV specific immune responses and HCV clearance 84.  
 
Closing remarks 
Treatment of chronic HCV has improved after the regulatory approval 
of DAAs. However, high costs, ongoing disease progression and viral 
resistance are of concern. A prophylactic or therapeutic vaccine is therefore a 
good alternative. Over the years, two types of prophylactic vaccines were 
evaluated in chimpanzees. The envelope-based vaccines that induce 
neutralizing antibodies and vaccines that induce HCV specific T-cells are 
predominantly based on more conserved non-structural proteins.  
The results discussed in this thesis have shown that strong vaccine-induced 
immune responses do not protect from HCV infection, but may protect from 
viral persistence.  
 
• We have shown that immunization with E1 can induce neutralizing 
antibodies. This was the first time that E1 alone was used as an 
vaccine and both animals generated E1-neutralizing antibodies. More 
importantly, both animals cleared the infection rapidly after exposure. 
These results may have important implications for vaccine 
development.  
 
• In another vaccine study we found that protection from chronic infection 
was associated with the induction of killing competent CD8 T-cells. 
Additionally we showed an association between vaccine-induced 
cytolytic T-cells and the genetic background of the animal. These 
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results emphasize the importance of the MHC system in the induction 
of fully functional effector T-cells. 
 
• In order for a prophylactic vaccine to be effective, it should be 
administered before the subject is exposed to the pathogen. Given the 
majority of the new infections in the Western World are identified in 
intravenous drug users, one can imagine that this and other high risk 
groups, could benefit from this type of vaccine. On the other hand, this 
thesis also provides data that may help to design a successful 
therapeutic approach. A therapeutic vaccine should meet other 
requirements compared to a prophylactic vaccine. Many mechanisms 
have been associated with immune dysfunction and HCV persistence. 
We have shown that low levels of expression of PD-1 in hepatic tissue 
was associated with HCV clearance 53. This suggests that a 
combination of restoration of the T-cells with monoclonal antibodies 
and a vaccine that boosts the CD4 and CD8 T-cell responses, may be 
an effective therapeutic approach. Therapeutic vaccines that are 
currently in clinical development 85, in combination with biological 
compounds like anti-PD-1 or anti-CTLA-4 or one single DAAs may be 
as effective as treatment current combinatorial DAA treatment, but less 
sensitive for antiviral resistance and less expensive.  
 
The final chapters of this thesis were committed to the consequences of HCV 
infection, and the value of the chimpanzee to investigate this.  
 
• Genetic diversity throughout different species and within one species is 
a characteristic of evolution. We have shown that the polymorphism 
near the IL-28B gene, which is associated with the outcome of human 
HCV infection, is not present in chimpanzees. We tested two SNPs and 
chimpanzees are homozygous for both alleles. One SNP represents 
the ‘risk allele’ while the other SNP represents the ‘good allele’. These 
data suggest that the polymorphism in humans was not driven by HCV 
as the selective marker, as one would expect that chimpanzees would 
either have ‘risk alleles’ ‘good allele’. This is a good example of how 
human medicine should benefit from translational research in animal 
models.  
 
• It is firmly believed that chimpanzees do not respond to IFN-based 
antiviral treatment, but this was based on one experiment in three 
204	  	  	  	  	  	   	   	  CHAPTER	  4	  
	  
chimpanzees. According to literature, at least two of them have a high 
virus load. In this thesis we provide data that chimpanzees with a high 
virus load resemble human non-responders. This may indicate that 
chimpanzees with a low virus load may benefit from IFN-based antiviral 
treatment. This was however never tested. 
 
• The translocation of bacterial products and consequent chronic 
systemic immune activation plays an important role during HIV 
associated disease progression 86. Increased microbial translocation 
has also been associated to HCV infection and liver fibrosis 87. In this 
thesis, we provide data that sCD14 is up-regulated in chimpanzees 
after HCV infection. Chimpanzees do typically not develop liver fibrosis 
as a result of HCV infection, and no evidence was found for mucosal 
damage of the small intestines in these animals. This suggests that the 
elevated sCD14 observed in HCV infected humans is not mediated by 
portal hypertension caused by fibrosis alone, as currently assumed.  
 
• Because of differential CD56 expression between human- and 
chimpanzee NK cells, it was not possible to divide the chimpanzee NK 
population into subsets; chimpanzee NK cells cannot be subdivided 
into CD56dimCD16pos and CD56bright cells. In this thesis we describe a 
new strategy to identify 4 functionally distinct NK cells based on the 
expression of CD94 and CD16; CD94dimCD16neg, CD94highCD16neg, 
CD94high/dimCD16high and CD94lowCD16high and enables the functional 
analysis of these cells.  
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SUMMARY 
 
Approximately 1 to 2 % of the world population is chronically infected 
with hepatitis C virus (HCV). Of these people, 15 to 30 percent will develop 
liver cirrhosis or liver cancer within 20 years after infection. HCV is therefore 
not just a social problem but also a large burden for the health care system. 
 
Only one in five individuals is able to spontaneously clear the virus. 
Since acute infection generally does not cause clinical signs, people are not 
aware of the fact that they are infected. As a result, the complicated 
interactions between the virus and the host early after infection are difficult to 
study in humans. Moreover, reliable baseline sampling is complicated to 
organize. An animal model circumvents these challenges, and enables 
experimental infection under controlled conditions.  
 
In the early 80s of the last century, HCV was identified as the causative 
agent of non-A-non-B hepatitis. Chimpanzees have played a crucial role in the 
discovery of HCV, identification of the modes of transmission of the virus and 
characterization of the course of HCV infection. More recently these animals 
were used to evaluate vaccine candidates. Growing ethical awareness has led 
to a ban on the use of chimpanzees for biomedical research in Europe since 
2003. With the near disappearance of chimpanzees as an animal model on 
one side, and the approval of direct acting antiviral drugs by regulatory 
agencies on the other, this thesis is positioned in an era of changing 
perspectives on HCV research. It summarizes the key role of chimpanzees 
and elaborates on potential mechanisms behind successful prophylactic 
vaccine candidates. In addition, consequences of chronic HCV are discussed 
as well as the translation to the human situation. 
 
Many studies in chimpanzees have shown that clearance early after 
HCV-infection is associated with relatively strong CD4 and CD8 T-cell 
responses, but there is also a role for neutralizing antibodies. In addition, 
innate immune responses have been described to play a role in controlling the 
infection. The similarities and dissimilarities between humans and 
chimpanzees are discussed in chapter 1. The aim of the research described 
in this thesis was to investigate HCV-related immune responses in 
chimpanzees as a model for infection in humans. In the first part, vaccine-
induced immune responses, and their potential contribution to protection from 
chronic HCV-infection were studied. In the second part, the consequences of 
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chronic HCV infection on the immune system are discussed. The majority of 
the experimental work described in this thesis was performed in chimpanzees 
and, when relevant, compared to humans. 
 
If one thing, HCV vaccine studies have shown that efficacy of the 
vaccine is very much a case of trial and error. Chapter 2.1 describes the 
evaluation of a so-called prime-boost vaccine efficacy study. In this study, four 
chimpanzees first received a HCV-DNA prime followed by an HCV-MVA boost. 
The vaccine elicited strong immune responses in all four animals. However, 
after experimental infection, in three animals the virus persisted, whereas one 
animal cleared the infection. Analysis of the CD4 and CD8 T-cell responses 
by intracellular cytokine staining was not conclusive in explaining why. To 
examine this in more detail, a FACS-based cytotoxicity-assay was developed. 
With this assay, we showed that the vaccine elicited killing-competent CD8 T-
cells in the animal that cleared the infection, whereas these specific vaccine-
induced cells were not present in the animals that became chronically infected. 
This is discussed in detail in chapter 2.2.  
 
In chapter 2.3, the protective role of vaccine-induced E1-neutralizing 
antibodies are discussed. While the HCV-E2 protein is known for its epitopes 
that bind to neutralizing antibodies, HCV persisted in two E2-immunized 
animals after experimental HCV infection. By contrast, two other animals that 
received a recombinant E1-vaccine, were able to clear the virus shortly after 
infection. Using the HCV pseudoparticle neutralization assay, it was found that 
serum from the E1-immunized animals could protect in vitro-cultured cells 
from infection with a heterologous HCV 1b virus. Serum from the two E2-
immunized animals did not show this protective capacity. 
 
Chapter 3 of this thesis focuses on the consequences of HCV infection.  
We investigated serum IP-10 levels in chimpanzees and compared these with 
the levels in human patients. IP-10 is a protein that is part of the innate 
immune system and that was found to be strongly up-regulated in patients 
that are difficult to treat. In chapter 3.1, the up-regulated levels of IP-10 in 
chimpanzees are discussed. These data suggest that, unlike the dogma, 
some chimpanzees may respond to IFN treatment. We were unable to test 
this hypothesis at the BPRC.  
 
In HIV patients, it was found that microbial translocation, the transfer of 
microbial residues from the gut lumen into the peripheral blood, is increased. 
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This was also found in HIV patients that were co-infected with HCV, but in 
patients that were infected with HCV alone, the results were inconclusive. 
However, it was postulated that liver fibrosis, as a consequence of HCV 
infection, would affect the clearance of bacterial products from the blood 
explaining the higher levels in humans with fibrosis. To examine this, we 
analyzed serum soluble CD14 levels in human patients with HCV-induced 
fibrosis, and compared the results with chimpanzees in whom typically no 
fibrosis is seen. We found up-regulated sCD14 levels in both humans and 
chimpanzees infected with HCV, suggesting that up-regulation of sCD14 can 
also occur in the absence of liver fibrosis. In addition, we showed that 
increased sCD14 levels during HCV infection are not a result of increased gut-
perturbation. By contrast, in a group of HIV/SIV infected chimpanzees sCD14 
up-regulation was accompanied by more enterocyte death and thus leakage 
of bacteria into the blood. These data show that microbial translocation does 
occur in chimpanzees, but not as a result of HCV infection. We discuss these 
findings in chapter 3.2.  
In the next chapter, we discuss yet another aspect of the innate immune 
system, the NK cells. In humans and rodents, functionally distinct NK subsets 
can be identified based on the expression of CD16 and CD56. This is not 
possible in chimpanzees. In chapter 3.3 a new method is described to 
distinguish between different NK subsets in chimpanzees. Next, we used this 
method to study the impact of HCV infection on NK subsets in chimpanzees. 
We observed spontaneous and NCR mediated killing were functional 
characteristics of different subsets in HCV infected chimpanzees. 
 
In the final chapter, chapter 4, an overview is presented of all 
prophylactic vaccine experiments that were performed in chimpanzees 
worldwide. In addition, a picture is painted of future HCV research without 
chimpanzees, and the pro and cons of this new era are discussed. 
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SAMENVATTING 
 
Naar schatting 1 tot 2 procent van de wereldbevolking is chronisch 
geinfecteerd met het hepatitis C virus (HCV). Hiervan zal 15 tot 30 procent 
leverfalen ontwikkelen. HCV is dan ook niet alleen een maatschappelijk 
probleem maar legt het ook een enorme druk op het gezondheidssysteem.    
 
Slechts een op de vijf mensen beschikt over de juiste tools om een 
besmetting met HCV adequaat te lijf te gaan. Dit betekent dat het virus in de 
rest van de patiënten een manier vindt om blijvend aanwezig te zijn, met een 
chronische infectie als gevolg. Doordat er kort na infectie nauwelijks sprake is 
van klinische symptomen, zijn mensen zich meestal niet bewust van HCV 
besmetting en worden dus niet door een arts gezien. Hierdoor is het bijna 
onmogelijk om een goed beeld te krijgen van hoe het virus en het 
immuunsysteem op elkaar reageren in deze vroege fase. Daarnaast is het 
ingewikkeld om bijvoorbeeld seriële bloedmonsters te verzamelen van 
dezelfde personen, inclusief van tijdstippen vóór de infectie heeft plaats 
gevonden. Een diermodel is de enige mogelijkheid om dit soort problemen te 
omzeilen en een infectie uit te voeren onder gecontroleerde omstandigheden. 
Tot op heden is de chimpansee de enige diersoort waarbij dit mogelijk is.   
 
In de vroege jaren 80 van de vorige eeuw werd de voornaamste 
veroorzaker gevonden van de zogenaamde non-A-non-B hepatitis, HCV. 
Chimpansees hebben een cruciale rol gespeeld bij deze ontdekking en later 
ook in de onderzoeken naar hoe het virus wordt overgedragen en hoe de 
infectie zich verder ontwikkelt. Daarnaast hebben chimpansees bijgedragen 
aan de ontwikkeling en evaluatie van potentiele vaccins. Meer kennis over 
chimpansees en hun zelfbewustzijn heeft geleid tot een ethische discussie 
over het gebruik van chimpansees in biomedische onderzoek. Mede hierdoor 
is het sinds 2003, binnen Europa, niet meer toegestaan om mensapen te 
gebruiken voor deze doeleinden. Met het verdwijnen van het enige 
gevalideerde proefdiermodel aan de ene kant, en doordat de autoriteiten 
goedkeuring hebben gegeven voor het gebruik van nieuwe antivirale 
middelen om HCV infectie te behandelen aan de andere kant, is het HCV 
onderzoek in een nieuw tijdperk beland. Dit proefschrift beschrijft de 
belangrijke rol die chimpansees hebben gespeeld in het HCV onderzoek. 
 
Door de jaren heen hebben studies in chimpansees laten zien dat 
spontane klaring van HCV geassocieerd is met relatief sterke CD4 en CD8 T-
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cel responsen. Ook is er een duidelijk een rol voor neutraliserende  
antilichamen en zelfs het aangeboren immuunsysteem. De overeenkomsten 
en verschillen tussen mensen en chimpansees tijdens HCV infectie worden 
uitvoerig beschreven in de algemene inleiding in hoofdstuk 1. Het 
wetenschappelijk deel van dit proefschrift was gericht op het kaart brengen 
van de immuun-responsen die chimpansees ontwikkelde tegen HCV, om zo 
de infectie in mensen beter te begrijpen. In het eerste deel worden met name 
vaccins besproken. Er worden immuun-mechanismen uitgelicht die mogelijke 
ten grondslag hebben gelegen aan de beschermende capaciteit van die 
vaccins. In het tweede deel is gekeken naar de mogelijke gevolgen van 
chronische HCV infectie op het immuunsysteem. Het overgrote deel van het 
werk dat wordt beschreven in dit proefschrift gaat over chimpansees en daar 
waar mogelijk worden de resultaten vergeleken met mensen. 
 
Wanneer het over HCV vaccins gaat, is er één ding duidelijk. Aan de 
hand van eerdere resultaten is niet te voorspellen hoe beschermend het effect  
van een vaccin is. In hoofdstuk 2.1 wordt een vaccinstudie in chimpansees 
beschreven. In deze studie werd een zogenaamde prime-boost strategie 
getest. Eerst wordt het immuunsysteem van de chimpansees ‘geprimed’ met 
een HCV-DNA vaccin om daarna ‘geboost’ met een ander vaccin, HCV-MVA. 
De vier dieren in de studie reageerde erg verschillend op de experimentele 
infectie die volgde en het vaccin bleek slechts één van de vier dieren te 
beschermen tegen chronische infectie. Omdat in eerste instantie niet duidelijk 
was waarom deze vaccin-strategie zo een verschillende uitwerking had in de 
individuele dieren, zijn we de CD4 en CD8 T-cel responsen in meer detail 
gaan onderzoeken. Omdat intracellulaire cytokine expressie geen verklaring 
bieden, daarom hebben we een nieuwe techniek ontwikkeld met behulp van 
de FACS. Met deze zogenaamde cytotoxiciteits-assay hebben we uiteindelijk 
kunnen aantonen dat de chimpansee die het virus geklaard heeft, de juiste 
genetische achtergrond had om precies de juiste cellen op te leiden om het 
virus te kunnen aanvallen. De uitkomst van dit onderzoek laat zien dat er 
mogelijk gedacht moet worden aan maatwerk-vaccins in plaats één vaccin 
voor iedereen, dit wordt bediscussieerd in hoofdstuk 2.2.  
 
In hoofdstuk 2.3 wordt dieper ingegaan op de beschermende rol van 
E1-neutraliserende antilichamen. HCV heeft twee envelop eiwitten aan de 
buitenkant van het virus deeltje, E1 en E2. Vanuit de literatuur is bekend dat 
E2 een aantal epitopen bevat voor neutraliserende antilichamen. In E1 zijn die 
in mindere mate aanwezig. Omdat de meeste vaccin-experimenten 
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gebaseerd zijn op een combinatie van E1 en E2 was er geen kennis over de 
individuele eiwitten. Wij hebben twee chimpansees gevaccineerd met E1, en 
twee met E2. In de twee E2 gevaccineerde dieren konden we echter geen 
neutraliserende antilichamen aantonen terwijl we die wel vonden in de E1  
gevaccineerde dieren. Dit was een zeer opmerkelijke bevinding omdat de 
twee dieren met die antilichamen ook nog eens in staat bleken te zijn het virus 
te klaren. Hiermee hebben we aangetoond dat E1 een belangrijke rol kan 
spelen in de bescherming tegen HCV.  
 
In hoofdstuk 3 focussen we ons op de consequenties van chronische 
HCV infectie. In mensen is gevonden dat het eiwit IP-10 een belangrijke 
voorspellende waarde heeft voor de behandeling van HCV met algemene 
antivirale middelen. Een lage IP-10 concentratie in bloed geeft aan dat de 
kans van slagen groter is dan een hoge IP-10 concentratie. Wij hebben 
gekeken naar de hoeveelheid IP-10 in het bloed van HCV geïnfecteerde 
chimpansees en hebben deze waarden vergeleken met mensen. In 
hoofdstuk 3.1 laten we zien dat de concentratie in chimpansees erg variabel 
is. In sommige dieren is het zelfs veel hoger dan wat in mensen gevonden is 
maar in ongeveer de helft is het vergelijkbaar met de concentratie die 
gevonden wordt in mensen die goed te behandelen zijn met IFNα/ribaverine. 
In tegenstelling tot het beeld dat bestaat, zou dit kunnen betekenen dat 
sommige chimpansees met een lage IP-10 waarde, ook succesvol met 
IFNα/ribaverine behandeld zouden kunnen worden. Echter dit idee hebben 
we niet daadwerkelijk kunnen testen in chimpansees. 
 
In mensen die geïnfecteerd zijn met HIV vind het fenomeen microbiële 
translocatie plaats. Dit wil zeggen dat er kleine stukje van bacteriën die 
aanwezig zijn in de darmen, door de darmwand lekken en in het 
onderliggende weefsel terecht komen. Dit gebeurt bij iedereen, en is zelfs een 
voorwaarde voor een goedwerkend immuunsysteem. In mensen met AIDS 
gebeurt het echter iets teveel waardoor er problemen kunnen optreden. Ook 
in patiënten die zowel HIV als HCV geïnfecteerd zijn is deze verhoogde 
translocatie aangetoond. In mensen met alleen HCV zijn de resultaten van 
verschillende onderzoekers niet in overeenstemming met elkaar. Het idee 
bestaat echter dat de verhoging van de bacteriële producten in de lever niet 
veroorzaakt wordt door verhoogde translocatie maar dat fibrose zorgt voor 
een verminderde werking van de lever waardoor er minder gezuiverd wordt. 
Om deze theorie te testen hebben we de sCD14 concentratie in humane 
patiënten met lever-fibrose, vergeleken met de sCD14 concentratie in 
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chimpansees. In chimpansees leidt HCV infectie namelijk niet tot lever-fibrose 
waardoor dit een goed model is om dit te testen. Wij hebben gevonden dat 
sCD14 verhoogd was in zowel mensen als chimpansees die geïnfecteerd zijn 
met HCV. Dit geeft aan dat verhoging ook plaats kan vinden in de afwezigheid 
van lever fibrose. Daarnaast hebben we geen aanwijzing gevonden voor een 
beschadiging van de darmwand in HCV geïnfecteerde chimpansees, wat 
aangeeft dat HCV geen extra lekkage veroorzaakt. Om er zeker van te zijn 
dat microbiële translocatie wel plaats kan vinden in chimpansees hebben we 
ook het bloed van een aantal HIV/SIV geïnfecteerde dieren getest. Hieruit 
bleek dat dit fenomeen inderdaad plaats kan vinden in chimpansees maar niet 
als gevolg van HCV infectie. Deze resultaten worden uitgebreid 
bediscussieerd in hoofdstuk 3.2.  
 
In hoofdstuk 3.3 gaan we dieper in op een ander onderdeel van het 
aangeboren immuunsysteem en onderzochten we de NK cellen. In mensen 
en knaagdieren worden verschillende subsets van deze cellen beschreven op 
basis van expressie van CD16 en CD56. In chimpansees is deze methode 
echter niet mogelijk. In dit hoofdstuk beschrijven we een alternatieve strategie 
om de NK populatie onder te verdelen in verschillende subsets. We 
gebruikten hiervoor de oppervlaktemarkers CD94 en CD16. Op basis van de 
expressie van deze twee moleculen hebben we vier functioneel verschillende 
NK subsets kunnen onderscheiden. Deze vier hebben we uitvoerig 
bestudeerd wat betreft uiterlijk en eigenschappen. Daarna hebben we 
onderzocht wat de invloed is van HCV infectie op deze cellen in chimpansees. 
We hebben gevonden dat spontane cytotoxiciteit en zogenaamde NCR-
gemedieerde cytotoxiciteit, eigenschappen zijn van verschillende NK subsets . 
 
Tenslotte wordt in hoofdstuk 4, een overzicht gegeven van alle profylactische 
HCV vaccin studies die wereldwijd zijn uitgevoerd in chimpansees en wordt 
een beeld geschetst van een HCV onderzoeksveld zonder chimpansees, en 
de mogelijke positieve en negatieve gevolgen hiervan.  
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ABBREVIATIONS 
 
aa  amino acids 
ADCC  antibody dependent cellular cytotoxicity 
AF-700  alexa fluor 700;  
AmCyan  anemonia majano cyan 
APC  allophycocyanin 
APC   antigen presenting cell 
APC-H7  phycoerythrin-cyanine7 
CCR7  chemokine (C-C motif) receptor 7 
CD  cluster of differentiation  
CFSE  carboxyfluorescein succinimidyl ester 
CTL  cytotoxic T-cell 
CTLA-4   cytotoxic T lymphocyte-associated antigen 4 
DNAM  DNAX Accessory Molecule-1, CD226 
E1  envelope protein 1 
E2  envelope protein 2 
ECD  phycoerythrin-Texas Red 
ELISPOT   enzyme-linked immunospot 
ELISA  enzyme-Linked Immuno Sorbent Assay. 
FACS  fluorescence-activated cell sorting 
FitC  fluorescein isothiocyanate 
HCV 
HCVpp 
 hepatits C virus 
HCV pseudo particles 
HIV  Human Immunodeficiency Virus 
ICS  intracellular cytokine staining 
IDO   indoleamine 2,3 dioxygenase 
IFN-α  interferon alpha 
I-FABP  Intestinal fatty acid binding protein 
IFN-γ  interferon gamma 
IL-2   interleukin 2 
IL-4   interleukin 4 
IL-6  interleukin 6 
IP-10 
KIR 
 killer-cell Ig-like receptor 
interferon gamma-induced protein 10 
LBP 
LPS 
 LPS binding protein 
Lipopolysaccharide 
MHC  major histocompatibility complex 
MoAb  monoclonal antibody 
MVA  Modified Vaccinia Ankara 
Nab   neutralizing antibody 
NCR  natural cytotoxicity receptor 
NK  natural killer  
NS3  non structural protein 3 
PBMC  peripheral blood mononuclear cells 
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PCR  polymerase chain reaction 
PD-1  programmed death receptor 1 
PE  phycoerythrin 
PE-Cy7  phycoerythrin-cyanine7 
PerCP  peridinin-chlorophyll-protein complex conjugate 
RT-PCR   Real-Time PCR 
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terug op de, enigszins door wodka, wijn of bier vertroebelde herinneringen die 
we delen, en ik hoop dat er nog veel zullen worden bijgemaakt. 
 
Zonder jou, Ivonne, had dit boekje nog heel wat langer op zich laten wachten. 
Dank je voor al het pipetteer werk en voor je nooit aflatende enthousiasme om 
weer achter de FACS te kruipen, in vloeibare stikstof te duiken of me uit de 
brand te helpen wanneer ik het even niet meer wist. Je bent een kanjer, en ik 
ben blij dat ik tijdens de laatste fase van het werk voor dit proefschrift gebruik 
mocht maken van jouw kundige handen. Ernst, wanneer ik iemand moet 
bedanken voor het boosten van mijn zelfvertrouwen, dan ben jij het. Lang 
geleden heb ik voor je mogen werken en de vanzelfsprekende zelfstandigheid 
die jij van de mensen om je heen verwacht, is me enorm goed bevallen. Jouw 
idee om verder te gaan met het Dengue virus en het West Nile virus heeft 
nieuwe onderzoekswegen geopend en ik vind het heerlijk dat je me aan boord 
wilt hebben. Daan, roomy!! Het is een feestje om met jou op een kamer te 
mogen zitten, en ongegeneerd cola te mogen drinken enzo. Sorry dat ik de 
afgelopen maanden af en toe een pain in the ass was maar ik beloof 
verbetering. 
 
Mijn twee paranimfen: Joyce, vriendinnetje voor het leven. Wat hebben wij 
samen al veel meegemaakt. Een moordaanslag met een tentharing op 
Lowlands, parachutespringen op Texel, kanoën in noodweer, kamperen 
tijdens een bruiloft in de Elzas, een biertje in de Bruine Pij, we hebben het 
allemaal overleefd. En Sylvia, wij doen samen hele andere dingen. Etentjes, 
vakanties, strand, musea, borreltjes en muziekoptredens, elk excuus om even 
lekker bij te kletsen. Ik ben supertrots dat jullie samen naast me willen staan, 
het maakt de dag helemaal compleet.  
 
Ondanks dat ik met regelmaat een high maintenance geval ben, staan jullie 
altijd voor me klaar, Saxwin, Alexander en alle andere mensen van Doxx. 
Zelfs na de onvergetelijke actie waarbij ik 17 gigabite aan FACS data had 
verwijderd van mijn computer, bleven jullie vriendelijk, en hebben juliie ervoor 
gezorgd dat ik alle data weer terug gekregen heb. Chapeau! Die 17 gigabite 
zijn nu overigens door Henk van Westbroek verwerkt tot één figuur in 
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hoofdstuk 2.2. Dank je Henk voor deze, en al die andere figuren, die je in de 
afgelopen jaren gemaakt hebt.  
 
Christine Rollier, one of the most inspiring people I ever had the pleasure to 
work with. She taught me that results can be “massaged” and depicted in 
many different ways. Graphs showing the same results but differ in how the 
message is brought. Even after al these years, I still miss you! Bert ‘t Hart, 
weinig mensen zullen jou ‘de stille kracht op de achtergrond’ noemen dus 
misschien ben ik de eerste. Marion Hoogendoorn, dankzij jouw feilloze 
begeleiding ben ik zonder al te veel kleerscheuren door deze laatste fase van 
het promoveren gekomen. Thea de Koning, voor de allerlaatste puntjes op 
de ‘i’. 
 
Omdat er tussen (oud) collega’s soms warme vriendschap ontstaat, lieve 
Susan, Anne-Marie, Sunita, Esther en Rudy. Maar ook Rob, Wim, Peter, 
Lennart, Jeannette, Bas en Tom, de dinertjes met jullie zijn top!  
 
Aan allen die de koffiekamer de koffiekamer maken: Henk, Herman, David, 
Zahra, Hester, Melanie, Sam, Roberto, Nicole, Annemarie, Michel, 
Richard, Yolanda, Claudia, Karin, Clemens, Erica, Frank, Ed, Bart, Onny, 
Sandra, Milena, Gwen en alle mensen die inmiddels hun carriere ergens 
anders voortgezet hebben.  
 
Zonder de andere chimps te kort te willen doen, Phil met je mooie ogen, 
grappige Ton, Femma met de gekke oortjes, Marcel met drinkfles en Peggy 
met je bolle buik. Tegen wil en dan hebben jullie hebben je belangeloos 
ingezet en hebben we veel kunnen leren over HCV infectie. Het werken met 
apen -en met name chimpansees- in een onderzoeksetting, kan alleen met 
zeer kundige mensen om je heen: Merei, Jaco, Gerco Rianne, Leo, Robin, 
André, Dennis, Edwin, Gert-Jan, Erik, Willem, Con, Wouter, Mariska, 
Fred, Chantal, Jeroen, Victor en alle anderen met wie ik in de afgelopen 
jaren in de stallen ben geweest.   
 
Omdat ik sterk het vermoeden heb dat dit de enige keer in mijn leven is dat ik 
een dankwoord schrijf, ga ik nog even door. Paul, Juliëtte, Sas, Tino, 
Margreet, Peter, Ineke, Karin, Mariëlle, Thomas, Hugo, Lion, Marjolein, 
Ben, Gerard, Ben en alle anderen. Jullie waren ‘part of the package’, maar in 
sommige pakketjes zit een kadootje. En die kadootjes zijn die gezellige dagen 
en avonden -en halve nachten- samen met jullie!  
 
Mijn oude Biesbosch-matties, Theo, zomaar omdat het kan, en ik jullie veel te 
weinig zie en Peter, omdat je aan het begin van dit traject al met een fles 
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champagne voor mijn deur stond. Sonja, Chris, Sandra, Richard en de rest 
van mijn carnavals-vriendjes en vriendinnetjes…Alaaaaffff. Ruud, omdat je 
me wel eens redt van een inzinking wanneer de trein vertraging heeft en ik het 
even niet meer zie zitten. Wijnand Nijs, als hoofdredacteur van 
BredaVandaag heb je mij de kans gegeven om niet alleen wetenschappelijk 
artikelen te schrijven, maar ook wat luchtigere zaken aan te kaarten. Met veel 
plezier heb ik het afgelopen jaar een wekelijkse column geschreven en ik leer 
hier elke keer weer wat nieuws van. 
 
De aanstichter van deze promotie Oom Cor. We wisten beiden dat je er niet 
meer zou zijn vandaag, maar jij hebt me destijds het vertrouwen gegeven om 
het in ieder geval te proberen “bel me even wanneer je er bent”.  
 
Maud en Guus, omdat jullie mijn leukste nichtje en neefje zijn.  
Guus, je vindt mij ‘veel te raar om op een lab te werken’. Hopelijk geloof je me 
nu wel? En Maud, zet ‘m op op school. Wie weet, misschien sta jij hier over 
15 jaar dan ook wel. 
 
Ivo, je zal altijd mijn kleine broertje blijven, en ik weet zeker dat we er altijd 
voor elkaar zullen zijn. Ik ben trots op jou, je doorzettingsvermogen, je kracht 
en je wil om er altijd het beste van te maken.  
 
Lieve Mama, de basis van dit alles ligt bij jou en papa. Jullie hebben Ivo en 
mij de vrijheid gegeven onszelf te zijn, en te blijven. Dat is misschien wel de 
mooiste eigenschap die je je kinderen mee kunt geven. Lieve mam, ik prijs me 
gelukkig met jouw onvoorwaardelijke liefde en jouw nimmer aflatende steun! 
Theo en Arthur, wat fijn dat jullie zo lief voor haar zijn. Dat ik dit vandaag met 
jullie mag delen, geeft de dag extra glans. 
 
Noud, de allerlaatste alinea is voor jou. Wat onvoorstelbaar leek in het begin 
is nu het meest dierbaar in mijn leven. Met jouw warme en sterke karakter, je 
heerlijke relativeringsvermogen, je verrassende inzichten en jouw innerlijke 
rust en humor, lever je een onmisbare bijdrage aan mijn leven in zijn totaliteit. 
Lieve Noud, er zijn geen woorden voor om te beschrijven hoe belangrijk je 
voor me bent, maar deze komen het meest in de buurt: ik hou van jou.  
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